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Abstract 
Globally, tuberculosis kills more people than any other infectious disease. 
Control of the epidemic is impeded by poor diagnostic approaches. My 
original contribution to knowledge presented in this thesis is towards 
diagnosis of tuberculosis by (meta)genomic approaches. 
 
In the work presented here, I established proof-of-principle that tuberculosis 
can be detected, identified and somewhat characterised using a shotgun 
metagenomics approach. I developed an approach for DNA extraction 
directly from sputum followed by metagenomic sequencing that allowed me 
to detect sequences from the M. tuberculosis complex in all sixteen samples 
with low coverage of the H37Rv reference genome. This allowed me to assign 
the lineage of the MTBC species in thirteen of these samples. This was the 
basis of the first publication to sequencing tuberculosis without prior culture.  
 
I determined that the proportion of human reads in the resulting 
metagenomic data was a major limitation to characterising the MTBC 
organisms with greater resolution and sought, though unsuccessfully, to 
determine methods to remedy this. In doing so, I identified a number of 
considerations that need to be made when designing studies of human DNA 
depletion from such heterogeneous clinical samples in the future.  
 
Addressing some of the other limitations to using genomics in the diagnosis 
of tuberculosis, I studied the genotype-phenotype association of first-line 
drug resistance found in patients in Peru and evaluated the performance 
diagnostic approaches used. This identified novel mutations associated with 
pyrazinamide resistance, flaws in the MODS method of antibiotic resistance 
testing and variation in resistance prediction tools.  
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1. Introduction 
1.1 What is tuberculosis? 
Briefly, tuberculosis (TB) is an infectious disease of humans and other 
mammals caused by the bacterium, Mycobacterium tuberculosis, and its close 
relatives in the M. tuberculosis complex (MTBC). Tuberculosis most commonly 
affects the lungs, but can also manifest in other parts of the body. In most 
cases, the infection remains latent but in around 10% of cases latent infection 
progresses to active disease, which if left untreated, kills about half of those 
infected. Active pulmonary TB presents with a chronic cough with blood-
containing sputum (haemoptysis), fever, night sweats and/or weight loss. 
Despite being a treatable disease, TB is the ninth leading cause of death 
worldwide, killing 1.3 million HIV-negative people and a further 374 000 
HIV-positive people in 2016 (1). In the same year, 10.4 million people were 
infected with the disease (1). 
1.2 Historical perspective 
Tuberculosis is an ancient disease that has plagued humans for thousands of 
years and been documented throughout medial history. Hippocrates (460-370 
BC) described phthisis (2), a wasting disease that was thought to be a 
hereditary condition at the time: 
“Early in the beginning of spring, and through the summer, and towards winter, 
many of those who had been long gradually declining, took to bed with symptoms 
of phthisis; …. Many, and, in fact, most of them died, and of those confined to 
bed, I do not know of a single individual survived for any considerable time, …. 
Consumption was the most considerable of the diseases which then prevailed, and 
the only one which proved fatal to many persons.  Most of them were affected by 
these diseases in the following manner; fevers accompanied with rigors, … 
constant sweats, … extremities very cold, and warmed with difficulty; bowels 
disordered, with bilious, scanty, unmixed, thin, pungent, and frequent 
dejections.  The urine was thin, colourless, unconcocted, or thick, with a deficient 
sediment.  Sputa small, dense, concocted, but brought up rarely and with 
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difficulty; and in those who encountered the most violent symptoms there was no 
concoction at all, but they continued throughout spitting crude matters.”  
Later, Aristotle (384-322 BC) described phthisis in pigs, concluding that the 
disease was most likely infectious rather than hereditary (3). By the 5th 
century AD the symptomology of the disease had been defined by Roman 
physicians and a treatment of ‘fresh air, milk and sea voyages’ was 
recommended (2). 
 
Though the written record of TB is sparse throughout the middle ages, the 
disease was clearly present, given palaeopathological evidence of TB at 
widespread sites (4). By the 1800s, tuberculosis was epidemic throughout 
Europe and known as ‘the white plague’ for the romanticised white 
appearance of its victims (2,5). The mortality rate in cities across Europe and 
America was as high as 800-1000 deaths per 100,000 per year (6,7). René 
Théophile Hyacinthe Laennec, a French anatomist and the inventor of the 
stethoscope, described the pathogenesis of TB and the physical signs of its 
pulmonary manifestation in a book first published in 1819. This initiated the 
modern understanding of tuberculosis and introduced many of the terms 
used to describe it today (8,9). The understanding of TB aetiology remained 
poor and there was division in opinion as to whether tuberculosis was an 
inherited or an infectious disease. In 1865, the infectious aetiology of 
tuberculosis was demonstrated experimentally by a French surgeon, Jean-
Antoine Villemin, who inoculated a rabbit with the liquid of a tuberculous 
cavity and then that it had developed tuberculous lesions three months later 
(10). Only a year later, William Budd published that TB “is disseminated 
through society by specific germs … cast off by persons … suffering from the 
disease” (11). Robert Koch developed methods for isolating pathogens in pure 
culture and hypothesised that an organism he had grown in the laboratory 
could cause TB, and went on to demonstrate this using guinea pigs (2,12,13). 
He gave this organism the name Mycobacterium tuberculosis.  
 
By the mid-19th century, mortality rates associated with TB had begun to 
decline in Europe and America. This decline is still continuing (14). Although 
the reason for this 19th century decline is yet to be concluded upon, it is thought 
to be associated with improved living conditions, better nutrition and herd 
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immunity from long-term natural selection of a more resistant human 
population (15). The first anti-TB drugs were developed in the 1950s and 
public health measures have further reduced the disease burden in developed 
countries. These measures led to only modest decreases relative to the 
enormous decline in the 19th century (16). A high burden of TB remains in 
some parts of world, where the consequences of poverty - poor sanitation, 
poor nutrition, poor living conditions and poor access to healthcare - and a 
high prevalence of HIV underlies transmission and infection with the disease 
(2). 
1.3 Clinical features, aetiology and transmission 
1.3.1 Presentation 
Tuberculosis can present as latent or active disease. Around a third of the 
global population is estimate to have latent infection, where the tubercle 
bacilli are present in their bodies but do not cause symptoms or disease. Only 
5-15% of people infected with TB will develop active disease that causes 
illness and may result in transmission (1,17). Active disease most often 
manifests as a respiratory condition causing a cough that may produce 
sputum or blood, fatigue, chest pain, fever, night sweats, loss of appetite 
and/or weight loss and without treatment almost certainly leads to death. In 
15-20% of people with active disease the infection affects extra-pulmonary 
locations (EPTB), most commonly the pleurae, central nervous system, 
lymphatic system, genitourinary system, bones and joints, each with a 
different clinical manifestation (18). Miliary tuberculosis is characterised by 
many tiny tuberculous lesions distributed throughout the body though it is 
classified as pulmonary TB since some lesions appear in the lungs (19). Some 
patients present with TB at multiple sites due to metastatic spread of the 
disease after the initial infection.  
1.3.2 Aetiology  
Tuberculosis disease is caused by organisms in the Mycobacterium tuberculosis 
complex (MTBC), a group of bacteria from the genus Mycobacterium, the 
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family Mycobacteriacaea, the order Actinomycetales and the phylum 
Actinobacteria. Whilst the MTBC originally included only M. tuberculosis 
sensu stricto and M. bovis (20), it now encompasses a number of species or 
‘ecotypes’ each with a primary host association (21).  
 
M. tuberculosis (Mtb), M. africanum (Maf) and the ‘smooth tubercle bacilli’, 
including M. canettii, are adapted to primarily infect humans. They are 
considered almost obligate human pathogens given they are not known exist 
in any substantial non-human reservoir and transmission of their diseases 
cannot be sustained in animals. Most human disease is caused by Mtb, but 
Maf is responsible for a significant proportion of disease burden concentrated 
in West Africa (22). There are two Maf sub-types with distinct geographic 
restrictions: M. africanum type 1 (M. africanum 1, lineage 5) dominates in the 
east West Africa and M. africanum type 2 (M. africanum 2, lineage 6) dominates 
in west West Africa, with overlap mainly in Ghana and Benin in south West 
Africa (23,24). Maf causes variable proportions of total tuberculosis disease 
throughout the region, from 31% of all TB cases in Mali and Burkina Faso, up 
to 66% in Benin (22). Outbreaks of Maf have also occurred outside the region, 
including an outbreak of Maf 1 in France with a Brazilian index case (25). The 
mortality rate in HIV-negative people treated for M. africanum is very similar 
to that when infected with Mtb at around 3% (26). Maf is generally considered 
less virulent than Mtb, given that 
• Although Maf is efficiently transmitted from human-to-human through 
aerosols, exposure to Maf is less likely to lead to infection than exposure 
to Mtb. Reduced pathology in Maf relative to Mtb leads to comparatively 
low transmission rates for Maf with the likelihood of transmission 
correlated with proximity of contact  (27). 
• People infected with Maf tend to be less immunologically robust than 
people infected with M. tuberculosis: A survey in The Gambia showed 
that the species has a greater tendency to infect people who are older, 
malnourished or HIV-positive (22), although a study in Ghana found the 
species has no preference for HIV-positive people (28). The fact that 
people become diseased at a greater age may reflect the slow progression 
of the disease. 
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• Relative to people with Mtb, patients infected with Maf are less likely to 
experience symptoms within 2 years (27) and reactivated disease is more 
common than a recently transmitted infection (28). 
• Maf grows more slowly than Mtb, taking approximately 10 weeks to 
culture relative to ~4 weeks for Mtb (29,30). 
Infection with the smooth tubercle bacilli is considered rare with around sixty 
cases of tuberculosis caused by M. canettii having ever been found, 
predominantly in Horn of Africa or in cases with links to this region (31).  
 
The other members of the MTBC are considered to be predominantly 
associated with animals. M. bovis widely infects cattle across the globe though 
it has a much broader host range including other livestock and wild animals. 
Other animal-associated MTBC species include M. microti (voles) (32,33), M. 
caprae (goats) (34), M. pinnipedii (seals) (35), M. suricattae (meerkats) (36), M. 
mungi (banded mongooses) (36), M. orygis (antelopes) (37), ‘the dassie 
bacillus’ (36) and ‘the chimp bacillus’ (38) that hae not been found to cause 
frequent zoonotic infection. The M. bovis Bacillus Calmette–Guérin (BCG) 
vaccine is also considered part of the MTBC, having been derived from M. 
bovis. It causes disease known as BCGosis in some immunocompromised 
individuals. 
 
Several other members of the genus Mycobacterium are collectively known 
as non-tuberculous mycobacteria (NTM), mycobacterium other than 
tuberculosis (MOTT), environmental mycobacteria or atypical mycobacteria. 
These do not cause tuberculosis in the strict sense, although some species may 
cause pulmonary disease that closely resembles it. Each species persists in its 
own niche environmental reservoir(s), including soil and water. The 
prevalence of pulmonary disease caused by NTMs is as high as 15% of 
suspected TB cases in Nigeria (39) whilst in the USA the prevalence was 47 
people per 100,00 in 2007 (40). NTMs pose a serious public health threat of 
their own, but owing to significant differences to TB disease, including 
treatment regimens, they are not addressed as part of the global epidemic of 
TB. 
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Recognising the aetiological species causing tuberculosis is important for 
appropriate treatment of infection. It is also necessary for implementing 
public health interventions to prevent further cases of disease arising in the 
population. 
1.3.3 Transmission  
Pulmonary TB, responsible for the over-whelming burden of global 
tuberculous disease, is spread by aerosolised droplets containing the 
pathogenic bacilli. Most commonly, these droplets are dispersed from 
infectious people by coughing—a symptom of pulmonary TB—but they can 
also be spread after sneezing, talking, spitting and singing (1). People may 
transmit bacilli when active TB that remains untreated or partially or 
improperly treated. This type of transmission requires that people are in close 
proximity since droplets will fall to the ground within a few feet. Since the 
infectious dose is very low, potentially a single bacillus, infectious patients 
are estimated infect as few as 10-15 people with each year of active disease 
(41).  
 
Some individuals are thought to spread more TB than others, especially those 
with smear-positive TB (42) or lung cavities, large gas-filled spaces caused by 
tissue necrosis  which accumulate bacilli that are readily expelled on coughing 
(43,44). In contrast to its effect on other diseases, HIV-TB co-morbidity is 
associated with lower rates of TB transmission, perhaps due to the lower 
prevalence of cavitary TB amongst people with low cluster of differentiation 
(CD)-4+ counts a consequence of untreated HIV (45).  
 
Human-to-human transmission is not typically observed with extra-
pulmonary TB so the patient is not considered infectious (46). A recent case 
of nosocomial transmission illustrates that this may occur in rare instances; a 
nurse, who nine months after dressing the suppurating nodes of the first 
extra-pulmonary TB patient, presented with peritoneal M. tuberculosis of the 
identical strain type as this original EPTB patient (47). Zoonotic transmission 
from diseased animals, most commonly cattle, occurs through direct contact 
with the animal or by consumption of its meat or unpasteurised milk (48). 
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Zoonotic TB is commonly associated with MTBC species other than M. 
tuberculosis or M. africanum and with extra-pulmonary disease (49). Since the 
introduction of pasteurisation, the incidence of human M. bovis cases has 
decreased in high- and middle-income countries (48).  
1.3.4 Pathogenesis 
The clinical outcomes after exposure to tuberculous mycobacteria are highly 
variable and are dependent on the interactions of the host immune system 
with the microbial virulence factors. Since the molecular bases of these 
interactions are not central to this thesis, they are summarised here only 
briefly in the text and in terms of their clinical and immunological outcomes 
in Figure 1.2. 
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Figure 1.1:  The spectrum of host-mycobacteria interactions in tuberculosis disease, adapted from Barry et al  (50) Within the 
tuberculosis disease spectrum, clinical classifications of disease are associated with dynamic states as mycobacteria interact with the human 
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After mycobacteria are inhaled into a human host, they are phagocytosed into 
alveolar macrophages initiating the innate immune response. Despite 
prolonged exposure to contacts with infectious tuberculosis, some people 
have delayed or absent tuberculin skin test (TST) conversion, which detects 
the biomarkers of the adaptive immune response to mycobacteria (51). This 
indicates that their innate immune responses alone may be sufficient to kill 
mycobacteria cells prior to initiating the adaptive immune response. People 
achieving early clearance of the pathogens in this way, are then considered 
‘putatively uninfected’; this phenomenon has been observed in populations 
across Africa, Asia and America since the 1930s (52,53). 
 
Should mycobacteria not be cleared from the body by the innate immune 
response, a further cascade of adaptive immune responses can be initiated. 
Clinically, these are described in a bimodal model as either latent or active 
disease (50). Latent disease is characterised by absence of symptoms but the 
detection of a mycobacterial specific immune response by either a tuberculin	
skin	 test	 (TST)	 or	 the	 interferon-gamma	 release	 assay	 (IGRA),	 discussed	 in	
section	 1.5.1.1.	 In active disease, replication of the mycobacteria is not 
controlled by the host immune response and infected people are able to 
transmit the disease via aerosolisation mechanisms, typically coughing. By 
comparison, latently infected individuals are non-infectious, due to control of 
replication and often containment of mycobacteria within caseous 
granulomas (54).		
	
This	 bimodal	 clinical	 model	 of	 tuberculosis	 disease	 fails	 to	 reflect	 the	 broad	
range	 of	 host-pathogen	 interactions	 that	 results	 from	 exposure	 to	 TB.	 This 
diversity of interactions creates heterogeneous microenvironments in which 
mycobacteria reside leading to a variety of mycobacterial phenotypes 
including slow replication, non-progressing ‘percolating’ infection or 
diminishing virulence in the latent phase (55). As a result of these diverse 
interactions, a number of immunological states may occur within the clinical 
latent phase, summarised in Figure 1.2. Contrary to earlier assumptions about 
latency, it is unclear whether mycobacteria ever actually adopt a state that 
might be considered ‘dormant’. Latent disease includes people who were 
infected but no longer harbour the pathogen because the infection was cleared 
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after initiation of the adaptive immune response. They are clinically 
considered latently infected since they have the biomarkers targeted by TST 
or IGRA tests but this is simply an acquired response phase that may not lead 
to replication of bacilli (53). Should infection not have been eliminated by 
either the innate or adaptive immune responses, the quiescent phase 
commences where the mycobacterial population is at a constant size but is 
continually active and it may be said to occupy a ‘persister’ state (56). That 
the bacteria are still replicating during the latent phase is indicated by the 
accumulation of genetic mutations during this period in the absence of 
disease symptoms (57,58). A growing population of mycobacteria is 
considered active infection and part of the clinically latent phase as no 
symptoms of disease are present. Spontaneous deactivation, where activated 
disease becomes inactive, has been reported to occur in up to 50% of patients 
prior to the introduction of antibiotics in the 1950s (59). This state is different 
from latency in that chest x-ray abnormalities are present.  
 
An important element of mycobacterial infection and pathogenesis is the 
potential dissemination of disease throughout the host beyond the lungs. 
After the initial infection of alveolar macrophages, mycobacteria replicate and 
survive by modulating phagosome trafficking	 via	 inhibiting	 fusion	 of	 the	
phagosome	 and	 lysosome	 (60). Some infected macrophages also leave the 
granuloma early in infection, disseminating through the lungs and blood and 
seeding secondary granulomas, first in the pulmonary lymph nodes, then in 
the liver and spleen (61,62). These secondary sites of infection may result in 
disseminated active disease, known as extrapulmonary TB, but most often 
remain sites of latent infection and have a role in activating the adaptive 
immune response (63,64). 
 
Fitting with the binary interpretation, the transition from a clinically latent 
state to an active one is known as reactivation. Reactivation may occur after 
decades of latent infection, triggered by weakened immune control over the 
infection associated with a number of risk factors. The only well-established 
mechanisms for reactivation are associated with HIV and anti-tumour 
necrosis factor (anti-TNF) treatments. They lead to low CD-4+ counts (65) and 
neutralised TNF (66) respectively, that impair the adaptive immune response 
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after infection has been established. These, along with other risk factors, 
account for just a minority of reactivated infections.  
 
The interactions of mycobacteria and the host immune response throughout 
pathogenesis are complex and lead to a spectrum of immunological states, 
clinically summarised as active and latent disease. This broad spectrum of 
states has equally diverse implications, including which patients may 
progress to active disease, respond to preventative therapy or relapse after 
treatment of active disease (67). 
1.4 Treatment and drug resistance 
Without treatment, the death rate from tuberculosis is high given that about 
70% of smear-positive people and 20% smear-negative-culture-positive 
succumb within ten years (59). The aim when treating tuberculosis is to rid 
the patient of the infection whilst avoiding adverse side-effects, such that the 
patient survives and further transmission of the disease is avoided. Such 
treatment relies on antibiotic drugs that are able to combat the aetiological 
MTBC organism. Owing to the unusual multi-layered structure of the 
mycobacterial cell wall, these antibiotics are distinct from those used to treat 
other bacterial infections. The particular drugs and the combinations used in 
a treatment regimen vary depending on the manifestation of disease or the 
species and drug resistance profile of the aetiological organism. Neither M. 
bovis nor M. canettii can be treated by pyrazinamide, a drug that is ideally used 
in all other treatment regimens except where it is contraindicated. Failure to 
identify M. bovis has led to treatment with regimens including pyrazinamide 
and fatal consequences (68). Some MTBC strains have also evolved drug 
resistance to particular agents, as discussed further below, which further 
restricts antibiotic choices. 
 
For patients with no TB symptoms, positive IGRA or TST and normal chest 
X-ray, latent tuberculosis can be diagnosed. This may be treated to prevent 
activation of the disease or the infection may be left untreated depending on 
the balance of benefits and harms of treatment and the length of time since 
the initial exposure (69). The WHO recommends one of four regimens to treat 
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latent TB including isoniazid monotherapy, rifampicin monotherapy or a 
combination of rifampicin and isoniazid (69).  
 
1.4.1 Acquisition and transmission of drug resistant 
strains 
Some strains of tuberculosis have acquired resistance to one or many of the 
antibiotic agents used to treat the disease. There are two mechanisms by 
which resistance develops in strains. The first is directly through genetic 
mutations by Darwinian evolution with inadequate antibiotic therapy 
providing a purifying pressure to select drug resistant strains. Inadequate 
treatment includes poor adherence to drugs and sub-therapeutic doses or 
pharmacokinetic variability owing to non-optimised dosing (70). It was 
exacerbated by early monotherapy treatments. The rate of genetic mutation is 
high in tuberculosis and mutations even develop during latency that cause 
drug resistance (57,70–74). Multiple drug resistance may have developed 
incrementally through this mechanism, given the heritable nature of genetic 
mutations, with one drug resistance mutation after another being introduced 
to the strain, presumably as a result of continued or repeated episodes of 
inadequate treatment (75). The second mechanism is via epigenetic changes 
in gene expression or protein modification that lead to phenotypically drug 
tolerant, non-growing persister bacilli (76–78). The presence of persisters 
requires longer durations of treatment and is associated with increased risk 
of relapse after successful treatment (79,80). A phenotypic change in this way 
may simultaneously facilitate tolerance to multiple drugs and may eventually 
lead to the development of genetic drug resistances for one or more drugs 
(70,81). Resistance can evolve dynamically in a single organism by both 
mechanisms (82). 
 
The mutations underlying genetic resistance have not all been identified and 
it is increasingly becoming clear that the relationship between a resistance-
associated mutations and drug resistance phenotype is complex. Thus far, 
there are in excess of 100 genetic loci that have been associated with resistance 
(83–87). Clinical resistance to one given drug may be caused by one or a 
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number of mutations and may involve many genes (88). Though the genetic 
basis of resistance is relatively well understood for rifampicin, isoniazid, 
further investigations to identify the genetic basis of resistance to other drugs 
need to be conducted (1). From what we know so far, some resistance-
associated mutations directly cause the resistance, others compensate for the 
loss of fitness or virulence associated with the resistance and some may be 
passenger mutations (89,90). Notably, confusion has occurred as some 
mutations in genes associated with drug resistance have been associated with 
particular lineages but not had any impact on resistance phenotypes (86).  As 
such, when resistance-associated mutations are identified, their role in the 
resistance phenotype must be evaluated though studies of functional or 
structural impacts or by allelic exchange (91). Genetic mutations associated 
with drug resistance are more likely to be acquired into particular genomic 
locations, such as genes associated with cell wall permeability phenotypes, 
transcriptional regulation and DNA repair (92), and in particular genetic 
backgrounds, such as the Beijing lineage which has a disproportionate 
abundance of MDR/XDR strains (93–95). 
 
Any TB strain, including those with drug resistance mutations, can be 
transmitted from person-to-person spreading the disease. Transmission of 
drug resistant strains has been thought to be reduced relative to drug 
sensitive strains (96) and the abundance of drug resistant strains has been 
attributed to acquired resistance. A number of studies using high-resolution 
methods to analyse transmission have shown that the majority of drug 
resistance in the populations that they have studied can be attributed to 
transmitted resistance, challenging this prior notion (75,83,97–102). Strains 
with drug resistance may be particularly prone to transmission given 
prolonged delays at diagnosis, longer duration of treatment and increased 
likelihood of treatment failure. Though drug resistant strains can be 
identified, the global burden from strains that have acquired resistance within 
the patient versus those where the drug resistant strains have been 
transmitted to the patient is unclear. It is important to understand the 
derivation of this resistance for public health purposes as distinct 
interventions are required depending on whether resistant strains are being 
acquired or transmitted in the given population (75,103). 
  16 
1.4.2 Clinical classifications of drug resistant strains 
Considerations when choosing the drugs and treatment regimen for a patient 
with active tuberculosis include the known or expected susceptibility profile 
of the infecting organism. This drug susceptibility profile should ideally be 
determined using diagnostic approaches as described in section 1.5.1.2.  Drug 
susceptibility testing (DST) is not available in all countries and it is only 
considered reliable and reproducible for rifampicin, isoniazid, 
fluoroquinolones and the injectable agents (104–106). When drug 
susceptibility testing is unavailable, resistance may be predicted based on 
recent surveillance data and the patient’s clinical history including whether 
they have previously been treated for TB or have had significant contact with 
a patient with known drug resistant TB or are failing to respond to treatment 
(107).  
 
The drug resistance profiles of tuberculosis strains are classified into groups 
for the purposes of patient management and surveillance. TB is classified by 
the WHO (108) as  
• Drug sensitive (DS) when it is not resistant to rifampicin (RIF) 
• Rifampicin resistant (RR) when resistant to rifampicin, but not isoniazid 
(INH), and any other antibiotic agents 
• Multidrug resistant (MDR) when resistant to at least rifampicin and 
isoniazid. 
• Extensively drug resistant (XDR) when resistant to rifampicin, isoniazid, 
a fluoroquinolone (FLQ) and an injectable agent, (amikacin (AMI), 
kanamycin (KAN) or capreomycin (CAP))  
Other classifications are used, including 
• Pre-extensively drug resistant (Pre-XDR) when resistant to rifampicin, 
isoniazid, a fluoroquinolone or an injectable agent (109). 
• ‘Extremely drug resistant (XXDR) TB’ and ‘Totally drug resistant (TDR)  
TB’, both proposed in response to cases resistant to all first- and second-
line drugs tested (97,110–112). 
There is on-going debate about how to classify strains that are considered 
more resistant than XDR-TB (113,114). The WHO has been reluctant to name 
these given issues with the concept of ‘total’ resistance for a number of  
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reasons: it is subject to drugs and DST available in-country; DST for second-
line drugs has issues with reliability and reproducibility; there is no 
consensus on methods or critical concentrations of DST and the term may fuel 
stigma around the disease (115–117). Additionally, the relationship between 
DST results and clinical responses has not been established for all drugs. 
Acknowledging the inadequacies of DST and national drug availability, 
patients who cannot be treated have been considered to have 
‘programmatically incurable tuberculosis’ (114,118–121). The drug resistance 
classifications used both inform clinical choices about patient treatment and 
are useful for epidemiology, public health interventions and research.  
1.4.3 Treatment regimens 
The first-line drug (FLD) regimen for adults consists of two phases: The first 
‘intensive’ stage uses isoniazid (H), rifampicin (R), pyrazinamide (Z) and 
ethambutol (E) daily for two months; the second ‘continuation’ stage then 
follows with only isoniazid and rifampicin three times per week for a further 
four months (104,122). Ethambutol may be continued for the full six months 
in settings with high levels of INH resistance and where INH testing is not 
implemented (104,122).  
 
There are now two second-line drug (SLD) regimens, a shorter and longer 
one, used for people with drug resistant tuberculosis, including RIF 
monoresistance. For people with pulmonary RR- or MDR-TB, less than one 
month of previous exposure to SLDs, no resistance to FLQ or injectable agents 
and without known or strongly suspected resistance to any of the drugs to be 
used, the shorter regimen of 9-12 months may be followed (107). DST against 
FLQ and injectable agents is recommended prior to commencing this 
treatment, in addition to DST for RIF and INH (107). This involves a four- to 
six-month intensive phase using gatifloxacin or moxifloxacin, kanamycin, 
prothionamide, clofazimine, pyrazinamide, ethambutol and high-dose 
isoniazid, until conversion to sputum smear-negative (see section 1.5.1.2). 
This is followed by a five-month continuation phase of gatifloxacin or 
moxifloxacin, clofazimine, pyrazinamide and ethambutol. No drug may be 
substituted or excluded from this regimen (107).  
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For people with strains resistant to rifampicin (RR-, MDR-, Pre-XDR and 
XDR-TB) who are not eligible for the shorter regimen whether HIV positive 
or negative, the longer regimen is used (107). This has an eight-month 
intensive phase using at least five drugs to which the strain is susceptible, 
ideally including the group D1 agents, pyrazinamide plus high-dose 
isoniazid and/or ethambutol for patients with RR- or MDR-TB without high-
MIC isoniazid resistance, and four further agents (Table 1.2), of which one 
should be from group A, one from group B and two from group C. If owing 
to further drug resistance or drug availability this may not be possible, then 
one agent from group D2 and others from group D3 should be added to total 
five drugs (107). Pyrazinamide is added routinely unless contraindicated by 
evidence of resistance by reliable DST or expectations or risks of significant 
toxicity, in which case a further agent from group C or D may be substituted 
(107). After the initial treatment phase, a less intense regimen is continued for 
a total duration of 18-24 months, typically around 20-months, in patients who 
have not been previously treated for tuberculosis but this may be guided by 
monitoring the patient’s response to therapy (123). For patients who have 
previously been treated for TB, the duration of treatment is guided by the 
patient’s response to treatment but optimal likelihood of treatment success 
was found after 27.6 and 30.5 months of treatment (124). For patients with 
pre-XDR- or XDR-TB treatment options are severely limited so inclusion of 
group D2 and D3 agents is almost always necessary and often drugs are used 
at the highest doses that patients can tolerate (107). For these strain 
classifications, use of more drugs is also associated with increased likelihood 
of treatment success (107,118). With increasingly drug resistant strains and 
access to some drugs being severely limited in many countries, some patients 
are considered programmatically incurable then discharged into the 
community until their death (121). Using the national or subnational drug 
resistance surveillance data, a standardised SLD regimen may be developed 
for use in specific countries (104). 
 
Table 1.1: Drugs recommended in the longer treatment regimen for drug 
resistant tuberculosis At least five drugs to which the strain is susceptible should 
be used in the longer treatment regimen, ideally including the group D1 agents, one 
drug from group A, one from group B and two from group C. Drugs in group D2 
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and D3 provide further treatment options to overcome limitations imposed by 
resistance to preferred drugs.  
Group Drugs 































*Carbapenems to be used with clavulanate, formulated as amoxicillin-clavulanated; † Drugs 
in group A and C presented in order of preferred use; §Thioacetazone must not be used in 
HIV positive individuals 
 
The choice of regimen may also be influenced by factors including the 
patient’s needs and likelihood of treatment success (104). The FLD and shorter 
SLD regimens are standardised and drugs cannot be substituted (107). They 
were designed to maximise the rate of treatment success, minimise severe 
adverse side effects and reduce the likelihood of acquisition of drug resistance 
in the strains, however they cannot be tailored to the specific 
contraindications of the patient. The longer SLD regimen is adaptable in the 
drugs used and the duration of treatment such that only agents expected to 
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be effective are used and the balance of benefits of treatment to harms of 
adverse side effects can be obtained. This can  also accommodate various 
patient groups including children, pregnant women and those infected with 
extra-pulmonary tuberculosis (107). Additionally, the regimen may be 
designed with consideration of difficulties with drug availability, financial 
costs, suitable preparations and dosages for children and quality assurance of 
the drug (107). Global treatment outcomes are reported as 85% success for DS-
TB using FLD but only 54% for RR/MDR-TB and 30% for XDR-TB, both of 
which are treated with SLD therapy (however, these statistics are based on 
studies prior to the introduction of the shorter SLD regimen and regrouping 
of drugs in the longer SLD regimen) (1). For patients meeting the inclusion 
criteria for this new shorter SLD regimen, the treatment success rate of 90% 
(patients cured and those who completed treatment, not those who relapsed, 
died or whose treatment failed) was significantly improved relative to the 
success rate of longer regimens at 78% (15). Additionally, these shorter 
regimens using less toxic drugs were associated with higher rates of treatment 
adherence and a lower financial cost per patient at US$1000 for the shorter 
SLD regimen versus US$2000-5000 for the longer SLD regimen (1). 
 
Treatment of RR/MDR-TB may include partial lung resection in addition to 
SLD therapy for HIV negative patients. This is associated with higher rates of 
treatment success than chemotherapy alone, though this may be because of 
patient selection bias in that only patients who were fit enough for surgery 
could undergo this treatment. It is not associated with decreased risk of death 
however, though this could be due to patient selection bias again should the 
patients selected for surgery have been more unwell than those who received 
drugs alone. Without knowledge of the patient prior to surgery, the relative 
performance of this treatment versus drug therapy alone cannot be evaluated 
(107).  
1.4.4 New drugs and regimens in the development 
pipeline 
Drug resistance really threatens our ability to effectively treat tuberculosis. As 
strains evolve further resistance, they become more difficult to effectively 
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characterise and treat with effective antibiotics. There is evidence that 
programmatically incurable strains are being transmitted throughout society 
(125) and the emergence of strains that may be resistant to all existing 
antibiotics would make curing these patients medically impossible. There is 
an arms race between tuberculosis evolving new drug resistance and 
clinicians which can only be won by development of new drugs, optimising 
drug dosages and defining improved treatment regimens. There are a number 
of new drugs in the development pipeline from the discovery stage up to 
stage 3 clinical trials (126), including those in new chemical classes, and these 
provide hope for additions to the treatment arsenal for the foreseeable future. 
The recent inclusion of bedaquiline and delamanid for treatment of DR-TB 
marks a success of these endeavours (107). The attrition rate from the pipeline 
is high so continuing discovery of new compounds is essential to sustain this 
success. Similarly, new treatment regimens are being trialed with the aim to 
increase treatment efficiency and the likelihood of successful treatment 
outcomes, reduce adverse side effects and emergence of additional resistance 
and decrease treatment time with a number of new regimens in the pipeline 
(127). The shorter SLD regimen for treatment of DR-TB was a product of such 
trials, being release in May 2016 (107). 
1.5 Diagnosis of tuberculosis 
1.5.1 Current diagnostic methods endorsed by WHO 
Diagnosis of tuberculosis is paramount both to patients being cured and the 
epidemic of disease being managed. Depending on the way that patients 
present to the healthcare setting, they may be assessed using immunological 
assays, chest X-rays, patient history and/or variable laboratory analyses.  
These might seek to identify any infection with MTBC, to differentiate latent 
disease from the active form, to identify active tuberculosis from other clinical 
infections or to characterise the aetiological mycobacteria. For active disease, 
the ideal diagnostic outcomes would be to detect tuberculosis, identify the 
aetiological species, test the drug susceptibility of the strain(s) and 
epidemiologically type the sublineage (128). These steps are not all routine 
globally, given limited resources and the obligation to prioritise healthcare 
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efforts (129). Detection of MTBC tends to be prioritised followed by drug 
susceptibility testing (DST). The World Health Organisation (WHO) endorses 
diagnostic tools for use under prescribed circumstances, after evaluating their 
accuracy and impact on both patients’ clinical outcomes and public health 
(105). Though national tuberculosis programmes may use diagnostic methods 
that have not been endorsed, the focus of this review is on only the superior 
methods that have gained WHO recommendation. 
1.5.1.1 Diagnosis of infection and active disease using host 
responses 
Immunological assays are used to identify people who are clinically 
considered infected with M. tuberculosis, regardless of whether the disease 
might be latent or active or where in the body infection may be. There are two 
assays that are used routinely depending on the income level of the country 
(69). The tuberculin skin test (TST) involves intradermal injection of 
tuberculin purified peptide derivative (PPD) into the forearm of the patient. 
Should a patient possess acquired immunity to mycobacteria, a larger hard, 
red raised induration will form at the injection site by 48-72 hours after 
administration. A positive test result depends on size of the induration 
relative to risk-stratified cut-offs determined locally and pre-test risk of 
infection (130,131). A limitation with TST is that PPD antigens are not specific 
to MTBC that cause tuberculosis. Exposure to environmental mycobacteria or 
prior Bacillus Calmette–Guérin (BCG) vaccination will cause false positive 
reactions which are particularly problematic in countries close to the equator 
where people are more likely to be exposed to non-tuberculous mycobacteria 
(132,133). This non-specific reaction is not a problem with the interferon-
gamma release assays (IGRAs); these group of in vitro tests each measure the 
response to early secretory antigenic target ESAT-6 and culture filtrate protein 
CFP-10 that are produced specifically in MTBC organisms other than 
Mycobacterium bovis BCG (132). For this reason, IGRAs are more specific than 
TST as an indicator of tuberculosis infection, however they are only 
recommended by the WHO in higher income settings owing to their higher 
costs and other issues may mean that TST is a better choice (134,135). Neither 
TST nor IGRAs can differentiate people who are currently infected with 
  23 
tuberculosis from those who were previously infected but have acquired 
immunity (50).  
 
Chest x-ray (CXR) and patient history may be used to indicate active 
pulmonary tuberculosis. Patient history includes consideration of signs, 
symptoms (discussed in section 1.3.1), prior TB contact and social risk factors. 
Symptoms, and not necessarily all TB-associated symptoms, are only present 
in actively diseased patients and are not present in people who have latent TB 
(54). These symptoms are also common to other diseases and further 
investigation is necessary to confirm that a person does have tuberculosis, 
even after immunological tests have indicated that they have been infected 
with tuberculosis. Chest x-ray allows visualisation of the lung structure by 
passing electromagnetic x-ray radiation though the body, where different 
tissues types allow the radiation pass through to varying extents onto an x-
ray sensitive film or electronic detector (136). CXR can highlight show 
abnormalities in the lungs and has a high sensitivity for diagnosing TB. It can 
only be used to rule out pulmonary TB amongst differential diagnoses in a 
symptomatic person, however, as features on the radiograph are common to 
other diseases and it has a low specificity (137).  
The lateral flow urine lipoarabinamannan (LF-LAM) assay may be used for 
the diagnosis of TB in HIV positive patients who have low CD4 cell counts or 
are seriously ill (138). Urine is applied to the test strip, which detects the LAM 
antigen, released from mycobacterial cell walls during metabolic activity or 
dying cells. Whilst it has good specificity (96%), its sensitivity is very poor 
(23%) so other methods of detection, such as GeneXpert, smear microscopy or 
culture, should be used in addition to LF-LAM (138). Given such poor 
sensitivity, it is not suitable for TB screening. The sensitivity is much lower in 
patients who do not have HIV co-infection. It was recommended by the WHO 
given its simplicity, minimal biosafety requirements and low financial cost, in 
addition to implementation in many high-burden HIV settings prior to 
endorsement. 
 
WHO-endorsed diagnostics based on host responses or pathology are limited 
to only detecting tuberculosis infection or pulmonary abnormalities. When 
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active disease is suspected, all of the methods must be followed up with 
laboratory analyses. 
1.5.1.2 Microbiological detection and drug resistance testing 
Laboratory detection methods should be used to confirm active tuberculosis 
infection then ideally followed up with drug resistance testing. Until the last 
decade, diagnosis of tuberculosis had relied on the microscopy and culture 
approaches pioneered in the 1880s (13,139). Development of new diagnostics 
was revived after the first outbreak of XDR-TB, in South Africa in 2006 (140). 
This lead to the WHO endorsement of the further methods described here. 
Some are used to detect active tuberculosis and others for drug susceptibility 
testing, both for initial diagnosis of patients monitoring the infection 
throughout the patient’s treatment. DST includes both phenotypic and 
molecular approaches that generally perform well for RIF and INH, but 
poorly for other drugs. Molecular DST approaches fail to distinguish 
susceptibility between individual FLQ and the group of second-line injectable 
aminoglycoside drugs, though this is possible with phenotypic approaches 
using the same drugs as provided in local treatment regimens (117). 
 
The WHO describes laboratory testing as being conducted within a 
hierarchical network of laboratories at the (105): 
• Peripheral-level to service sub-districts and communities 
• Intermediate-level for regional and district service 
• Central-level (reference laboratories) 
These are guidelines, however, and the diagnostic methods used and 
intended outcomes (e.g. screening, case-finding, treatment follow up, 
surveillance) may not be the same throughout laboratories at a similar level 
in different countries or regions. The diagnostic tools available in a setting 
laboratory are subject to their ability to meet the needs of the epidemiological 
landscape of the region they serve, alongside limitations to financial support, 
trained laboratory staff, laboratory infrastructure and biosafety measures. In 
turn, this informs diagnostic algorithms that vary greatly between countries 
(105). 
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Smear microscopy is used to detect tuberculosis directly from sputum. The 
WHO recommends that two consecutive smears are assessed in the same day 
for TB to be diagnosed by this method (141). Sputum samples are prepared 
either with the Auramine-O or Ziehl-Neelsen (ZN) staining methods where 
the thick lipid-containing cell walls of mycobacteria preserve stains after 
decolourisation with acid, earning mycobacteria the name ‘acid-fast bacilli’ 
(AFB) (105).  The sputum preparations are visualised with a light-emitting 
diode fluorescence or Brightfield microscope, respectively, and TB is 
diagnosed after counting at least one AFB across 100 microscopic fields, in 
one or both smear preparations (141,142). Smear grades can be designated by 
the number of AFB seen and used as a proxy for bacterial load both to monitor 
the progress of treatment and as a guide to infectiousness (143,144). 
Conversion from smear positive to negative is used to determine treatment 
success. The Auramine-O procedure is considered more sensitive than ZN 
approaches and equally as specific (145) though the sensitivity of smear 
microscopy is generally low, requiring a minimum of 5000 AFB per millilitre 
of sputum to produce a positive result (105). It is expected that smear 
microscopy is available in every tuberculosis diagnostic laboratory and 
recommended that smear is performed as an initial diagnostic, at the end of 
the intensive phase of treatment and at treatment completion (105). 
 
Culture of mycobacteria can be undertaken on solid media or in liquid media, 
with the latter achieved manually or through automation. Sputum must be 
decongested and decontaminated prior to inoculation of the media to prevent 
over-growth of contaminants, though this may still occur. Cultures must be 
incubated at 36-37 °C for several weeks, requiring incubators to do this, and 
liquid cultures should be agitated continuously. Mycobacterial growth may 
be detected visually and confirmed with rapid immunochromatographic 
assays to confirm and identify mycobacteria or through automated detection 
of metabolites (146). Commercial liquid culture systems with automated 
detection of metabolites, such as the BD BACTEC™ MGIT™ automated 
mycobacterial detection system (Becton Dickinson) (BACTEC), 
revolutionised culture of MTBC by reducing time to culture positivity and 
providing increased culture yield relative to propagation on solid media 
(105,147). It came with the disadvantages of slightly decreased sensitivity, an 
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increased risk of contamination and higher biosafety requirements than solid 
media culture, also with increased financial expense. Culture-based 
diagnostics are available throughout most countries, regardless of income 
level, but not necessarily in every laboratory.  
 
Drug susceptibility testing can be conducted by incorporating drugs into the 
media used for culturing tuberculosis in a number of ways: 
• In the proportion method, a standardised inoculum of mycobacteria is 
grown on both drug-free and drug-containing solid media and the 
resistant proportion is determined by the relative number of colonies on 
each plate. When more than 1% of colonies are resistant (for RIF and 
INH), therapy is likely to fail and the patient should be treated with a 
drug resistant therapy regimen (148). Automated methods used 
modified versions of this approach (149–151). 
• The absolute concentration incorporates dilutions of the drug into solid 
or liquid media and adds a standardised inoculum of culture. The 
minimum inhibitory concentration is determined as the lowest 
concentration of the drug with which culture grows (152). 
• The resistance ratio method is as the absolute concentration method 
except it divides the MIC value of the clinical isolate by the MIC value 
for a susceptible strain. When the ratio is 2 or less the clinical isolate is 
considered susceptible and when the ratio is eight or more, the sample is 
considered resistant. Only inoculum size needs to be standardised in this 
approach (150,151). 
These methods represent the gold standard for DST, though they may fail to 
detect some mutations causing rifampicin resistance (153). Though many of 
the methods used are able to provide minimum inhibitory concentrations 
(MIC) for a particular strain against a given drug, resistance is defined using 
critical concentrations of the drug used by the WHO (154). These methods are 
slow, taking 9-12 weeks to produce a result using solid media or 3-5 weeks 
using liquid media (105,146). 
 
The Xpert MTB/RIF assay which automates a closed-cartridge nucleic acid 
amplification test using the multi-pathogen GeneXpert diagnostic platform 
was endorsed for use by the WHO in 2010 and recommended as an alternative 
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to smear microscopy in 2013 (155,156). It simultaneously detects the presence 
of MTBC species and predicts resistance against rifampicin directly from 
sputum or some extra-pulmonary clinical samples in less than 2 hours. 
Detecting rifampicin resistance is particularly important as it determines 
whether first- or second-line drugs should be used for the treatment of disease 
and indicates that further DST should be undertaken. An update of this 
product, the GeneXpert Ultra, was released this year (2017) improving the 
sensitivity of detection by 5%, particularly in children and HIV-infected 
people, though decreasing specificity by 3.2% due to increased detection of 
non-viable mycobacteria (157). This assay improves on the sensitivity of 
smear microscopy, making it an attractive alternative as a first-line detection 
tool when the additional expense, consumable reagents and local 
infrastructure are not prohibitive.  
 
Another smear alternative, the tuberculosis loop-mediated isothermal 
amplification (TB-LAMP) or Loopamp™ Mycobacterium tuberculosis complex 
(MTBC) detection kit, Eiken Chemical Company, was endorsed by the WHO 
in 2016 for detection of pulmonary TB (no DST) in patients with signs and 
symptoms suggestive of TB (158). It was recommended that this assay should 
not replace other rapid molecular tests that also detect rifampicin resistance, 
like the GeneXpert and despite lower financial costs of the assay, it is unclear 
whether it offers operational advantages over the GeneXpert assay. 
 
Line probe assays (LPA), such as the GenoType MTBDRplus assay (Hain 
Lifescience, Nehren, Germany), can be used as an initial test to determine 
genetic resistance to RIF, INH, FLQ, ETB and second-line injectable drugs 
(SLIDs) directly from smear-positive sputum or cultured MTBC isolates 
(106,159,160). Testing of these SLDs with LPAs can be conducted on smear-
negative sputum (106). LPAs involve DNA extraction directly from sputum, 
polymerase chain reaction (PCR) of the relevant resistance-determining 
region with biotinylated primers then application of the PCR product to test-
strip embedded with oligonucleotide probes. Hybridisation of the amplicon 
and probes will occur in the absence of resistance-associated mutations 
promoting colorimetric development on the test-strip indicative of drug 
sensitivity. They were endorsed by the WHO in 2008 for RIF and INH testing 
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then in 2016 for FLQ, ETB and SLID testing (106). LPAs provide a relatively 
rapid assessment of resistance to the most important drugs for determining 
which patients are suitable for shorter SLD regimen or which drugs may be 
suitable in longer SLD regimen. This method of DST may be completed in 24-
48 hours directly from sputum, though may not be suitable for use in 
peripheral-level laboratories given moderate needs for staff training, 
consumables, laboratory infrastructure and biosafety measures (105). Where 
available, LPAs should be used in preference to phenotypic DST. 
 
The WHO has recommended non-commercial DST approaches under highly 
specified circumstances for the detection of RIF and INH resistance (161): 
• The microscopic observation drug susceptibility (MODS) assay involves 
culture of decontaminated sputum or prior cultured isolates in liquid 
media with and without drugs. The cultures are visualised with an 
inverted microscope and resistance to the drug is determined by the 
characteristic cords of mycobacterial growth in both cultures with and 
without the drug (161). Susceptibility to the drug is indicated by the 
absence of growth in its presence but not in the drug-free culture. Growth 
may be detected in 2-21 days from inoculation with sputum or in 3-4 
weeks after inoculation with culture and requires significant training and 
moderate laboratory infrastructure, comparable with commercial liquid-
culture DST (105). 
• The nitrate reductase assay (NRA) exploits the biochemistry of 
mycobacteria since they reduce nitrate to nitrite during culture. Culture 
can be undertaken in the presence of the drug and growth of the 
organism, indicative of resistance to the drug, can be detected by 
colorimetric change that occurs by addition of Griess reagent (162). The 
NRA can be performed directly from sputum in 6-9 days or from culture 
in 7-11 weeks with minimal laboratory infrastructure and moderate 
needs for consumables, staff training and biosafety precautions, similar 
to solid culture of TB (105).  
• The colorimetric redox indicator (CRI) assay uses liquid cultures of 
mycobacteria and exposes them to the drug of interest. Colorimetric 
indicator added to the culture causes colour change that is proportional 
to the number of viable mycobacteria (105). This method is slow relative 
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to molecular tests or automated liquid-culture DST and requires a high-
level of biosafety precautions, but also less expensive and requires 
minimal infrastructure.  
These methods are suitable for use in intermediate-level and central 
laboratories as an interim option until the capacity for GeneXpert, LPAs or 
automated culture-based DST can be established (161). There are concerns 
about reproducibility of the MODS assay, NRA and CRI method alongside 
elevated issues with biosafety risks and staff training, relative to the 
performance of methods preferred by the WHO. 
 
There are a number of other short-comings amongst diagnostic tools that lead 
to substantial inadequacies in diagnosis throughout the world. Both the 
advantages and disadvantages of individual detection and DST method are 
summarised in Table 1.2 and 1.3, respectively. The main concerns are 
associated with accuracy and rapidity of diagnosis and the feasibility to 
implement these tools in all settings across the world. Collectively, these 
approaches also fail to provide clinically useful information about  
• susceptibility to all drugs used within the treatment regimens in a short 
time frame. Should drug resistance go unidentified, regimens including 
poorly suited drugs may be used and lead to treatment failure. 
• mixed infection. Infection with multiple strains of TB may impede 
adequate treatment if these have mixed clinical susceptibility, should the 
resistance not be detected (163). This may lead to fixation of resistance 
within the infecting TB population and to transmission of this resistant 
strain (164–166). 
• the species of infecting MTBC.  This is important as both M. canettii and 
M. bovis are intrinsically resistant to pyrazinamide (167). Unidentified 
infection with NTMs, may lead to use of typical drug regimens that are 
insufficient for their treatment (68,168). Immunocompromised 
individuals may also have become infected with the M. bovis Bacillus 
Calmette- Guérin (BCG) vaccine strain, an infection called BCGosis, 
which may offer the first indicator of their immune status. 
• epidemiological type of the strains that may inform local public health 
interventions (discussed further in section 1.5.3.1) 
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Even the most advanced diagnostic technologies implemented together are 
inadequate for providing all information required for prompt treatment of all 
patients. 
 
The diagnostic methods used and their roles in the diagnostic algorithm of a 
tuberculosis laboratory network vary between countries and sub-regions 
depending on the epidemiological demands of the area and resources 
available. In highly resourced networks, the most highly performing methods 
are used, including GeneXpert, rapid DST and gold standard DST by culture 
in the presence of further drugs (beyond RIF, INH, FLQ and SLIDs (154)), 
along with culture for subsequent epidemiological characterisation. In low 
resource countries, laboratories are limited to using the financially cheapest 
and least demanding diagnostic methods, which may simply amount to only 
smear microscopy. The capacity of most laboratories falls somewhere 
between these two ends of the spectrum.  
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Table 1.2: Advantages and disadvantages of diagnostic methods for the 





































































































* Improved sensitivity and specificity with GeneXpert Ultra, released 2017; information in 
table obtained primarily from WHO policy reports (105,158,161) 
 
Table 1.3: Advantages and disadvantages of methods used for drug 
susceptibility testing in MTBC 
Diagnostic 




diagnosis of drug 
resistant TB though fails 




• Slow  
• Suitable for use only in central 
laboratories 
• Accuracy of detection varies 
according to drug  
• Requires high-level of staff 
training 
• Extensive infrastructure required 




• Sensitivity: 95%* 
• Specificity: 98%* 
• Expensive 
• Tests for RIF resistance only 
• Requires stable electricity supply 
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Diagnostic 
method Advantages Disadvantages 
• Low biosafety 
precautions required 
• Minimal training 
required 
• May be used in low 
level laboratories 
• Room temperature around 
machine cannot exceed 30 °C  
• Cartridges must be stored below 
28 °C and used before expiry 
• A computer must accompany the 
device 
• GeneXpert system requires 
annual calibration 
• Assay must be repeated when 
RIF resistance is predicted in 
patients considered at low risk of 
drug resistance 
• Discordance with phenotypic 
DST may occur, requiring DNA 






• High sensitivity and 
specificity (variable for 
each drug) 
• Conventional culture and DST 
still required 
• Recommended for smear-positive 
sputum and Mtb samples only 
(for FLDs) 
• Suitable for use at 
central/regional laboratories only 
• Sensitivity for INH resistance 
lower than for culture methods; 
INH sensitive samples should be 
tested by culture-based DST, 
particularly in high INH-
resistance regions 
• Lower accuracy for determining 
MDR-TB than other methods 
• Culture still required for DST of 
other drugs; there are further 
disadvantages associated with 
culture. 
• 3 rooms with unilateral workflow 
required 
MODS 
• High sensitivity (98%) 
• High specificity (RIF: 
99%; INH: 91%) 
• Slow, though quicker than 
conventional culture directly 
from culture 
• Requires highly-skilled staff 
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Diagnostic 
method Advantages Disadvantages 





• Requires inverted light 
microscope, used uniquely for 
this TB diagnostic method 
• Moderate biosafety measures are 
required 
• Must be used at higher levels of 
laboratory network 
NRA 
• High sensitivity (97%) 
• High specificity (RIF: 
100%; INH: 99%) 





• Requires minimal 
infrastructure or 
equipment  
• Slow, though quicker than 
conventional culture directly 
from culture 
• Requires moderate staff skills 
• Requires inverted light 
microscope, used uniquely for 
this TB diagnostic method 
• Moderate biosafety measures are 
required 
• Must be used at higher levels of 
laboratory network 
CRI 
• High sensitivity (RIF: 
98%; INH: 97%) 
• High specificity (RIF: 
99%; INH: 98%) 





• Requires minimal 
infrastructure or 
equipment  
• Testing must be carried out on 
prior culture 
• Slow 
• Requires highly-skilled staff 
• High-level biosafety precautions 
are required 
• Must be used at higher levels of 
laboratory network 
* Improved sensitivity and specificity with GeneXpert Ultra, released 2017; information in 
table obtained primarily from WHO policy reports (105,158,161) 
1.5.1.3 Epidemiological typing of the MTBC 
Epidemiological typing is a useful part of the diagnostic paradigm that is 
often overlooked (128). Various molecular epidemiology techniques have 
been developed to discriminate between clinical strains of MTBC. These 
techniques are based on the genetic variations between strains of 
mycobacteria, both amongst the MTBC species and NTMs. While the MTBC 
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was thought to be genetically monomorphic until the 1990’s, recent 
techniques have instead highlighted their genomic diversity. Over time, the 
genetic resolution with which we can analyse these species has improved and 
it continues to expand our abilities to analyse transmission networks, to 
identify contamination and discriminate between relapse and re-infection 
(169–171),  
 
During the last few decades, various molecular techniques of DNA 
fingerprinting have been used to discriminate between clinical strains of 
MTBC. A subset of these are used more commonly in public health 
microbiology, including 
• IS6110 restriction fragment length polymorphism (RFLP) typing, 
developed in 1991 (172,173). It differentiates strains by the copy number 
and location of the insertion sequence(IS) 6110, a mobile genetic element 
found exclusively in the MTBC. The method is practically onerous, 
difficult to standardise for comparison between laboratories and not 
suited for strain classification (174). It has been beneficial to the study of 
transmission and to identify outbreaks (173,175–181).  
• Spacer oligonucleotide typing (spoligotyping), developed in 1997 (182). 
It is based on the presence or absence of (usually) 43 unique regions 
intercalated between direct repeats in the Clustered Regularly 
Interspaced Short Palindromic Repeats region (CRISPRs) of the MTBC 
genome. Relative to other classification methods, it is able to discriminate 
fewer lineages and these usually have low statistical support (174). 
Owing to its ease of use, cost-effectiveness, reproducibility, it has been 
widely adopted for use in laboratories (183) to provide groupings of 
genotype families, though it has limited use for understanding the 
phylogeny or transmission of strains. 
• Mycobacterial interspersed repeat-unit-variable-number of tandem-
repeat (MIRU-VNTR) typing (184,185), developed in 2006. This classifies 
MTBC strains by the number of tandem repeats at VNTR loci across the 
genome. Carrying out this strain typing is labour intensive but it is 
considered the gold standard approach epidemiological typing method 
for tuberculosis and its discriminatory ability increases with the rising 
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number of loci investigated (183).  The classifications are globally 
comparable. 
More recently, whole genome sequencing has been used to compare TB 
strains using two main genomic features. Region of Difference (RDs) or Large 
Sequence Polymorphism (LSP) (186) are deletions of genomic regions and 
unidirectional markers of evolution since horizontal gene transfer (HGT) is 
rare in the MTBC (187). As such, they were used to define six primary lineages 
within the MTBC which are each geographically associated with particular 
global locations and a seventh was later added (187,188). Single nucleotide 
polymorphisms (SNPs) are substitutions of individual nucleotides in one strain 
relative to another that have surpassed a critical frequency threshold in the 
bacterial population. Below this threshold, they are considered ‘mutations’ 
and the term ‘single nucleotide variant’ is used to define both SNPs and 
mutations (189). Owing to low SNP frequency and absence of HGT or genetic 
recombination amongst the MTBC, SNPs are reliable phylogenetic markers 
that help to resolve sub-lineages of MTBC and distinguish individual strains 
(190). Comas et al produced the first global phylogeny of the human-
associated MTBC derived from whole genome variants in 2010 (191), 
providing the basis for phylogenetic studies going forward. The numbers of 
SNPs that differentiate two strains, called the ‘SNP difference’, can be used to 
define outbreak populations and indicate direct transmission between 
individuals. Whole genome based epidemiological analysis is not available 
globally owing to the unaffordable costs of sequencing for much of the world, 
but it provides the ultimate genetic resolution with which to compare TB 
strains (192). 
1.5.1.4 New diagnostics in the development pipeline 
In 2016, there was a huge gap between the estimated incidence of 10.4 million 
tuberculosis cases and the 6.3 million new cases being reported (1). Rather 
than the target that every TB patient should receive a rifampicin susceptibility 
test, this was only the case for 41% of patients (1). These inadequacies prevent 
the timely diagnosis and treatment of patients from this curable disease. 
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Having evaluated the diagnostic tools available, there is evidently a lacking 
technical capacity for diagnosis of tuberculosis. New and improved tools are 
needed to circumvent the short-comings of those currently available. For this 
reason, target product profiles have been constructed to focus developers on 
the needs of the end users (193). Alongside targets for improved biomarker 
and triage tests, there is the aim to provide an upgraded test to replace smear 
microscopy for the detection of TB at point-of-care and to offer a rapid DST 
assay for detection of first-line drug resistance in peripheral-level 
laboratories. Fitting with this there are a number of rapid molecular tools 
scheduled for WHO evaluation in the next few years including sequencing 
technologies (discussed further in section 3.1.3), expansions of the GeneXpert 
system and other molecular drug resistance assays, some of which include 
resistance testing to confirm XDR-TB (1). This is just the tip of a 
comprehensive diagnosis pipeline that has a multitude of new products 
aiming to meet the target product profiles (193,194). 
1.6 Unmet needs and the global challenge 
Tuberculosis is now the leading cause of death from infectious disease (1). 
Despite being a treatable disease, it is one of the top ten causes of death 
worldwide and killed 1.7 million people in 2016 (1). Alongside this 
unacceptable burden of mortality, 10.4 million people are newly infected each 
year (1). For those individuals, life typically includes significant social, 
economic and psychological trauma alongside the severe symptoms of the 
illness.  
 
Tuberculosis was explicitly mentioned in the Sustainable Development Goals 
set out by the United Nations for the years 2015-2030 by calling for an “end to 
the epidemic”. In line with this, the Global Plan to END TB was developed 
with the goals to reduce mortality by 90% and the incidence rate by 80% 
relative to those in 2015 (195). To meet this, the annual decline in incidence 
rate must fall to 10% by 2025, according to models. To put the enormity of this 
challenge in context, a 10% decline has only ever been achieved in countries 
with well-performing universal health care and high levels of socioeconomic 
development. Steps to achieve these goals focus on early and comprehensive 
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TB diagnosis, actively finding cases amongst the people at highest-risk of 
disease, treatment of all disease including drug-resistant tuberculosis and 
latent disease in people at high-risk of progression to active disease, and 
implementation of an effective anti-TB vaccination. This is reliant on both 
socio-political support and significant research for implementation of new 
diagnostics, drug and vaccines, underpinned by an improved understanding 
of pathogenesis and epidemiology (195). 
1.7 Objectives and outline 
1.7.1 Thesis objectives  
Combatting the TB epidemic requires a new diagnostic approach that is 
timely, cost-effective, informative, sensitive, specific and feasible in resource-
deprived locations. Though the work presented in this thesis, I have taken the 
first steps in exploring shotgun (meta)genomics for this purpose. The 
overarching aims were to: 
1. Develop a clinically-feasible shotgun metagenomics method that could 
potentially diagnose infection with any pathogen from a clinical 
sputum sample, using tuberculosis diagnosis to illustrate this in 
principle (chapters three and four). 
2. Investigate the genotype-phenotype relationship in drug resistant 
MTBC in Peru (chapter five) 
a. Predict drug resistance profile using whole genome sequencing, 
including identification of novel mutations associated with 
pyrazinamide resistance. 
b. Evaluate the performance of drug resistance detection 
approaches. 
1.7.2 Thesis outline 
The work presented in chapters three and four was carried out in 
collaboration with colleagues in The Gambia. This West African country 
ranks 173 of 188 countries in the 2016 human development index, with a life 
expectancy of just 60.5 years and a mean of just 3.3 years of schooling (196). I 
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spent approximately a year in The Gambia developing methods for extraction 
of DNA directly from sputum such that MTBC organisms could be detected 
after shotgun metagenomic sequencing. The approaches that I took were 
feasible in this resource-poor setting within the facilities of the MRC Unit, The 
Gambia. Chapter three describes my initial attempts to identify a method of 
extracting DNA from sputum with which I could detect MTBC by 
metagenomic sequencing. In chapter four, I then attempted to optimise the 
method by addressing the biggest challenge to characterising the MTBC 
organisms, the overwhelming proportion of human DNA in the extract. 
 
A distinct project, presented in chapter five, addressed other challenges that 
need to be overcome before genomic and metagenomic approaches could 
fulfil their full clinical potential. This study was conducted in collaboration 
with researchers in Peru, using methods of phenotypic drug resistance testing 
and DNA extraction that are feasible in this resource-poor country. As yet, 
our understanding of the genetic basis of resistance is limited for some of the 
antibiotics used in anti-TB therapy, particularly pyrazinamide. In this study, 
we used numerous phenotypic methods for determining pyrazinamide 
resistance, as well as the MODS method for determining rifampicin and 
isoniazid resistance, and compared these outcomes with predictions made by 
bioinformatic software after whole genome sequencing of the cultured 
organisms. I then looked for new mutations in resistance-associated genes 
that had not been identified by the bioinformatic tools. This allowed me to 
evaluate both novel genetic patterns associated with resistance and the 
methods used for determining this resistance.  
 
In both projects, I was able to conduct cutting-edge genomic research in 
resource-limited developing countries, with exchanges of knowledge that 
benefitted both me and my foreign collaborators. My understanding of the 
limitations of tuberculosis diagnosis and healthcare in these countries has 
been expanded and I was able to train collaborators in DNA sequencing 
techniques and share my knowledge of genomics to colleagues in The 
Gambia.  
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2. Materials and Methods 
2.1 Ethical approvals 
The metagenomic projects described in chapters three and four were 
undertaken at the Medical Research Council Unit, The Gambia (MRCG) using 
sputum samples obtained in two on-going projects: 
• the Enhanced Case Finding project (197)  
• The Gambian Nationwide Tuberculosis Prevalence survey (GAMSTEP) 
(198)  
Through these parent projects, informed consent was obtained and six 
months of Directly Observed Treatment short course (DOTS) was provided 
free of charge by the National TB control Program for all participants. The 
sputum metagenomics investigations were approved by the MRCG’s 
Scientific Co-ordinating Committee under reference SCC 1232. 
 
Ethical approval for work on Peruvian samples, described in chapter five, was 
obtained from the institutional review board of Universidad Peruana 
Cayetano Heredia. Consent was not obtained from participants because the 
data were analysed anonymously after checking for duplicated patients. 
Institutional approval for the study was obtained from the Peruvian Ministry 
of Health. 
2.2 Microbiology 
All microbiology methods were undertaken by collaborators at MRCG for 
chapters three and four or Universidad Peruana Cayetano Heredia for 
chapter five. 
2.2.1 Smear microscopy for all chapters 
Aliquots of decontaminated sputum (see section 2.4.1.1) were stained with 
Auramine-O and evaluated by smear microscopy, according to standard 
procedures. In samples where acid-fast bacilli (AFB) were detected, Ziehl-
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Neelsen (ZN) staining was used to confirm and quantify the number of 
tuberculous bacilli present. ZN smear grades were given as +, ++ or +++ 
according to the number of ZN-stained AFB observed as specified in Table 
2.1. 
 
Table 2.1: Ziehl-Neelsen smear results and grades  
Sputum is graded by the density of acid-fast bacilli (AFB) observed with microscopy 
in the specified number of fields for that smear grade, as detailed below. 
AFB observed No. fields examined Result (grade) 
10 AFB per oil immersion field 20 
Positive 
(+ + +) 
1-10 AFB per oil immersion field 50 
Positive 
(+ +) 
10-99 AFB in 100 oil immersion fields 100 
Positive 
(+) 
1-9 AFB in 100 oil immersion fields 100 Scanty 
No AFB in 100 oil immersion fields 100 No AFB seen 
2.2.2 Mycobacterium tuberculosis complex culture: 
Chapters three and five 
At the MRCG, all diagnoses of TB were confirmed by culture of the M. 
tuberculosis complex. Sputa were decontaminated by the sodium hydroxide 
and N-acetyl-l-cysteine (NaOH/NALC) method as described by Kent et al 
(199). Decontaminated sputa were inoculated into the BACTEC™ MGIT™ 
960 System (Becton Dickinson) according to the manufacturer’s protocol. 
Subsequently, liquid culture was transferred to Lowenstein–Jensen (LJ) 
slopes for solid media culture.  In Peru, cultures from samples were obtained 
during the microscopic-observation drug susceptibility (MODS) assay 
described in section 2.2.3. Liquid cultures from the control tests, that did not 
use drugs, were sub-cultured onto solid LJ medium for further study. 
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2.2.3 Microscopic-observation drug susceptibility assay: 
Chapter five 
MODS testing was conducted on separate sputum aliquots for rifampicin, 
isoniazid and pyrazinamide as described by Caviedes (200) with the 
following modifications: 
• Sputum-medium mixture preparation: 2 mL of each decontaminated 
sputum aliquot was diluted in 15 mL of Middlebrook 7H9 broth 
containing a final concentration of 20 !l/ml PANTA Antibiotic 
Supplement Stock and 10% Oleic Albumin Dextrose Catalase. 
• Antibiotic testing: 900 µL of each sputum-medium solution was 
inoculated into five wells of a 24-well plate each with 100 µL drug 
solution, to result in a final concentration of either 0.4 !g/ml  
• , 1.0 !g/ml RIF, 400 !g/ml PZA, 800 !g/ml PZA or 100 µL 7H9 broth to 
act as a negative control.  
• Determining results: After five days, wells were examined every one or 
two days for the presence of mycobacteria under an inverted light 
microscope at x40 magnification. An aliquot was considered sensitive to 
the given drug after nine days of incubation without observed growth in 
its presence. Observation of microbial growth in the no-drug-control and 
in the presence of an antibiotic was determined as resistance to it. 
2.2.4 BACTEC 960 PZA resistance testing: Chapter five 
The BACTEC™ MGIT™ 960 PZA assay (Becton Dickinson, Sparks, MD) was 
performed on isolates from solid culture according to the manufacturer’s 
instructions using a critical concentration of 100 µg/ml pyrazinamide.  
2.2.5 Wayne’s pyrazinamidase assay: Chapter five 
The Wayne’s pyrazinamidase assay that measures activity of the pcnA gene 
as a proxy for determining pyrazinamide resistance, was conducted on 
cultured isolates in chapter five as described by Wayne (201). In total, two 
isolates from each sputum expectorate were subjected to this assay in separate 
tubes, the first was examined after four days, then again four hours later if 
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negative, and the second examined after seven days should the first have been 
negative both times. If a pink colour was present in either of these assays, the 
result was positive, indicating pyrazinamidase activity associated with PZA 
sensitivity. 
2.2.6 Spoligotyping: Chapter three 
Spoligotyping, used in chapter three, was undertaken from cultured isolates, 
which were derived from a single colony on solid medium, using standard 
protocol (182,202). 
2.3 Sample collection and handling  
2.3.1 Sputum samples: Chapters three and four  
Sputum samples were collected from participants in the ECF project at MRCG 
between February 2012 and February 2014 and from participants in the 
GAMSTEP survey between March and August 2015. Patient-identifying 
information was removed before samples were processed, but basic 
biographical details were retained. Participants included males and females, 
ranging in age from 16 to 73 years. HIV status was unknown. Samples were 
collected before or after TB treatment had been started. Patients expectorated 
sputum into a sterile cup that was immediately sent to the laboratory and 
aliquotted. As part of the standard diagnostic procedures, sputum aliquots 
from each patient expectorate were subjected to microbiological analysis. 
Samples selected for further analysis had an even distribution in terms of 
colour and viscosity between the analysis groups. 
2.3.2 Cultured samples: Chapter five 
Patients from the DIRESA-Callao region and Hospital Dos de Mayo, Lima, 
Peru provided sputum expectorates in the periods July-December 2016 and 
October- December 2016, respectively as part of an on-going project, the MP 
project. The 73 selected samples were smear-positive and had previously been 
characterised by rifampicin, isoniazid and pyrazinamide phenotypic 
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sensitivity testing with complete metadata and DNA suitable for Nextera XT 
library preparation. 
2.3.3 Storage and maintenance of samples: All chapters 
At the MRCG, sputum aliquots were refrigerated until use. After culture on 
LJ slopes, multiple colonies were collected with a sterile loop and inoculated 
into storage medium for storage at -80 °C. In Peru, all DNA extracts were 
maintained in EB or TE buffer at -20 °C. 
2.4 DNA preparation 
2.4.1 Chapter three DNA preparation 
2.4.1.1 Sputum decontamination with NaOH-NALC: Chapter 
three methods A and B, chapters four and five 
Sputa were decontaminated using the method described in section 2.2.2.  
2.4.1.2 Sputum decongestion with NALC: Methods C-F 
Sputa of various positive smear grades were decongested using a 
modification of the decontamination protocol in 2.2.2, replacing the NaOH 
with an equal volume of sterile water. After the final centrifugation, pellets 
were retained. 
2.4.1.3 Depletion of human DNA: Methods E and F 
A protocol modified from Lim and colleagues (203)was initially used to 
attempt to deplete human DNA from the decongested sputum. Pellets 
resulting from sputum decongestion were resuspended in 10 mL sterile 
deionised water, incubated at room temperature for 15 min then centrifuged 
at 3330 x g for 20 min. The supernatants were discarded and this resuspension 
and centrifugation was repeated. The pellets were resuspended with minimal 
water, 25 µL DNase (2.73 Kunitz/ mL) and 100 µL RDD provided in the 
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RNase-Free DNase Set (Qiagen, Hilgen, Germany) then incubated at room 
temperature for 2 hours with repeated inversion of the tubes. The suspensions 
were centrifuged at 3800 x g for 15 min and the pellets were resuspended in 
10 mL TE buffer, then this was repeated before a final centrifugation at 3800 
x g for 15 min to collect the pellets for DNA extraction. 
 
2.4.1.4 Mechanical lysis and Qiagen kit extraction: Methods A 
and D 
The DNA from decontaminated samples or samples decongested by NALC 
was extracted using methods modified from Aldous et al (2005). The pellets 
were resuspended in 0.5 mL TE and added to 2 mL microcentrifuge tubes 
containing 0.1 mm zirconia beads (Scientific laboratory supplies, Nottingham, 
UK). The tubes were centrifuged for 5 min at 1800 x g then incubated at 99 °C 
for 10 min. After a brief centrifugation to remove the beads, 200 µL of the 
supernatants were incubated with 50 µL TE buffer containing 0.08 mg/mL 
lysozyme and 150 U/mL mutanolysin at 37 °C for one hour. The solutions 
were purified using the Qiagen DNA mini kit (Qiagen, Hilgen, Germany) 
according to the tissue protocol but using EB buffer to elute DNA.  
2.4.1.5 CTAB DNA extraction: Methods B, C and E 
Sputum pellets resulting from decontamination, human-depletion or 
decongestion by NALC (chapter three) or cultured material (chapter five) 
were resuspended in 0.5 mL TE buffer, incubated at 80 °C for 20 min to kill 
live bacilli, then supplemented with 50 µL 10 mg/mL lysozyme and 
incubated on a rocker at 37 °C overnight. After incubation, 100 µL 20% 
Sodium diethyl sulphate and 10 µL 10 mg/mL proteinase K were added. The 
solutions were mixed gently and incubated at 60 °C for 40 min. Next, 100 µL 
of 5 M NaCl and 100 µL of cetyltrimethylammonium bromide (CTAB) were 
added, the solutions were vortexed until they appeared ‘milky’ and then 
incubated at 65 °C for 10 min. This was followed by the addition of 750 µL 
chloroform: isoamyl alcohol (24:1) and the solutions were vortexed for >10 
seconds. The aqueous phases were separated by centrifugation at 11000 rpm 
for 8 min then gently mixed with 5 µL glycoblue (Ambion, Applied 
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Biosystems, Foster City, CA, USA) and 550 µL -20 °C isopropanol. The tubes 
were incubated at -20 °C overnight and centrifuged for 15 min at 15000 rpm. 
The pellets were resuspended in 1 mL -20 °C 70% ethanol, the tubes were 
inverted to wash out the isopropanol then centrifuged at 11000 rpm for 5 min. 
The supernatants were discarded and the pellets were allowed to air dry 
before resuspending them in 20 µL EB buffer (Qiagen). The DNA extracts 
were kept at 4 °C overnight before storage at -20 °C. 
2.4.1.6 Nucleospin tissue kit extraction: Method F 
The human-depleted sputum pellets were resuspended in 0.5 mL TE buffer 
then heated to 80 °C for 20 min. The DNA was extracted using the 
Nucleospin® Tissue kit (Macherey-Nagel, Düren, Germany) according to the 
manufacturer’s support protocol for hard-to-lyse bacteria including 
overnight incubation with proteinase K. 
2.4.2 Chapter four DNA preparation 
2.4.2.1 Sputum decongestion with sputolysin 
Sputum aliquots were added to 970 µg/mL sputolysin (Sigma Aldrich, St 
Louis, MO, USA), using an equal volume of sputum to sputolysin, and 
vortexed vigorously for 30 seconds. The solutions were incubated at room 
temperature for 15 min then centrifuged at 3220 x g for 20 min.  The pellets 
were resuspended in 1 mL phosphate-buffered saline (PBS), which was then 
divided equally between two tubes to provide equivalent treatment and 
control samples from each sputum aliquot. These suspensions were then 
centrifuged again at 13000 x g for 5 min to produce pellets to be used for 
human DNA removal. 
2.4.2.2 Depletion of human DNA: Method G 
The sputum pellets were resuspended in 50 mL PBS, mixed thoroughly by 
vortexing then centrifuged at 300 x g for 5 min to pellet human cells. The 
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supernatant solutions were transferred to new tubes and centrifuged at 3220 
x g for 20 min to collect remaining cells.  The supernatants were discarded. 
2.4.2.3 Depletion of human DNA: Method H 
The sputum pellets were resuspended in 10 mL sterile deionised water. After 
incubation at room temperature for 15 min, the suspensions were centrifuged 
at 3220 x g for 20 min and the supernatants were discarded. The resuspension 
and centrifugation were repeated. The resulting pellets were resuspended in 
0.5 mL water, mixed thoroughly with 0.9 mL AMPure XP (Beckman Coulter, 
Indianapolis, IN, USA) to bind extracellular DNA and placed on a magnetic 
rack for 10 minutes to separate the bound DNA from remaining bacilli. These 
supernatants were centrifuged at 13000 x g for 5 min and the resulting 
supernatants were discarded. 
2.4.2.4 Depletion of human DNA: Method I 
Sputum pellets were resuspended in 10 mL sterile deionised water and 
incubated at room temperature for 15 min. These solutions were centrifuged 
at 3220 x g for 20 min, the supernatants were discarded then the resuspension, 
incubation and centrifugation were repeated. The supernatants were 
discarded, the pellets were resuspended in 100 U DNase in 1.5 mL buffer as 
supplied by Biolabs (Ipswich, MA, USA) and these suspensions were 
incubated at 37 °C with gentle rocking for two hours. After centrifugation at 
13000 x g for 5 min, the supernatants were discarded. 
2.4.2.5 Depletion of human DNA: Method J 
The pellets were resuspended in 7.2 mL 1 mM Tris-HCl pH 8 and rocked at 
room temperature for 90 min.  Tris-HCl and MgCl2 were added to make 200 
mM and 10 mM respectively and a total volume of 8 mL. The solutions were 
rocked with 250 U benzonase (Novagen, EMD Millipore, Darmstadt, 
Germany) at 37 °C for 2 hours. The benzonase digestion was quenched by 
vortexing with 88 µL 0.5 M EDTA and 880 µL 1.5 M NaCl. The suspensions 
were centrifuged at 3220 x g for 20 min and the supernatants were discarded. 
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2.4.2.6 Depletion of human DNA: Method K 
Filters were prepared by washing with 3 mL PBS with 3% BSA. The sputum 
pellets were resuspended in 10 mL PBS and sequentially passed though 
Whatman filters with 80 µM, 20 µM then 10 µM pore sizes using a syringe. 10 
mL PBS was passed through the filters to collect any remaining bacterial cells. 
The filtrate was centrifuged at 3220 x g for 20 min and the supernatant was 
discarded. 
2.4.2.7 Nucleospin tissue kit extraction 
Extraction undertaken as for chapter three, described in section 2.4.1.6. 
2.4.3 Chapter five DNA preparation 
2.4.3.1 CTAB extraction from culture  
The CTAB extraction was performed by our Peruvian collaborators in the way 
described in section 2.4.1.5 starting from multiple colonies of culture. 
2.5 DNA quantification and fragment length 
determination: All chapters 
DNA was quantified using the Qubit 2.0 fluorimeter (Invitrogen Ltd., Paisley, 
United Kingdom) and either the HS (high sensitivity) or BR (broad range) 
Qubit® dsDNA Assay Kit according to manufacturer’s protocol. The 
quantitation range for the two kits are 10 pg/µL to 100 ng/µL and 100 pg/µL 
to 1000 ng/µL, respectively. In chapters three and four, negative control 
samples were subjected to HS quantification to determine the absence of 
detectable DNA. When appropriate, DNA fragments were analysed using the 
Bioanalyzer high sensitivity DNA assay (Agilent technologies, Santa Clara, 
CA, USA). 
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2.6 DNA sequencing 
2.6.1 Nextera XT library preparation: Chapters and three 
and five 
For Nextera XT library preparation used in chapters three and five, the DNA 
concentrations of samples were adjusted to 0.2 ng/!L and processed into 
sequencing libraries using the Illumina Nextera XT library preparation kits 
according to the manufacturer’s instructions (Illumina UK, Little Chesterford, 
United Kingdom). The selection between a v2 and v3 Nextera XT kit was 
made based on estimates of the total DNA quantity to be sequenced in one 
run of the MiSeq. For TruSeq library preparation used in chapter four, DNA 
extracts were diluted to have a 60 µL total volume with up to 200 ng DNA.  
2.6.2 TruSeq Nano library preparation: Chapter four 
The TruSeq Nano DNA HT library preparation kit was used with 
modifications to the manufacturer’s instructions (Illumina UK, Little 
Chesterford, United Kingdom) to prepare sequencing libraries. All steps to 
fragment DNA were omitted. The protocol to select library size was amended 
to use 200 µL AMPure XP (Beckman Coulter, Indianapolis, IN, USA) to clean 
up the DNA in place of the SPB reagent and the removal of small fragments 
was omitted. For the PCR enrichment, 15 PCR cycles were used rather than 8.  
Libraries were sequenced using the Illumina MiSeq and reagents facilitating 
either 2 x 251 bp paired-end reads (chapter three and four) or 2 x 301 bp 
(chapter five) paired-end reads to generate FASTQ files. 
2.7 Bioinformatic analyses 
2.7.1 Read alignment: All chapters 
Sequence reads were aligned to reference genomes in a number of ways, 
depending on the application: 
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• ‘Relaxed’ alignment of sequence reads to the Mycobacterium tuberculosis 
H37Rv (GenBank accession number AL123456) was undertaken using 
the --very-sensitive-local pre-set option using Bowtie 2 version 2.1.0 
(204).  
• ‘Stringent’ alignment against the H37Rv reference was undertaken using 
Bowtie 2 with the options --ignore-quals --mp 10,10 --score-min L,0,0.725 
--local --ma 1, as adapted from recent studies on ancient DNA (205,206). 
• In the initial metagenomics study, chapter three, alignment against the 
hg19 human reference genome (GenBank Assembly ID 
GCA_000001405.1) used Bowtie 2 with --fast-local pre-set option.  
• In the follow-up metagenomics study, chapter four, alignment against 
hg19 was performed using Bowtie 2 with the –sensitive-local pre-set 
parameters. 
Summary statistics about alignments were obtained using Qualimap (207). 
2.7.2 Phylogenetic placement: Chapters three and five 
For chapter three, H37Rv-aligned reads were placed into a phylogenetic tree 
previously built by Dr. Martin Sergeant and Dr. Zhemin Zhou from published 
TB strains with designated lineages as described by Doughty et al (208). Dr. 
Sergeant used pPlacer software (209) to define single lineages of MTBC 
present in samples with very few reads. In chapter five, I used MGplacer (210) 
was used to define samples with mixed lineages in a similar manner. 
2.7.3 Small variant calling: Chapter five 
Small nucleotide polymorphisms (SNPs), insertions and deletions (INDELs) 
were determined from the Peruvian whole genome sequences after relaxed 
alignment of reads to H37Rv.  Previously defined repetitive regions (191) 
were excluded from further analysis with a custom script. Variants with a 
minimum coverage of 5 bases, quality score above 20, minimum variant 
frequency over 0.1 and a p-value greater than 0.001 were determined using 
Varscan2 (211). SNPs that fell near to INDELs were excluded and the 
remaining SNPs for each sample were compiled into a list. 
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2.7.4 Genomic prediction of drug resistance: Chapter 
five 
Prediction of drug resistance phenotypes in the Peruvian whole genome 
sequences was undertaken by a number of approaches. Initially, software 
tools, Mykrobe predictor, KVarQ and PhyResSE, were used to identify known 
resistance-causing mutations from databases of known genotype-phenotype 
associations (212,213).  These web-tools identified resistance-causing 
mutations to corroborate most resistance phenotypes, but there was 
discordance in the phenotypes and genotypes of some samples relating to 
pyrazinamide and rifampicin susceptibility. For all samples, the lists of small 
variants previously generated were searched for mutations in resistance-
associated genes and upstream of their predicted operon start sites in the 
following genomic regions relative to the reference genome NC_018143: 
• Pyrazinamide 
o pcnA: 2289607-2289707; 2288689-2289249 
o rpsA: 1833449- 1834991 
o panD 4044041- 4044460; 4046297-4046397 
o hadC: 731830-731930; 732828-733328 
• Rifampicin 
o rpoB: 759659- 763328 
o embB: 4235452-4235552; 4246692- 4249988 
o Rv2629: 2955677-2956901 
Mutations present in the resistance-associated regions of phenotypically 
resistant strains, but not in any phenotypically sensitive strains were 
considered potentially-resistance-causing. 
2.8 Statistical analyses: Chapter four 
The statistical analyses in chapter five were conducted in collaboration with 
Dr. Peter Kimani. The percentage of reads per sample that aligned to the 
human reference genome were calculated to summarise the data. Using the R 
package, metaphor (214), a restricted maximum-likelihood mixed effects 
model (REML) was fitted to the data using random-effects meta-analysis 
(rma). 
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3. Initial Attempts at Metagenomic 
Diagnosis of Tuberculosis 
 
The work presented in chapter three has been published here: 
Doughty EL, Sergeant MJ, Adetifa I, Antonio M, Pallen MJ. Culture-
independent detection and characterisation of Mycobacterium tuberculosis and 
M. africanum in sputum samples using shotgun metagenomics on a benchtop 
sequencer. PeerJ. 2014 Sep 23;2: e585. doi: 10.7717/peerj.585. 
 
3.1 Introduction 
3.1.1 The need for new TB diagnostics 
Currently available tools fail to diagnose and characterise all active TB cases 
in a timely manner. Some patients are failed at every stage of the diagnostic 
process, from diagnostic facilities not being available to them to poor 
performances of those laboratory diagnostic technologies available. The 
WHO estimates that 10.4 million people developed new active tuberculosis 
disease in 2015, however, only 6.1 million cases were notified (108). As a 
consequence of those diagnostic failures, it is assumed those missing were 
unable to obtain treatment. Even of the bacteriologically confirmed cases, only 
30% were able to obtain drug susceptibility testing (DST) against even 
rifampicin meaning potential drug resistant infections went both 
undiagnosed and untreated (108). From every stage of diagnostic failure, 
people have been left ill, as potential vectors to spread disease and undermine 
TB control efforts. 
 
A core component of the End TB Strategy is early detection of TB with 
universal DST (215). Mathematical modelling employed by the End TB 
strategy predicts that improved implementation of current diagnostics could 
lead to a 10% annual decline in global incidence by 2025 (215). The ultimate 
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goal, to end the TB epidemic by 2035, requires accelerated reduction in decline 
rate that cannot be achieved with the tools presently endorsed by the WHO 
(215). New technologies that address the gaps in active TB diagnosis are 
needed both for the market in resource-limited countries and in resource-rich 
settings as challenges exist in each setting. The priorities including 
development of a higher sensitivity rapid test to replace smear-microscopy 
for detection of MTBC species and a rapid drug susceptibility test for all first-
line drugs that can be used at peripheral levels of the healthcare system 
(193,216,217).  DST must include capacity for testing antibiotics that are likely 
to be part of new drug regimens in the near future (218).  
3.1.2 Short-comings of current diagnostic methods 
The diagnostic ideal is for detection, species identification, full susceptibility 
testing and epidemiology of tuberculosis disease in a timely manner with 
high levels of sensitivity and specificity (128). Diagnostic algorithms 
(discussed in greater detail in section 1.5) currently rely heavily on smear 
microscopy and culture in all settings, leaving challenges with detection 
sensitivity and rapidity. Settings with greater resources may have access to 
automated culture systems and molecular testing that can reduce the rapidity 
of detection and DST to a matter of hours to weeks, depending on the system 
being used and the drug in question. In a few of the most resource-rich 
countries, whole genome sequencing is being used increasingly to support 
drug susceptibility testing and epidemiological requirements (192,219–226).  
 
Species identification is often overlooked by commonly used diagnostic 
approaches when epidemiological analysis is not immediately undertaken. 
This is important because species identification is needed to inform successful 
patient drug regimens. Within the M. tuberculosis complex, the M. bovis and 
M. canettii lineages are intrinsically resistant to pyrazinamide (68,168) whilst 
mycobacteria outside the complex often do not respond to conventional TB 
treatment (68,168). Species identification is also important epidemiologically, 
for example highlighting the likelihood of transmission from animals and the 
need for appropriate public health interventions (227).  Strain evaluation 
beyond the species level using traditional epidemiological typing methods 
  54 
are onerous and lack the resolution needed to reconstruct transmission 
chains, with the exception of WGS of cultured samples (192,228).  
 
Current diagnosis methods, often including WGS, fail to recognise mixed 
infection because conventional diagnostic approaches sometimes rely on 
isolation and follow-up of single colonies. WGS of liquid cultures, such as the 
MGIT, can lead to identification of mixed infections though growth of the 
organisms may distort the ratio of lineages identified (229). Failure to identify 
mixed infection can lead to inadequate treatment of resistant strains, resulting 
in amplification of drug resistance and relapse (165,230–233). It also distorts 
the understanding of the epidemiology of disease in a region. 
 
Drug susceptibility testing is essential to inform the most appropriate 
treatment choices, whether that’s the standard first-line treatment regimen or 
identifying the appropriate combination of second-line drugs. As the 
GeneXpert can identify rifampicin resistance, it can determine whether a 
patient should be treated with a first or second-line drug regimen. It cannot 
determine the full drug resistance profile for an organism so rifampicin 
resistant organisms should undergo further DST to determine an appropriate 
drug combination. This testing may be conducted using rapid line probe 
assays, slower phenotypic susceptibility testing of cultured organisms or 
through whole genome sequencing. That second-line drug testing is usually 
only conducted after first-line drug resistance is identified meaning causing 
long delays before the correct drug regimen can be commenced (234).  
 
Even in resource-rich countries, it typically takes one two months to fulfil the 
entire diagnostic paradigm because of the continued dependency on 
culturing tuberculosis which is timely and onerous (235). Combinations of the 
available approaches can diagnose most patients, given enough time and 
resources, however there are numerous difficulties and many patients are not 
adequately diagnosed. Moreover, in resource-limited settings, many of these 
technologies are not suitable owing to unavailability of electricity, skilled-
workers, laboratory facilities or finances. This leaves gaps in the diagnostic 
paradigm and these settings are more likely to rely on older technologies that 
take longer and perform with poorer sensitivities and specificities. New 
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diagnostic methods are needed to address the current short-comings in 
species identification, detection and characterisation of mixed infections, 
high-resolution epidemiological typing, timely susceptibility testing for all 
drugs and accessibility to improved diagnostics in all settings. 
3.1.3 Genomic sequencing in diagnosis  
Whole genome sequencing is beginning to be used for epidemiological 
analysis of MTBC species, but not for the full diagnostic paradigm due to the 
reliance on traditionally slow culture of the organism prior to DNA extraction 
and sequencing. The ideal sequence-based diagnostic test for TB (193,216,236) 
would: 
• work on sputum, with minimal safe sample-preparation steps. 
• detect M. tuberculosis and provide a drug resistance profile, with high 
sensitivity and specificity relative to culture.  
• provide results within 20 minutes. 
• cost just a few dollars per sample.  
 
Before commencing this study in September 2013, a number of steps had been 
made, paving the way for further investigation of metagenomic DNA 
sequencing in TB diagnosis: 
• Whole genome sequencing had been adopted into some TB reference 
laboratories for sensitivity testing and epidemiology (192,225,237). 
• Steps to reduce culture time prior to WGS had been made. In a study by 
Köser et al (238), sufficient culture was obtained by growth in the MGIT 
system for 3 days to extract DNA directly from the MGIT then sequence 
it. From the WGS, a mixture of two M. tuberculosis strains was identified 
and resistance was predicted to nine drugs, making the sample 
extremely drug resistant. The genetic prediction of the DST profile 
correlated with phenotypic results and WGS was able to identify and 
characterise the mixed infection that MIRU-VNTR had not. The time to 
culture positivity, 3 days, was shorter than for most samples and even 
combined with Illumina sequencing, the time from sample receipt to 
results was significantly improved relative to typical methods.  
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• Metagenomic analysis of mummified lung tissue had previously 
identified and characterised M. tuberculosis after DNA extraction directly 
from the tissue and sequencing using an entire run of the Illumina MiSeq 
(205). That the DNA was obtained from mummified tissue was expected 
to pose different challenges than from contemporary samples, given that 
for the ancient samples the resulting DNA read lengths would be shorter 
and human DNA would have been degraded. 
• A metagenomics approach had been employed to the investigation of 
other pathogens including 
o Many viruses (239)  
o The aetiological agent causing diarrheal disease, Campylobacter 
jejuni. It was detected by unbiased metagenomic sequencing of 
DNA extracted directly from a patient’s faecal sample 
indicating the potential to diagnose any pathogen using this 
approach (240). 
o The Escherichia coli O104:H4 outbreak strain of 2011. 
Retrospective analysis of the faecal samples was used to 
reconstruct and characterise the outbreak strain (241). 
3.1.4 Rationale for this study 
At the time of starting this study in September 2013, shotgun metagenomics 
showed theoretical potential as a diagnostic method for tuberculosis but this 
had not been demonstrated experimentally (128). It had been speculated that 
this approach might fulfil in a single laboratory step with fully automated 
analysis all steps in the diagnostic paradigm: detection, identification, DST 
and epidemiology. Simultaneously, the cost of DNA sequencing had been 
falling and the speed of sequencing had been rising taking this potential 
approach closer to being financially feasible for use in clinical practice (242). 
As such, this study aimed to experimentally explore the feasibility for shotgun 
metagenomics to detect and characterise MTBC strains. DNA extraction 
methods were employed that might progress both towards fulfilling the 
ideals of a new TB diagnostic and providing a universal diagnostic method 
for any pathogen in a clinical sample. Smear-positive sputum samples from 
patients from The Gambia in West Africa were used owing to their ready-
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availability and the DNA extractions were carried out at the MRC Unit, The 
Gambia. 
3.2 Methods 
Details of general materials and methods can be found in chapter two. The 
laboratory and bioinformatics workflow for this study is shown in Figure 3.1. 
  58 





DNA extracted from eight sputa 
and two 




A B C D E F
A B C D E F
DNA quanitification
DNA sequencing, 
2 samples per extraction 
method





Alignment of reads against 
H37Rv and hg19, pPlacer
H37Rv hg19
  59 
3.2.1 Sample collection, selection and processing 
For this project, 48 sputum were selected for metagenomic analysis from 
specimens collected between February 2012 and May 2014 under the auspices 
of the Enhanced Case Finding project at the MRC Unit, The Gambia and 
processed at their TB diagnostic laboratory(197). Prior to selection for 
metagenomic investigation, an aliquot of each sample had been subjected to 
microbiological analyses by MRC diagnostic staff: Smear microscopy, culture 
on LJ slopes and in the BACTEC MGIT 960 Mycobacterial Detection System, 
and spoligotyping of cultured isolates. Spoligotype patterns were converted 
to SITVIT clades using the knowledge-based Bayesian network (KBBN) 
method via the TB Lineage online tool (243). The samples used were all smear-
positive and culture-positive with unknown HIV status of the donor patients. 
The selected samples were split into six groups, each for use with a distinct 
sample processing method. For each method, eight sputum samples and two 
negative controls consisting of sterile water were used. The sample names 
were prefixed with A-F according to the extraction method used and 
numbered 1-8 to denote their derivation from unique sputum expectorates. 
Samples numbered 9 and 10 were negative controls. 
 
DNA extraction was performed in the TB laboratory at the MRC Unit, The 
Gambia. Sputum aliquots were processed by one of six methods (Table 3.1). 
These steps addressed the anticipated obstacles to handling sputa and 
detecting TB, principally sputum viscosity, human DNA content and TB cell 
lysis.  
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Table 3.1: Methods of DNA preparation used to detect TB from sputum by 
metagenomics  
Six methods of DNA preparation, A-F, were applied to sputum in an attempt to 
detect M. tuberculosis by downstream metagenomic analysis. Each extraction 
method comprised of a method sputum decongestions, human DNA depletion then 
extraction of DNA from bacteria present. 
Method Decongestion method 




A Decontamination Mechanical lysis and kit 
B Decontamination CTAB 
C NALC None CTAB 
D NALC None Mechanical lysis and kit 
E NALC Differential lysis and DNA degradation CTAB 




3.2.2 Library preparation and sequencing  
DNA extracts were sent to the Warwick Medical School where all further 
laboratory and bioinformatics analyses were performed. The concentration of 
DNA present in each extract was determined and negative control samples 
were considered uncontaminated when there was no detectable DNA. From 
each processing method, two samples with adequate DNA were initially 
converted to sequencing libraries using the Nextera XT protocol and 
sequenced on one run of the Illumina MiSeq. The remaining samples from the 
two most-promising methods were later sequenced in the same way. 
3.2.3 Analysis of human and mycobacterial sequences 
The resulting sequence reads were assessed by alignment to the M. 
tuberculosis reference genome, H37Rv (GenBank accession numbers 
AL123456) using Bowtie 2 version 2.1.0 (204) with a relaxed protocol that 
exploited the option --very-sensitive-local. However, the ‘relaxed’ alignment 
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parameters were found to be too non-specific, matching reads from other 
bacterial species in the sample to the reference genome. An alternative 
‘stringent’ alignment protocol was thus developed that avoided this. The 
stringent protocol allowed only limited mismatches (3 per 100 base pairs) and 
soft clipping of poor quality ends, by exploiting the options --ignore-quals --
mp 10,10 --score-min L,0,0.725 --local --ma 1.  
 
The number of reads aligning to hg19, the human reference genome, and total 
number of reads were determined using Bowtie 2 under the --fast-local 
settings and Qualimap. 
3.2.4 Species and lineage assignment using low-
coverage SNPs 
Epidemiological analysis of the strains was achieved by phylogenetic 
placement. A phylogenetic tree was built from representative genomes from 
each MTBC species and major lineage, using the lineage designations 
reported by PolyTB (244). These genome sequences were obtained from 
entries to the short-read archive, ERP000276 and ERP000124 (245), and 
mapped against M. tuberculosis H37Rv with Bowtie 2 under its default settings 
(204). The SNPs were called using VarScan2 (211) excluding those that fell 
within previously published repetitive regions (191). A phylogenetic tree was 
constructed from these SNPs with RAxML version 7 (246) using its default 
parameters and the GTR-gamma model.  
 
Reads from the samples in this study were mapped against the reference 
strain, M. tuberculosis H37Rv, again using the default settings in Bowtie 2 
(204). SNPs were identified without quality filtering from the majority base 
called at each mutational position and when no base was present at a position, 
a gap was used. At this point, the pPlacer program (209) was used to assign 
each SNP sequence to a species and lineage of the phylogenetic tree.  
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3.3 Results 
3.3.1 DNA quantification and validation of controls 
Most extracts contained enough DNA for Nextera XT library preparation, 
with the exception of those obtained by method B (Table 3.2) For the negative 
control samples to be considered uncontaminated, they must have contained 
no detectable DNA when analysed with the Qubit HS kit, which is sensitive 
to 10 pg/µL DNA. DNA was detected in one negative control sample of 
method C and both negative control samples of method D.  
 
Table 3.2: Evaluation of methods detect TB from sputum by metagenomics 
The extracts obtained by the six preparation methods used, A-F, were initially 
evaluated by Qubit fluorimetry to determine whether adequate DNA, 0.2 ng/µL, 
was present in each DNA extract and whether any DNA could be detected at all in 
negative controls. The outcomes of the initial evaluations are summarised for each 










A 8/8 0/2 
B 2/8 0/2 
C 8/8 1/2 
D 8/8 2/2 
E 8/8 0/2 
F 8/8 0/2 
3.3.2 Selection of best extraction method 
Two samples from each extraction method were sequenced, this included a 
negative control sample from methods C and D as these contained detectable 
DNA and the remaining DNA extracts sequenced had been obtained from 
sputum. The sequence reads were aligned under the relaxed settings to the 
Mycobacterium tuberculosis H37Rv reference; Method A resulted in very few 
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sequences that aligned to the H37Rv genome. The negative control samples 
from methods C and D yielded reads aligning to H37Rv whilst the DNA 
extracted from sputa by these methods did not yield a significantly greater 
proportion of reads aligning to H37Rv. As such it was not considered 
beneficial to investigate these extraction methods further. The largest 
proportion of reads aligning to H37Rv were from samples processed by 
method B, however it had already been established that only two of eight 
samples contained enough DNA for sequencing and the number of aligned 
reads was not significantly greater than methods E and F. Methods E and F 
gave samples with the largest proportions of reads derived from TB without 
being compromised by sample contamination and consistently provided 
enough DNA for sequencing.  
3.3.2 Detection of MTBC in sputum samples 
Metagenomic sequences were obtained from all smear- and culture-positive 
sputum samples processed by methods E and F. The number of sequence 
reads in each sputum-derived metagenome ranged from 989,442 to 2,818,238. 
 
Sequence reads from all DNA extracts resulting from methods E and F were 
aligned under the ‘relaxed’ parameters against the H37Rv reference genome 
(Table 3.4). These parameters are typically used for alignment of reads 
derived from whole genome sequencing of cultured isolates but were found 
not to be suitable for reads generated from metagenomic DNA. Two values 
were calculated to assess the quality of read alignment against H37Rv. 
Average genomic coverage describes the average number each nucleotide of 
the whole H37Rv reference could be covered by a read and assumes random 
distribution across the genome. Average read depth on the other hand is a 
calculation of the average number each nucleotide is actually covered by a 
read. Therefore, if the average coverage observed was less than one against 
H37Rv the expectation for a uniformly sequenced genome would be that the 
read depth would also be one, although this could also approach two if pair 
end sequencing was used and the DNA fragments were short. Comparing the 
two values helps with evaluating how evenly the reads cover the genome. 
When coverage plots were generated using Qualimap, it became apparent 
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that the average genome coverage observed was less than one for all but one 
sample, whereas the read depth was as high as 32.8x. This suggested that the 
matched sequence reads were unevenly distributed across the reference 
genome. The high average read depth and clustering of reads across the 
genome under ‘relaxed’ alignment conditions arose where conserved 
sequences in both MTBC and other species matched the H37Rv reference. 
 
In order to identify the reads truly derived from MTBC organisms, alignment 
parameters must match only reads derived from MTBC to the H37Rv 
reference genome. In previous metagenomic analyses of mummified material 
containing TB (205), ‘stringent’ alignment parameters had been developed 
that only matched reads that were very closely related to the reference 
genome. Similar parameters were used that allowed reads to align with soft-
clipping ends of poor quality reads and only three mismatched positions per 
100 bases. This resulted in average genome coverage ranging from 0.002 to 
0.693 (Table 3.4) and read depths that never exceeded 2x, in line with 
expectation for when only MTBC species are aligning.  
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Table 3.3: Detection of M. tuberculosis complex sequences in sputum 
samples  
Reads from each sample were aligned to the H37Rv M. tuberculosis reference 
genome under relaxed and stringent mapping conditions. For each sample, the 
number of reads aligning, genomic coverage and average read depth across the 
genome were determined and it could be observed that these metrics were altered 
different when comparing those obtained under relaxed and stringent mapping 
conditions. An average read depth between one and two was expected, given the 
average genomic coverage around one, and accepted as an indicator or specific 





Under relaxed mapping 
conditions 













E1 34750 0.008 1.3 15698 0.004 1.3 
E2 3614561 0.819 2.9 1058815 0.240 1.7 
E3 3864651 0.876 2.0 1824712 0.414 1.5 
E4 44004 0.010 1.9 11515 0.003 1.4 
E5 3640048 0.825 13.6 174053 0.039 1.4 
E6 63818 0.014 1.9 21342 0.005 1.2 
E7 123748 0.028 3.2 21177 0.005 1.3 
E8 2916936 0.661 32.8 26385 0.006 1.6 
F1 410228 0.093 2.2 141906 0.032 1.3 
F2 5685901 1.289 2.3 3057187 0.693 1.9 
F3 99643 0.023 1.3 54413 0.012 1.2 
F4 40019 0.009 1.9 10840 0.002 1.3 
F5 732623 0.166 2.5 238451 0.054 1.3 
F6 94023 0.021 2.3 34704 0.008 1.7 
F7 1366309 0.310 11.4 50873 0.012 1.5 
F8 1725816 0.391 7.7 109514 0.025 1.3 
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3.3.3 Phylogenetic placement 
Strain typing is an important yet often neglected part of the full diagnostic 
paradigm (128). The methods typically used to characterise TB strains, such 
as spoligotyping and MIRU-VNTR, rely on analysis of specific repeat regions 
that cannot be reconstructed by short read shotgun sequencing. Likewise, 
lineage assessment from whole genome data relies on high-confidence SNPs 
and RDs from across the full genome that is not possible with the partial 
genomic data available here. pPlacer (209), offers an alternative way of 
characterising TB using the few short reads available from metagenomic 
sequencing with maximum likelihood and posterior probability phylogenetic 
placement into a reference phylogenetic tree. Of the 16 samples analysed, 13 
could be phylogenetically placed at the strain, lineage and sub-lineage level 
with the posterior probability >0.97 in all but sample E1 which had a posterior 
probability of 0.5 with a very low coverage of the genome. (Tables 3.5 and 3.6). 
The placement for all samples corresponded with the spoligotypes of the 
cultured isolates, except for those in sample E2. Interestingly, sample E2, 
where the sample was designed as the LAM clade by pPlacer but the T clade 
by spoligotyping, was from the same patient as sample F1 where both 
methods were concordant in their LAM clade result. The majority of strains 
were found to be part of the globally dominant M. tuberculosis species and 4 
were found to be M. africanum clade 2, concurrent with knowledge of the TB 
population structure through West Africa. 
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Table 3.4: Phylogenetic placement by pPlacer and spoligotyping: Method E  
Assignment of strain type of each sample by pPlacer analysis of metagenomic reads was verified by comparison to spoligotyping of cultured 
material. Posterior probability abbreviated to pp 
 
 pPlacer Spoligotyping 
Sample Species, lineage, clade pp SITVIT clade by KBBN Spoligotype 
E1 
M. africanum/ Lineage 6  
clade 2 
0.5 AFRI_1 1111110001111111111111111111111111111101111 
E2 
M. tuberculosis Euro-American/ Lineage 4 
LAM clade 
1 T 1111111111111011111001111111111100001111111 
E3 M. tuberculosis Euro-American/ Lineage 4  H clade 1 H3 1111111111111111111111111111110100001111111 
E4 Not determined <0.2 H3 1111111111111111111111111111110100001111111 
E5 M. tuberculosis Euro-American/ Lineage 4  T clade 1 T1-RUS2 1111110000000000000000000111111100001111111 
E6 M. africanum/ Lineage 6 clade 2 0.97 AFRI_1 1111110001111111111111111111111111111101111 
E7 M. tuberculosis Euro-American/ Lineage 4  T clade 0.98 T1-RUS2 1111110000000000000000000111111100001111111 
E8 Not determined <0.2 AFRI_1 1111110001111111111111111111111111111101111 
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Table 3.5: Phylogenetic placement by pPlacer and spoligotyping: Method F  
Assignment of strain type of each sample by pPlacer analysis of metagenomic reads was verified by comparison to spoligotyping of cultured material. 
Posterior probability abbreviated to pp 
 pPlacer Spoligotyping 
Sample Species, lineage, clade pp SITVIT clade by KBBN Spoligotype 
F1 M. tuberculosis Euro-American/ Lineage 4  LAM clade 1 LAM2 1101111111110111111100001111111100001111011 
F2 M. tuberculosis Euro-American/ Lineage 4  H clade 1 H3 1111111111111111111111111111110100001111111 
F3 M. africanum/ Lineage 6 clade 2 1 AFRI_1 1111110001111111111000001000011111111101111 
F4 M. tuberculosis Euro-American/ Lineage 4  H clade 0.99 H3 1111111111111111111111111111110100001111111 
F5 M. africanum/ Lineage 6 clade 2 1 AFRI_1 1111110001111111111111111111111111111101111 
F6 Not determined <0.2 AFRI_1 1111110001111111111111111111111111111101111 
F7 M. tuberculosis Euro-American/ Lineage 4  H clade 0.97 H3 1111111111111111111111111111110100001111111 
F8 M. tuberculosis Euro-American/ Lineage 4  T clade 1 T1-RUS2 1111110000000000000000000111111100001111111 
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3.3.4 Assessment of human DNA quantity 
The amount of human DNA as a proportion of total DNA in samples was 
anticipated to be a major limitation to the number and proportion of reads for 
detection and characterisation of MTBC. The proportion of reads aligning to 
hg19 the human reference genome, relative to the total reads per sample was 
calculated. The proportion of reads in each metagenome mapping against the 
human genome ranged from 20% to 99% (Table 3.7), with the remaining reads 
associated with other organisms.  
 
Table 3.6: Proportions of reads aligning to the human reference genome, 
hg19, in each sample 
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3.4 Discussion 
This study provides the first proof-of-principle that TB can be detected and 
characterised by metagenomic analysis of DNA extracted directly from 
sputum. Furthermore, this has been achieved with simple, low-cost, non-
commercial approaches to DNA extraction. The most successful method 
included sputum viscosity reduction and a first attempt at human DNA 
depletion without target-specific capture, amplification or microbiome 
depletion.  
 
Some of the hypothesised advantages of metagenomic TB diagnosis have 
been confirmed by this study (235). Here, the best approaches to sample 
processing facilitated detection of TB in all sputum extracts and 
epidemiological results in 13 of 16 of these. Coverage of the genomes was low, 
especially compared to WGS of cultured isolates, limiting the extent to which 
they could be characterised. In this study, the samples could not be 
characterised in terms of drug resistance but the species could be identified in 
most cases and epidemiological typing by pPlacer matched that by 
spoligotyping of the cultured samples in all but one case. The epidemiological 
resolution provided by spoligotyping was greater than by pPlacer but only 
when the spoligotype patterns were analysed by SITVIT. Standard 
interpretations of spoligotype patterns provided by MRCG had lower 
epidemiological resolution. Should both spoligotyping and pPlacer been 
accurate, the discordance between the results for sample E2 with those from 
sample F1 may have been caused by mixed infection. This highlights that the 
potential for mixed infection and heterogeneous strains in sputum cannot be 
appreciated either via this metagenomic approach with low coverage of the 
MTBC species’ genome or by methods using a single colony culture from 
sputum. It was not possible to determine which samples contained mixed 
infections from this level of genomic coverage. In a clinical laboratory, 
employment of this single-laboratory method would replace many onerous 
approaches for detection and epidemiological typing of TB (235) 
circumventing the bottleneck of culture in timely epidemiological analysis.  
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The samples sequenced from method A, decontamination and extraction by 
mechanical lysis and the Qiagen kit, yielded very few reads aligning to 
H37Rv, even with the relaxed alignment approach. The abundance of the 
reads must have been obtained from either human DNA or the DNA of other 
organisms in the microbiome. This may be owing to the failure of the 
mechanical lysis and simple Qiagen kit extraction to lyse the mycobacterial 
cells whilst it would have been adequate to lyse other bacteria and human 
cells. 
 
Method B, decontamination followed by a CTAB extraction, resulted in a very 
low concentration of DNA in the extract. It is expected that this is due to 
depletion of much of the microbiome that would have yielded DNA during 
the decontamination step and perhaps poor extraction efficiency by the CTAB 
method. It highlights a potential problem with a direct sequencing approach 
that depletes non-target DNA, that after this kind of extraction approach, the 
concentration of the resulting DNA may be too low for sequencing. An 
additional amplification step might be required.  
 
The methods, C and D, both using decongestion then either extraction by the 
CTAB or mechanical lysis and Qiagen kit method, resulted in DNA in the 
negative control samples. Two samples obtained by each of these methods 
were sequenced to determine if a large and significant proportion of the reads 
aligned to H37Rv, warranting repeating these extraction methods. This 
showed that there was very little difference in the quantity of DNA in the 
samples obtained from sputum and the contaminated negative controls. 
There was also not a huge proportion of reads aligning to H37Rv from the 
extracts obtained from sputum. It was decided to not investigate these 
samples further in this study and that repeating the extractions was unlikely 
to aid the identification of a better extraction method for the goals of this 
study. The extractions in these methods were likely contaminated by not 
using sterile tubes for the final elution of DNA, due to a laboratory evacuation 
whilst the samples were being process. After evacuation, the only elution 
tubes available were not sterilised and could not be sterilised in the necessary 
timeframe. This highlights the issue with equipment contamination that is 
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pervasive throughout may molecular methods and is particularly 
problematic in metagenomic investigations (247). 
 
Methods E and F, using decongestion with NALC, attempted differential lysis 
of human cells then removal of human DNA followed by DNA extraction by 
either the CTAB or Nucleospin tissue kit addressed the goals in this study 
most successfully. It is unclear how much impact the attempts to remove 
human DNA made on the proportion of human to bacterial sequence reads 
but it was very apparent that these human reads made up an overwhelming 
proportion of the total reads sequenced from each sample. There was little 
difference in the concentration of DNA or proportion of reads aligning to 
H37Rv between the methods using the Nucleospin Tissue kit and CTAB 
extraction steps. These approaches were the best given that they consistently 
resulted in DNA concentrations above 0.2 ng/µL and provided reads aligning 
to the H37Rv genome. 
 
The diagnostic metagenomics approach illustrated here shows several 
obvious shortcomings and areas of unclear clinical performance remain: 
• Though the DNA extraction method is inexpensive, the full diagnostic 
method including the sequencing is costly, at around £50 per sample. 
• It requires a sophisticated laboratory and bioinformatics set-up and the 
laboratory workflow is too laborious relative to minimum requirements 
specified for an improved laboratory diagnosis test (193,216). 
Nonetheless, this is early in the development of this diagnostic approach 
and feasible improvements in this method could address these issues. 
• The depth-of-coverage obtained is insufficient to confidently call all 
relevant SNPs required for prediction of drug resistance profiles, for full 
single-nucleotide resolution epidemiology and inferring transmission 
networks. This is limited by the small proportion of the total reads that 
align to the H37Rv genome; the vast majority of reads in each sample 
align to the human reference genome.  
• It is insensitive: all sputum samples used here are smear-positive, but 
some are negative on metagenomics, so metagenomics has a poorer 
sensitivity than microscopy.  
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• It is of uncertain specificity. Whilst average read depth and evenness of 
coverage suggest that stringent parameters aligned reads derived only 
from MTBC, specificity remains unknown without its application to TB-
negative samples.  
• Information about HIV-seropositivity of patients was not available so 
performance of this method in HIV co-infected individuals could not be 
assessed. Given that smear microscopy performs poorly in HIV-positive 
people and the elevated incidence, severity, mortality and transmission 
associated with co-infection, this is an important patient cohort to 
address (248–250).  
Despite these drawbacks, a metagenomic approach appears promising for the 
future of TB diagnosis and more widely in microbiology. The approach 
developed here could be used as a one-size-fits-all approach for any sample 
containing any pathogen that may facilitate the re-unification of TB diagnosis 
with the rest of microbiology.  Prior success of metagenomic diagnosis of 
other respiratory pathogens, especially viruses, is encouraging and suggests 
that identification of co-infection between two species of pathogen may be 
possible (251–255). A key challenge is that the number of reads derived from 
the TB bacillus were overwhelmed by human reads or those derived from 
other microbes. Depletion of human reads from samples before sequencing 
could potentially increase the number of reads from M. tuberculosis obtained 
from each sample—this challenge is addressed in the subsequent chapter. 
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4. Metagenomic Diagnosis with 
Depletion of Human DNA 
4.1 Introduction 
In the previous chapter (chapter three), it was established that shotgun 
metagenomics can detect and epidemiologically type tuberculosis directly 
from sputum. The diagnostic information obtained using this method was 
limited by the absolute number of sequence reads associated with the 
pathogen that could be obtained from the sample. In most samples, human-
derived sequence reads overwhelmed those from the MTBC. Consequently, 
the coverage of the tuberculosis-associated genomes obtained was too low to 
reliably call SNPs for antibiotic resistance prediction or for single nucleotide 
resolution epidemiology as can be obtained via WGS for transmission 
analysis. 
 
Previous metagenomic and PCR-based studies have explored approaches to 
minimise the challenge presented by high ratios of target to non-target DNA. 
The ‘target’ might be a specific organism or a group of organisms, like all 
bacteria or all microorganisms, whilst the ‘non-target’ might be host or human 
cells or microorganisms that are not of interest. There are three main 
approaches to improving the detection of such target organisms within 
metagenomics samples: 
• Increasing the depth of sequencing such that more reads are associated 
with every organism represented in the metagenomic DNA extract. 
• Enrichment of the target organism(s) or their DNA, by culture; target-
specific capture; or random or target-specific amplification.  
• Increasing the relative amount of target DNA by specific depletion of 
non-target cells and/or DNA during DNA extraction.  
 
Employing the first approach would mean increased cost per sample, 
particularly since the depth of sequencing may need to increase significantly. 
This approach has been taken to identify tuberculosis from historical samples, 
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purely for research purposes (205,206) but it would be financially infeasible 
in a clinical diagnostic laboratory, especially for TB as it is most prevalent in 
resource-poor settings. It does not fulfil the aim of improving an extraction 
method to facilitate metagenomic diagnosis.  
 
The second approach risks compromising the open-endedness of diagnostic 
metagenomics by targeting only expected organism(s), prohibiting 
metagenomics as a universal diagnostic method. When this study 
commenced, two publications had characterised tuberculosis in this way:  
1. Bouwman et al (256) used hybridization capture of 260 specific 
polymorphic regions of the M. tuberculosis genome to enrich target 
ancient DNA extracted from the rib of a 19th century skeleton. From this 
approach, 664,500 of the total 726,848 Sequencing by Oligonucleotide 
Ligation and Detection (SOLiD) reads (91.4%) aligned to the M. 
tuberculosis reference genome in the targeted regions which enabled 
characterisation of 218 of 247 SNPs, eight of nine RDs, TbD1, the IS1081 
and IS6110 insertion sequences, and the mtp40 locus. The strain was 
classified within lineage two and no attempt to analyse drug 
susceptibility was reported. The main disadvantage of this approach was 
the extent of missing genomic data, both from the regions that were not 
captured by the baits and from the uneven coverage across these 
sequenced regions. It is also unclear how this would perform on species 
other than M. tuberculosis, if cross contamination of amplicons between 
samples might be a concern and how expensive this approach might be. 
2. In another study by Köser et al (238), one sample of decontaminated 
smear-negative sputum was cultured in the MGIT automated system. 
Once it flagged positive, the DNA was extracted and sequenced. Though 
72% of the sequence reads failed to align to the M. tuberculosis reference 
genome, H37Rv, the remaining reads were sufficient to provide 52-fold 
coverage of the genome. This facilitated DST, lineage classification and 
identification of mixed infection characterising the strain as XDR-TB and 
indicating a more appropriate treatment regimen. Relative to the ideal, 
this culture-first approach was limited by the additional time and cost 
associated with culture. It also employed a large number of sequencing 
reads, totalling 1.98Gb, adding to the cost of the method, though many 
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of the reads sequenced were not the target. When the same MGIT culture 
was inoculated onto an LJ slope and further cultured, improved results 
were obtained with only 1% of the reads failing to align to H37Rv, 
however this added yet more time and cost to the diagnostic process and 
jeopardized the ability to detect mixed infection.  
Approaches aiming to enrich target DNA in an extract have failed to provide 
the results that are required for a clinical metagenomic diagnostic method. 
 
The third approach, to deplete non-target cells or DNA, seemed most likely 
to fulfil the goals of a universal diagnostic method using metagenomics. 
Though this approach has not been employed in studies that have identified 
tuberculosis disease, it has been investigated a number of times in other 
studies where removal of human DNA has been necessary for detection of 
bacteria (Table 4.1). These studies have sought to reduce human DNA, 
thereby enriching the bacterial proportion of DNA obtained, from various 
clinical sample types, for various purposes, with various target organisms and 
reporting the efficiency of the human DNA depletion in various incomparable 
ways. It is not possible to determine which approaches have been most 
successful, nor which might have the greatest impact on the composition of 
DNA extracted from sputum. The methods all involve some loss of bacterial 
DNA with the human DNA which may impede detection of bacteria, would 
restrict biodiversity analyses and potentially compromise the universal 
potential for diagnostic metagenomics. Commercial methods, including the 
NEBNext DNA library preparation kits (New England BioLabs, Hitchin, UK 
(257)) and MolYsis kits for human DNA removal (Molzym GmbH & Co. KG, 
Bremen, Germany), are available and have showed significant reductions in 
human DNA content with minimal impact on microbial DNA. Whilst 
effective, these commercial methods are prohibitively expensive for routine 
diagnostic purposes. For the purposes of metagenomic diagnosis of 
infections, including tuberculosis, from sputum it was unclear which 
approach might be most effective. 
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Table 4.1: Prior studies attempting to deplete human DNA from clinical samples or laboratory-derived proxies  
Method Sample type Outcome Assessment method Reference 
Selective lysis using buffer or water, digestion 




Statistically significant depletion of 
human DNA relative to no treatment 
control, little impact on bacterial DNA 
qPCR (258) 
Differential centrifugation by pulsing to 5000 x 
g to remove human cells 
Dental 
plaque 
Statistically significant depletion of 
human DNA relative to no treatment 
control, large bacterial DNA loss 
qPCR (258) 
Differential centrifugation by pulsing to 5000 x 
g to remove human cells after treatment with 
detergent (Triton X-100 or Tween 20) 
Dental 
plaque 
Statistically significant depletion of 
human DNA relative to no treatment 
control, bacterial DNA loss 
qPCR (258) 
Differential centrifugation by pulsing to 5000 x 




Statistically significant depletion of 
human DNA, relative to no treatment 
control, significant reduction in bacterial 
DNA; clinically insignificant impact on 
human-bacterial DNA ratio 
qPCR (258) 
Filtration through 6 µm Whatmann paper Mouth wash  
89% reduction in human DNA; 
proportionate enrichment of bacterial 
DNA 
qPCR (259)  
Enzymatic digestion of skin samples, 
sequential filtration through nylon filters of 80 
µm, 20 µm and 11 µm; flow cytometry to 
remove mitochondria 
Skin  0.02% reads assigned to human genome; 95% reads assigned to bacteria;  
Shotgun 
metagenomics (260)  
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Method Sample type Outcome Assessment method Reference 
Differential centrifugation at 2000 x g for 30s Urine 
Sufficient DNA for sequencing in 23/35 
samples; limited human DNA 




Treatment with ß-mercaptoethanol, osmotic 
lysis and treatment with DNase, prior to 
bacterial DNA extraction 
Sputum 13-97% human DNA, able to characterise microbiome from remaining reads 
Shotgun 
metagenomics (203)  
Selective lysis of human blood cells using ox 
bile and degradation of human DNA by 






Significant reduction in human DNA and 
enrichment of Salmonella Typhi DNA 
leading o 1000-fold enhancement of 
Salmonella detection by qPCR 
qPCR (262) 
Selection of human and bacterial DNA with 
non-methylated GATC sequences by binding 
with DpnII restriction endonuclease under 
conditions where DNA is not cut and can be 




Enriched human DNA with little binding 
to E. coli DNA qPCR (263)  
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4.1.1 Study rationale and objectives  
In the previous chapter, the goal of characterisation and detection of MTBC 
genomes by metagenomics was limited by the small number of reads 
associated with these pathogens. Simultaneously, many of these samples 
contained a high proportion of reads that aligned to the human reference 
genome, minimising information about mycobacterial infections and the rest 
of the sputum microbiome. After assessing the potential approaches to 
enriching mycobacterial reads in the metagenomic sequences, it was 
considered that depleting human DNA offered the greatest hope to achieve 
this whilst maintaining the universal nature of metagenomics to potentially 
detect any other pathogen present in the sputum. The work presented in this 
chapter aimed to take initial steps to explore methods for depletion of human 
DNA and human-derived reads from metagenomic sequences, generating 
preliminary data for on-going method development towards a universal 
sputum diagnostic approach. 
 
A number of methods aiming to reduce the proportion of human DNA in 
sputum extracts were investigated in this study. These methods were chosen 
based upon the availability of reagents and equipment in The Gambia, where 
this work was conducted, the cost of extracting DNA from each sample given 
that it should be clinically feasible and prior research found in the literature. 
The methods using osmotic lysis were of particular interest since the only 
metagenomics study with sputum had used this approach successfully. Five 
methods were devised with the following considerations of the method steps: 
• Centrifugation to remove human cells at 300 x  g  for 5 mins: A method 
in the literature had used centrifugation to 5000 x g and successfully 
reduced the amount of human DNA in the final extract but had also 
removed much bacterial DNA (258); another study had centrifuged 
urine at 2000 x  g  resulting in little human DNA contamination but this 
was considered more likely to be due to the sample type, urine, where 
human cells are less likely to be found (261). Being conscious to not 
pellet and discard bacteria, like in this first study, minimal 
centrifugation was used in an attempt to pellet only human cells. The 
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centrifugation speed and duration was chosen to reflect conditions 
typically used by cell biologists (personal communication). 
• Osmotic lysis of human cells in water then degradation of extracellular 
DNA using DNase: This method was repeated from chapter three, 
using a higher concentration of DNase, such that the method could be 
evaluated relative to no-treatment controls and because it was felt the 
insufficient DNase may have limited the human DNA degradation in 
the previous work.  
• Osmotic lysis of human cells in Tris-HCl then depletion of extracellular 
DNA with benzonase: Looking at ways to improve the osmotic lysis 
method, an alternative lysis solution and DNA degradation enzyme 
was investigated based on the statistically significant depletion of 
human DNA from dental plaque metagenomes using these methods 
(258). 
• Osmotic lysis of human cells in water then removal of extracellular 
DNA using AMPure XP: Again, looking at ways to improve osmotic 
lysis, use of AMPure XP was investigated for its alternative mechanism 
of removing extracellular DNA. 
• Filtration was undertaken given the 89% reduction of human DNA 
reported from mouthwash (259) when 6 µm Whatman paper was used. 
Since the sputum samples were still quite viscous after decongestion, 
80 µm and 20 µm Whatman paper was used to remove large structures 
in the sample and avoid clogging the final filter which was intended to 
allow only small structures, ideally only bacteria, to pass. The final 
filtration was through 10 µm Whatman paper since this would be large 
enough to inhibit human cells from entering the filtrate and 6 µm 
Whatman paper could not be sourced. 
 
 
Steps other than those aiming to deplete human DNA were standardised 
across the study for processing a sample from sputum to metagenomic 
sequence. These steps were amended from the previous study described in 
chapter three and included replacement of the decongestant agent sputolysin 
(dithiothreitol) with the aim to improve decongestion and sample handling. 
Sputolysin was chosen for its known capacity as a decongestant, availability 
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at the MRCG and given that it was not known to cause human cell lysis. The 
Nucleospin Tissue Kit DNA extraction method was chosen from the previous 
analyses given its rapidity and practicality relative to the CTAB method 
without discernible difference in performance. 
 
The study design for evaluating the methods was chosen after considering the 
number of samples available; heterogeneity in human DNA proportions and 
physical characteristics of sputum; and the aim of this study to generate 
preliminary data for further method development. Whilst the Gambia, where 
samples were collected for this study, has a higher burden of TB than the UK, 
it was challenging to obtaining excess sputum for research purposes. Only 40 
samples were available in an appropriate time frame, even including both 
smear positive and negative sputa. As reported in chapter three, previous 
work had indicated that there was a wide range and distribution of human 
DNA proportions in sputum, from 4 to 99% and a median of 74% human DNA 
in the samples extracted after osmotic lysis and extracellular DNA 
degradation. There was no evidence about the human DNA proportions in 
untreated extracts, as methods C and D had been compromised, but it was 
assumed to be equally variable. With only 40 samples, these were not enough 
to conduct this study with adequate samples in each group to which a 
treatment (or no treatment, as a control) would be applied to overcome the 
between sample heterogeneity. The samples had to be split to provide 
treatment and control subsamples from each clinical sample. Ideally, there 
would have been large volumes of each sputum sample so each could be split 
between all five groups. This would have maximised the number of samples 
per group and minimised the heterogeneity of samples between the groups. 
With small volumes of excess sputum available, typically less than 1.5 mL, 
this was not feasible so the study was instead designed with a pairwise control 
for every sample. To implement this, the samples available were split between 
the five groups with eight samples per group and each sample was split in 
half to provide a treatment and control subsample for extraction, analysis and 
comparison. This study design, with few samples per group, had the potential 
to result in low statistical power to evaluate and compare treatments on the 
groups samples, especially should the effect size of the treatment have been 
small like reported in some studies found in the literature. Given that effect 
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size could not be indicated through the compromised results in chapter three 
and enormous variation, even between similar methods, presented in the 
literature, it remained quite unknown. It was determined that investigating 
all five treatment methods proposed was most congruent with the aim to 
generate preliminary data indicating further avenues of development of a 
human depletion approach that could be investigated with a larger sample 
size in the future. Moreover, should a method have provided clinically 
significant depletion to all samples, this would have been immediately clear 
without the need for statistical evaluation. The sputum expectorates had also 
been highly variable in terms of viscosity, homogeneity and colour. In attempt 
to circumvent some of the issues associated with this sample heterogeneity, 
distribution of samples between groups was considered, attempting to create 
groups of samples with roughly equal characteristics. 
 
The best way to evaluate the effectiveness of human DNA depletion was 
considered carefully. Initially use of a quantitative PCR approach using 
primers targeted at a universal molecular barcode (e.g. the 16S rRNA gene) 
was considered. However, the use of universal 16S primers to assess the 
quantity of all bacteria present was likely to also lead to amplification of 
laboratory contaminants due to the high sensitivity of 16S qPCR. Such an 
approach would also not assess the impact of depletion on sequence data, 
only on DNA proportions. Sequencing followed by mapping of reads to the 
human reference genome was therefore used as a quantitative method to 
replicate the clinical diagnostic approach as closely as possible. Technical 
replicates from sputum samples and sequencing libraries were not used given 
that only a small volume of sputum was available from each patient and 
because this genomic sequencing approach results in such a large number of 
reads per sample.  
 
The number of reads aligning to the human reference genome, as a percentage 
of all sequenced reads, was used as the metric for evaluating each treatment 
and control subsample. Under the advice of Dr. Perter Kimani, the 
comparison of human read percentage between the treatment and control 
sample subgroups was undertaken by a random-effects meta-analysis (rma) 
that was used to fit a restricted maximum-likelihood mixed effects model 
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(REML) to the data. This statistical approach was chosen to represent the 
study design; it evaluated a small number of samples as part of a much larger 
population of data by transforming the normally distributed continuous data 
of the dependent variable of interest so that random effects caused by 
parameters other than the one of interest, i.e. heterogeneity between samples, 
had no effect. Using a linear regression, proportions of human DNA were 
then predicted for an entire population of sputum, accounting for its full 
range of variability. The difference between treatment and control subsample 
groups was used to evaluate and compare the methods.   
4.2 Methods 
Detailed materials and methods can be found in chapter two. The laboratory 
and bioinformatics workflow for this study is shown in Figure 4.1. 
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Figure 4.1: Methods undertaken to analyse samples in chapter four 
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Statitistical analysis: Odss ratio 
and REML analysis
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4.2.1 Sample collection, selection and processing 
In total, 40 sputum samples were collected from different patients enrolled in 
the ECF or GAMSTEP projects at the MRC Unit, The Gambia between March 
and July 2015. Upon collection samples were subjected to smear microscopy 
that defined each as ‘No AFB seen’ or as positive with ZN grade +, ++ or +++. 
Samples were visually characterised in terms of colour and viscosity.  
 
Depletion steps and DNA extractions were performed at the MRCG. Samples 
were divided between five groups, each for treatment with a different human 
DNA depletion method, with approximately equal division of the smear 
grade, viscosity and colour characteristics of the samples in each group. Each 
group also contained two negative control samples consisting of sterile water, 
which were processed in the same way as the sputum samples. All samples 
were decongested with sputolysin to reduce the viscosity of samples.  
 
After decongestion, each sputum sample and negative control was 
homogenised by gentle vortexing and divided in half to create two 
subsamples from each sputum aliquot. One subsample was treated with a 
method that attempted to reduce the proportion of human DNA, before 
extraction of the remaining DNA. For the other ‘paired-control’ subsample, 
DNA extraction was performed without any human-DNA depletion. Five 
treatments to reduce human DNA were attempted (Table 4.2). The 40 sputum 
samples given a letter G-K corresponding to the depletion method and were 
then numbered sequentially, 1-8. For each sample, the treated subsample was 
denoted with ‘t’ and the paired-control with ‘c’. 
 
DNA was extracted from the solutions resulting from the treated and the 
paired-control subsamples with the Nucleospin Tissue Kit, used previously.  
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Table 4.2: Methods used to deplete human DNA from sputum samples 
Five methods of human DNA depletion, G -K, were applied to sputum in an attempt 
to alleviate the limitation in detecting M. tuberculosis or other pathogens present in 
metagenomic reads derived directly from sputum.  
Method Description 
G Centrifugation to remove human cells 
H Osmotic lysis of human cells in water then degradation of extracellular DNA using DNase 
I Osmotic lysis of human cells in Tris-HCl then depletion of extracellular DNA with benzonase 
J Osmotic lysis of human cells in water then removal of extracellular DNA using AMPure XP 
K Filtration 
4.2.2 Library preparation and sequencing 
DNA extracts were shipped to Warwick Medical School for library 
preparation and sequencing. The concentration and quality of DNA in each 
extract was assessed using the Qubit fluorimeter and Bioanalyzer high 
sensitivity assay, respectively. Library preparation was performed with the 
TruSeq Nano kit using a modified protocol that allowed the fragmentation 
and size selection steps to be omitted.  All 80 libraries, prepared from the 
treated samples and their paired-controls, were sequenced together on a 
single MiSeq run. 
4.2.3 Bioinformatic and statistical analysis 
The sequenced reads were aligned against the human reference genome, 
hg19, using the Bowtie 2 pre-set parameters --sensitive-local. Given that the 
TruSeq library preparation method did not fragment the DNA nor select the 
read lengths, read lengths were variable. The ‘local’ parameter for alignment 
against the human reference was chosen as this includes soft-clipping of 
mismatched ends to somewhat compensate for the variable read lengths. The 
total number of reads and number of human reads per subsample were 
quantified using Qualimap, then the number of non-human reads was 
deduced. 
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Statistical analyses were applied to determine and compare the extent of 
human read depletion by each of the treatment methods. 
• The percentage of human reads in each method’s pooled treated and 
paired-control subsamples was calculated and used to deduce the 
difference in percentage human reads. 
• A random-effects meta-analysis (rma) was used to fit a restricted 
maximum-likelihood mixed effects model (REML) to the data. 
Confidence intervals and p-values were calculated to describe the 
statistical accuracy of the estimated reduction in human reads by a given 
treatment. This was implemented in the R package, metaphor (214), in 
collaboration with Dr. Peter Kimani. 
4.3 Results 
DNA extracts were successfully obtained from all sputum subsamples using 
all methods, though some contained very low concentrations of DNA. No 
DNA was detected in the negative control samples using Qubit fluorimeter 
with the high sensitivity kit. Analysis of DNA fragment length using the 
Bioanalyzer indicated that the DNA was highly fragmented so in much 
shorter lengths than expected (Figure 4.2). The fragment lengths were too 
short to support use of the Nextera XT library preparation kit so the TruSeq 
library preparation kit was used. Metagenomic sequences were successfully 
obtained from every subsample, despite DNA concentrations obtained from 
some samples being lower than recommended for conventional TruSeq 
library preparation. A mean average of 456,625 reads was achieved for each 
subsample with a range from 33,310 to 1,032,324 reads. The lengths of the 
reads within each subsample were variable and the read lengths were 
unequally distributed between subsamples and between the groups of 
subsamples (Figure 4.3). There was no apparent association between the 
length of the reads and any of the treatment methods when the read length 
distribution was visualised.  
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Figure 4.2: Graphs, as produced by the Bioanalyzer software, showing the 
frequency of DNA fragment lengths from two representative DNA extracts 
The numbers associated with each peak, indicated by the bar across the base of the 
peak, show average fragment size in base pairs from integration of the peaks. Though 
a Bioanalyzer graph from a sample without hyper-fragmented DNA is not available 
since it is not typically analysed, these fragments are much shorter than typically 
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Figure 4.3: Distribution of read lengths in all control subsamples 
Box and whisker plots show distribution of read lengths in each of the control samples. Whiskers represent the maximum and minimum 
read lengths. The top and bottom of the box represent the upper and lower quartile, respectively; the intermediate bar represents the 
median and the mean read length is marked by a cross. The maximum read length and upper quartile are very close for most samples. 
In typical sequence reads generated from NextEra XT libraries and sequenced with V2 sequencing kit, read lengths would all be 250 
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The aim of this study was to develop a method of depleting human DNA from 
sputum such that, after DNA extraction and sequencing, the resulting reads 
data would contain the lowest possible proportion reads derived from human 
DNA. In order to evaluate the treatment methods, each was assigned a group 
of eight sputum samples and two water samples that had been halved; the 
treatment method was applied to one subsample (treated subsample) but not 
the other (control subsample) then the DNA was extracted from both halves 
of each sample in the same way. The sequence data was analysed to identify 
the number of human and non-human reads in each subsample and statistical 
approaches were used to determine the impact that each treatment method 
had had on the number of human reads in the treated samples relative to their 
controls.  
 
In order to evaluate a method, the impact of the treatment on the whole group 
of samples to which it was applied, needed to be determined. Plotting the 
percentage of human derived reads in each of the treatment and control 
samples (Figure 4.4) illustrated the significant variation in the proportion of 
human reads between samples, even amongst the controls which had all been 
prepared in using identical methods across the study. Furthermore, the initial 
frequency of human reads in the control subsample seemed to influence the 
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Figure 4.4: Percentage reads aligning to human reference genome in each sample, grouped by treatment method  
Black lines between cross markers link the percentage of human reads in the control and treated half of each sample. Grey dot markers represent 

























Percentage reads aligning to human reference genome in each sample, separated by sample group, and showing difference 
between control and treatment sample halves
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REML estimation of adjusted proportions of human reads resulting from a 
given treatment method and the impact of the treatment method relative to 
no treatment in the paired-controls was investigated with a random-effects 
meta-analysis (Table 4.4). This approach accounted for the variability in the 
numbers of human reads between samples in a group. Comparison of the 
difference in human reads between treated and control groups for each 
method indicated that method J had the greatest impact on any sample, 
regardless of the characteristics of the individual samples that it was applied 
to. This was followed by methods H, I, K then G, in order of decreasing 
depletion of human reads. However, these summary effects for human read 
depletion by the treatment were not supported by confidence intervals or p-
values for any of the treatment methods. Large p-values, much above the 
typical significance level of p < 0.05, showed that it was likely chance alone 
was responsible for the differences in human reads observed. The confidence 
intervals were large and spanned zero, indicating that the impact of the 
treatment on a sample may have resulted in either increase or decrease of the 
proportion of human reads relative to not treating it. Conclusions about the 
relative impact of the treatment methods on any given sputum sample, those 
other than used in this study, cannot be made from this analysis.  
 
The REML analysis also provided descriptive statistics of heterogeneity that 
were able to separate the variation caused by the treatment method from 
underlying variability in the human proportion of reads between samples in 
each group.  These indicated that the residual	heterogeneity	or	variability	that	
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Table 4.3: Adjusted proportions of reads aligning to the human reference 
genome per method group, as calculated through random effects meta-
analysis  
The impact of the treatments on a sputum sample is determined by the ‘difference in 
















Controls	 Treated	 Lower	 Upper	
G	 93.7	 92.6	 1.1	 -6.9	 9	 0.79	
H	 80.8	 73.5	 7.3	 -15.8	 30.4	 0.53	
I	 96.2	 87.8	 4.8	 -4.6	 14.2	 0.32	
J	 84.5	 71.5	 13.0	 -15.5	 41.6	 0.37	
K	 84.5	 83.2	 1.3	 -12.3	 14.8	 0.85	
4.4 Discussion 
The aim of the work presented in this chapter was to generate preliminary 
data used to develop a method to reduce human DNA in sputum extracts. 
None of the methods, as presented here, were able to provide clinically 
significant depletion of human DNA. Depletion of human DNA in most 
samples was so minimal that statistical evaluation of the relative performance 
of each method with the REML analysis was not supported by p-values or 
confidence intervals. These indicated that most of the variation in frequency 
of human reads between the treated subsamples and controls could be 
attributed to the residual heterogeneity between samples rather than the 
treatment method itself. The few samples used here along with the small 
treatment effect was not enough to provide statistical power. The study was 
compromised by hyper fragmentation of DNA in the extracts that may have 
compromised the results of the study.  
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4.4.1 Performance of treatment methods in this study for 
removing human DNA 
In this study, all five methods achieved little depletion of human DNA and, 
regardless of the treatment method used, a lot of human DNA was left in most 
treated subsamples. Such minimal depletion was neither enough to be 
clinically impactful for a diagnostic approach nor statistically significant. 
REML analysis indicated the average extent of depletion in each sample 
group, therefore the relative performance of the methods, though these 
results were not statistically supported.  
 
The results of the statistical analyses provide cautionary indicators to inform 
further method development. Methods G and K, centrifugation to remove 
human cells and filtration, had very little impact on the removal of human 
DNA. Methods H, I and J, all of which employed osmotic lysis, had a greater, 
though still minimal, impact on the depletion of human reads. The two 
methods, H and J, using sterile water for the lysis stage may have had slightly 
better impact on the resulting human read frequency than method I, using 
Tris-HCl for lysis. This is in contrast with the results of applying similar 
approaches to selectively remove human DNA from dental plaque, where 
Tris-HCl had a markedly bigger impact than water for causing human cells 
lysis and removing human DNA (258). The proportion of human reads was 
reduced slightly more when AMPure XP beads were used in an attempt to 
remove extracellular DNA after differential osmotic lysis than when DNase 
was used. 
 
There was a distinction between the treatment methods that had slightly 
greater impact (methods H, I and J) and those that had very little or no impact 
(methods G and K). The more impactful methods exploited cell lysis and 
removal of extracellular DNA whilst the less impactful methods relied on 
human cells being in-tact and would have incorporated extracellular DNA in 
the final extract for sequencing. Treatment with sputolysin may have been 
associated with human cells but it is not thought to lyse mycobacterial cells, 
given its use prior to mycobacterial culture. Similarly, though sputum 
samples were processed as quickly as possible after collection from patients, 
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this delay may also have resulted in cell lysis. It would have been useful to 
use a microscope to visualise the human cells at various staged in the sample 
processing to determine if any steps caused cell lysis, though this was not 
possible. Despite some success in removing the extracellular DNA by the 
methods using lytic approaches, many human reads remained in the 
subsamples that had been processed in this way. This may have been due to 
failure to lyse the human cells, failure to remove or degrade human DNA by 
use of AMPure beads, DNase or benzonase at their concentrations employed, 
extracellular mycobacterial DNA being degraded or a combination of these.  
 
The filtration and centrifugation methods failed to remove human cells or 
captured both human and bacterial cells in equal proportion. This may have 
resulted from methods failing to separate the human cells from bacterial cells, 
or lysis of these cells before or during the processing step to remove the 
human cells. Viscosity of the samples, having not reduced to a water-like 
liquid, may have prohibited these mechanical methods. Cell lysis may have 
occurred through centrifugation with excess force, through shearing of the 
cells as they were pushed through the filter, or during processing prior to 
attempting human cell removal as described above. Providing similar 
outcomes, a prior study attempting to selectively remove human DNA from 
dental plaque found methods of lysing the human cells produced favorable 
results to centrifugation (258). 
 
Though the aim of this study was to develop a method to reduce the 
proportion of human reads in the metagenomic sequences of sputum, the 
approaches used here were only partially successful: some reduced human 
reads but none could achieve this to an extent that would be useful for a 
diagnostic application. As presented here, these methods do not improve on 
the prior attempts, described in section 4.1, to remove non-target DNA to 
enrich target reads amongst the metagenomic sequences. The methods that 
attempted to lyse human cells before removing extracellular DNA were better 
able to fulfil this aim than those that attempted to remove whole cells only. 
Going forwards, improvements on the capacity to capture or degrade 
extracellular human DNA would require assessment of why human DNA 
remained using microscopy to visualise in-tact cells at various stages in the 
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DNA extraction protocol.  Differential lysis might be pursued preferentially 
to the mechanical separation techniques, either by improving the proportion 
of human cells that are lysed or, should this already be adequate, by 
improving the removal or degradation of the extracellular DNA. A 
combination of both mechanical removal of in-tact human cells and 
extracellular DNA may also prove beneficial. 
4.4.2 Statistical analysis approaches and limitations of 
this study design 
This study was primarily intended to provide guidance in future method 
development, investigating many approaches to human DNA depletion. 
REML estimation could not provide statistically significant results to 
conclude the impact of the treatment methods on samples. The statistics of 
heterogeneity associated with REML analysis indicated that there was more 
variation between samples than between the treated and control subsample 
derived from the same sputum aliquot. This was reflected in the insignificant 
p-values above 0.05, confidence intervals that spanned 0.00 and acceptance of 
the null hypothesis from the REML estimation. In the visual illustration of 
human DNA in each sample (Figure 4.4), it could also be seen that the 
proportion of human reads in the group of treated subsamples broadly 
corresponded to the proportion in their paired control group.  
 
The considerations of sample selection and study design, including splitting 
samples between groups based on physical characteristics and using pairwise 
controls, were insufficient to overcome the heterogeneity amongst sputa and 
provide statistical power to the determine human DNA depletion. As such, 
the results presented for each treatment are only relevant to the specific 
samples that they were applied to in this study and are not reflective of the 
impact the treatment method would have on any given sputum sample.  
Failure to account for variation in the clinical samples represents a flaw in the 
design of other similar studies that conclude changes in human DNA or read 
proportions (203,258). In order to achieve statistical power, future studies 
should consider the heterogeneity amongst sputa, as presented here for the 
first time. These studies would either need to use large sample sizes or achieve 
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greater reduction in the proportion of human reads with treatment in order 
to overcome the confounding effects of heterogeneity and produce 
statistically significant results.  
4.4.3 Unusual fragmentation of DNA 
The DNA resulting from the extractions in this study was found to be highly 
fragmented, resulting in short DNA fragments and subsequently short 
sequence read lengths. For this reason, the Nextera XT library preparation 
could not be used in this study and a modified TruSeq library preparation, 
usually used for ancient DNA, was used instead. The short fragments of DNA 
are unusual after DNA extraction. Supporting this, similar DNA extraction 
methods used in chapter three did not have this issue and library preparation 
was achieved using the Nextera XT kit.  
 
There were delays in transporting the DNA extracts from the MRC Unit, The 
Gambia, where the extractions were performed, to the Warwick Medical 
School where the fragment length analysis and DNA sequencing was 
undertaken. The transportation process took approximately two weeks rather 
than a few days as was advised, expected and had occurred with the transport 
of the samples in chapter three. The samples originally left the MRCG 
packaged with ice packs in an insulated container, were returned to MRCG a 
few days later and then were sent again to the UK on the next available flight, 
but it is unclear how the samples were stored throughout the duration of this 
time. The climate of The Gambia is particularly warm. Certainly, when the 
samples arrived at the Warwick Medical School they were packaged in the 
same manner as when they originally left the MRCG, though the ice packs 
were then at ambient temperature. DNA extracts are typically stored at -20˚C 
in the long-term or at 4 ˚C for short periods (e.g. overnight) whilst they can be 
handled at room temperature for at least a few hours. If the DNA extracts 
were not stored properly during this delay period, warmer temperatures may 
have contributed to the hyper-fragmentation.  
 
The impact of the DNA fragmentation on the outcomes of this study cannot 
be determined. It is not clear whether, or how, the shorter read lengths would 
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affect the likelihood of a read to align the human reference genome. Longer 
read lengths facilitate improved assemblies of genomes and identification of 
the origin of reads when it is unknown and this fragmentation would have 
had an impact if these bioinformatic processes were necessary. This issue, 
likely caused by delays in transportation, highlights one of the difficulties of 
conducting research between multiple countries, particularly those with 
challenging infrastructures. Ideally, this whole study would have been 
conducted at the MRCG and, though this was not possible in this research 
project, this may be considered for future projects. 
4.4.4 Conclusions 
This study was not able to identify an adequate method for depletion of 
human DNA to suit the needs of a metagenomic diagnostic. It indicated some 
avenues for future improvement of the method, how to conduct a similar 
investigation and the potential difficulty of undertaking genomic sequencing 
across distinct sites, meeting the aims of the chapter. Ideally future studies of 
this ilk would be conducted in iterations, analysing whether cells were in tact 
at various stages throughout the extraction process and responding 
accordingly. The impact that the unexpected hyper-fragmentation of DNA 
that occurred in this study is unclear and would be most easily avoided by 
undertaking sample analysis in the same laboratory where DNA was 
extracted. This could be achieved using either qPCR or metagenomic 
sequencing with the highly portable Oxford Nanopore MinION (264). 
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5. Performance of drug 
susceptibility testing approaches in 
Peru  
5.1 Introduction 
5.1.1 TB in Peru 
Statistics on the state of tuberculosis in Peru paint a picture of a high TB 
burden (>40 cases per 100,00) with especially high rates of drug resistance. 
According to WHO estimates, in 2016 there totalled 37,000 (117/ 100,000) new 
cases of TB in Peru of which 3500 cases were MDR/RR-TB (9.5%) (265). Peru 
is in the WHO’s list of high MDR-TB burden countries for 2016-2020 given its 
incidence rate, identifying it as a location where significant progress is 
required to reach the END TB targets (266). Of a population of 32 million in 
2015, around 9 million people live in the capital Lima and TB 
disproportionately afflicts people in this city. Around 60% of Peru’s TB cases 
are concentrated in the capital and the adjacent region, Callao, including 80% 
of MDR-TB infections and 90% of XDR-TB (267,268).  
 
As in much of the world, gaps exist in the diagnosis and successful treatment 
of TB in Peru. Of 31,079 TB cases notified in 2016, 82% of pulmonary TB cases 
were bacteriologically confirmed and nearly all of these, 25,144 (81%), were 
tested for rifampicin resistance (269). However, this lead to estimates of 2300 
MDR/RR-TB cases of which only 1457 (63%) were laboratory confirmed. In 
2016, 1645 patients, including those who had been diagnosed before 2016 or 
whose cases had not been laboratory confirmed, were started on treatment 
(269). From these confirmed MDR/RR-TB cases in 2016, 1104 (76%) cases were 
tested for second-line drug resistance, 88 cases of lab confirmed XDR-TB were 
notified and all were started on treatment (269). From the new TB cases 
registered in 2015, 87% of total TB cases were treated successfully, but the 
latest statistics, from 2014, show that treatment was a success for only 34% of 
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MDR/RR-TB cases and 65% of XDR-TB patients (269). It appears that in Peru, 
rates of first-line drug resistance testing and treatment success is particularly 
poor, despite the numbers of patients with laboratory confirmed TB being 
similar to the number being treated.  
5.1.2 Drug susceptibility testing 
Drug susceptibility testing is an essential element of the tuberculosis 
diagnostic paradigm and is increasingly important as resistance threatens to 
undermine global TB control (see section 1.5.1.2 of this thesis). The ‘gold-
standard’ method for characterising drug resistance is via a series of MTBC 
cultures, one against each drug of interest. This takes weeks to months to 
produce results causing delays to treatment. The Gene Xpert and line probe 
assays have also been endorsed by the WHO, providing rapid molecular 
approaches to detect mutations known to cause resistance to a drug 
(106,155,156). These depend on the resistance-causing mutations being closely 
located on the genome for target by the DST approach, limiting their 
sensitivity (270). Their specificity is limited since they cannot differentiate 
determine that an amino acid substitution is non-synonymous and may not 
impact the resistance phenotype (271). The Gene Xpert provides prediction of 
RIF susceptibility whilst the LPA can predict susceptibility to RIF, INH, FLQ, 
ETB and SLIDs (106,159,160).  The WHO-endorsed methods of DST are also 
often difficult to access across the world given to their prohibitive reliance on 
infrastructure and financial expense. As such, in many settings DST is 
performed only for select patient demographics and in others DST is not 
performed at all. Which DST methods are used depends on the resources and 
disease epidemiology of the setting in question. 
5.1.2.1 Use of MODS in drug susceptibility testing 
The first-choice DST methods, such as the culture-based approaches with the 
BACTEC MGIT system, are prohibitively expensive for use in developing 
countries yet the need to characterise drug resistance remains. The 
microscopic observation drug susceptibility (MODS) assay was developed in 
Peru as a lower cost DST method that can diagnose TB and drug resistance 
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reliably and efficiently in less than 2 weeks (272). The median time to culture 
is comparable for MODS and MGIT and quicker than growth on LJ slopes 
albeit with slightly lower sensitivity and specificity (273–277).  
 
MODS has been employed throughout the world and used for the diagnosis 
of rifampicin and isoniazid resistance (276) though is recommended by the 
WHO for use only in highly specified settings (161). For rifampicin, the 
sensitivity of the assay is 98·0% (95% CI 94·5–99·3) and the specificity is 99·4% 
(95% CI 95·7–99·9) (278). For assays using 0.1 !g/mL isoniazid, the sensitivity 
and specificity are 97·7% (94·4–99·1) and 95·8% (88·1–98·6), respectively (278). 
When using 0.4 !g/mL isoniazid, sensitivity falls to 90·0% (84·5–93·7) but 
specificity increases to 98·6% (96·9–99·4) (278). Recent investigations using 
pyrazinamide in the MODS assay have been disadvantaged by the lack of a 
gold standard for pyrazinamide-susceptibility testing and small number of 
samples but have shown discordance with results obtained using both LJ 
slopes and the MGIT system (279–281). Lower sensitivity and specificity 
combined with insufficient concordance of the MODS assay with other DST 
methods have prevented use of the assay with the other first-line drugs, 
ethambutol and streptomycin (273,274). Second-line DST using this approach 
has yielded sensitivity from 88.1% to 100% and specificity from 92.3% to 100% 
in the small number of studies that have investigated it (282,283). 
5.1.2.2 Whole genome sequencing in drug susceptibility testing  
Whole genome sequencing has been widely used to study the epidemiology 
of tuberculosis (284) and is an emerging technology in TB reference 
laboratories of high-resource countries (192,225,237). Owing to the 
dependency on culture, investment in laboratory infrastructure, staff training 
and expense (as discussed in chapters three and four), genomics is not 
presently appropriate for the detection of tuberculosis. Within the landscape 
of well-established and widely-used diagnostic tools, it instead provides the 
opportunity for characterisation of any mutation that may cause resistance to 
any drug after an MTBC organism has been detected by culture. This may be 
most appropriately implemented once rifampicin resistance has been 
established. Additional advantages of WGS in the diagnostic paradigm 
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include identification of the lineage of aetiological strains, comparative use of 
the data for ultimate-resolution epidemiological approaches and 
characterisation of mixed infections when sequencing is not undertaken from 
an isolated colony.  
 
Beyond obtaining adequate coverage of the genome (which isn’t as issue for 
WGS from cultured samples), the sensitivity and specificity of genomic DST 
is dependent on the bioinformatic tools used to analyse sequence data. In the 
MTBC, this means detection of mutations based genome reconstruction and 
SNV-calling algorithms then interpretation of the clinical consequences of 
these mutations based on our prior understanding of the genotype-phenotype 
relationships. A number of publicly available bioinformatic tools exist to fulfil 
this purpose, each reliant on its own algorithms and databases of  genotype-
phenotype associations though these databases are not thought to be publicly 
available. (212,213,285). When previously uncharacterised mutations are 
discovered in genomic regions associated with resistance, these should be 
characterised phenotypically and the outcomes of this added to ever-growing 
databases of resistance-associated mutations. 
5.1.2 Pyrazinamide  
5.1.2.1 Pyrazinamide in the treatment of TB 
Pyrazinamide (PZA) is an important anti-TB drug. It is now considered 
critical to TB treatment regimens for its ability to kill non-replicating persister 
bacilli, those with low metabolic activity (286). Inclusion of PZA in the 
treatment standard regimen enabled the reduction of treatment time from 9-
12 months to 6 months (287). Pyrazinamide is included in all new anti-TB 
regimens currently undergoing stage II or stage III clinical trials (288) and is 
likely to be important for future drug regimens, due to synergistic interactions 
with new TB drugs, including new drugs, bedaquiline and PA-824 (289–295). 
 
Efficacy of pyrazinamide was initially demonstrated in mice, before being 
shown to work against MTBC organisms in humans. It exhibits no in vitro 
activity against actively growing M. tuberculosis under normal culture 
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conditions (296). Its antibacterial activity was later found to be dependent on 
a low extracellular pH of 5-6, as in the phagosome of macrophages, and 
preferentially towards non-replicating, low metabolic activity persisters 
(286,294,296). It has long been a held assumption that PZA activity requires 
this low extracellular pH, however has recently been challenged by 
pyrazinamide susceptibility of M. tuberculosis cultured on neutral and alkaline 
media under other diverse stressors (297–299).  
 
Our understanding of the mechanism of action of PZA remains incomplete. 
Pyrazinamide is a prodrug that enters the TB bacilli through passive 
diffusion. The pyrazinamidase enzyme, a nicotinamidase that is encoded by 
the pncA gene, converts it to pyrazinoic acid (POA) in the cytoplasm (300). 
POA is pumped out of the cell and then, under acidic extracellular conditions, 
is protonated to HPOA which can be reabsorbed. Inside the cell, HPOA 
releases its proton, acidifying the cytoplasm and becoming POA once again 
to continue this cycle. The cell becomes increasingly acidic and POA 
accumulates in the cell disrupting the balanced energy requirements of the 
non-replicating persister bacilli (291). The consequences are lethal and include 
inhibition of various enzymes, destruction of the proton motive force and 
effecting membrane transport. POA is also thought to bind to the ribosomal 
S1 protein encoded by rpsA (301), although this has recently been contested 
(302). It is proposed that POA competes with tmRNA to inhibit trans-
translation, a process that manages stalled ribosomes during translation in 
non-replicating bacilli (301). In turn synthesis of proteins translated from 
damaged mRNA is prevented and stress survival, associated with diverse 
conditions, is aided (298,303–305).  
5.1.2.2 Pyrazinamide resistance  
Our understanding of pyrazinamide resistance, including its prevalence, 
remains inadequate despite its essential role in TB treatment (306). In a meta-
analysis by Whitfield et al. (307), it was estimated that  
• Globally 1.4 million pyrazinamide-resistant TB cases occur annually. 
• The worldwide prevalence of pyrazinamide resistance is 60.5% amongst 
MDR cases and 16.5% in patients with any form of TB.  
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• The Americas region has highest proportion of pyrazinamide resistance 
of any WHO-region, with 21.9% of all cases being PZA resistant. 
These estimates are limited by a paucity of global data about pyrazinamide 
susceptibility that arises as testing against the drug is not undertaken 
routinely (308). Both M. bovis and M. canettii are known to be intrinsically 
resistant to the drug, though species identification is also not undertaken 
routinely (167). 
 
In a meta-analysis of mutations underlying pyrazinamide resistance, 
undertaken in 2015, around the commencement of the study presented here, 
Ramierez-Busby et al found that 83% of all PZA-resistant isolates had a 
mutation in pncA or its promoter region (306). Such mutations reduce PZAse 
activity leading to absent or reduced conversion of PZA to POA. Assessing 
2760 resistant isolates, they identified 641 unique mutations in the region 
containing the pncA gene and its promoter (306). Similarly, the meta-analysis 
by Whitfield  et al. (307) found 608 unique SNPs at 397 positions in the 561bp 
pncA gene. Of the mutations described in the Ramierez-Busby et al  analysis, 
79% caused an amino acid substitution, 16% were a nucleotide insertion or 
deletion and other isolates had more than one mutation (306). Isolates from 
one study they described were reported with complete deletion of the pncA 
gene. Resistance-associated mutations are dispersed throughout the gene’s 
coding sequence and promoter region (309). The effects of pncA mutations on 
PZA susceptibility are highly inconsistent: 
• Mutations are associated with diverse MICs. 
• Mutations causing non-synonymous amino-acid substitutions may be 
associated with PZA sensitivity (310,311). Amongst 3329 sensitive 
samples assessed, Ramirez-Busby et al  found 96 mutations in the pncA 
gene (306). 
• Mutations causing synonymous amino acid substitution have been 
associated with phenotypic resistance as well as sensitivity (312). 
• Mutations have been identified that are common to both phenotypically 
resistant and sensitive samples, as the only mutations found in the pncA 
gene (306).  
No individual mutation, or even subset of mutations, has a strong predictive 
value for pyrazinamide resistance.  
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In the Ramirez-Busby et al analysis, 18% of resistant samples had a wild type 
pncA (306). These are instead thought to have mutations in other genes or the 
susceptibility phenotype may be considered ‘unexplained’ (291). Studies of 
pyrazinamide resistant samples without pncA mutations have led to 
identification of mutations in the rpsA, panD and hadC genes,(313,314,309,315–
320). Other studies have concluded that these mutations are not associated 
with resistance so their role in susceptibility remains unclear (320,317). 
• The rpsA gene encodes the 30S ribosomal protein S1. Over-expression of 
rpsA is associated with in vitro resistance to pyrazinamide  and mutations 
in rpsA alter POA binding to the ribosomal S1 protein and allowing trans-
translation to occur uninhibited (301). Most, though not all, variation 
between PZA sensitive and resistant samples occurs in the C-terminal 
domain of the RpsA protein, a potential target of POA (301,309). 
Mutations in rpsA are  have been associated with phenotypic resistance 
and sensitivity, including via synonymous amino acid substitution 
(309,315,318). Many samples have been described with mutations in 
neither rpsA or pncA (316,317). Further characterisation of the role of 
these mutations, including the associated MICs, is needed to verify the 
utility of rpsA in diagnosing PZA resistance (309,316–318). 
• The gene, panD, encodes the enzyme aspartate-alpha-decarboxylase 
involved in beta-alanine biosynthesis. Mutations in this gene have been 
identified in in vitro generated PZA resistant mutants; M. canettii which 
is naturally resistant and in naturally occurring M. tuberculosis without 
mutations in either pncA or rpsA (313,314). Resistance-associated 
mutations cluster in the C-terminal domain of PanD; in one study, 24/30 
mutations in PanD resulted in the same change, Met117Ile in the C-
terminal domain (314). Whilst PanD is unlikely to be the main target of 
PZA or POA, activity of the aspartate-alpha-decarboxylase enzyme is 
inhibited by POA (314,320). It has been suggested that PZA resistance 
may be caused by binding of POA to this C-terminal domain, inhibiting 
production of pantothenate and co-enzyme A from beta-alanine and 
interfering with the cell’s metabolic functions (321). 
• Mutations have been identified in the hadC gene amongst pyrazinamide 
resistant strains without pncA and rpsA mutations. The gene encodes the 
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beta-hydroxyacyl-acyl carrier protein dehydratase involved in mycolic 
acid elongation during growth of the cell envelope (313). Owing to the 
role of hadC in actively growing bacilli, rather than persister cells, it is 
thought to be unlikely that it has a role in PZA resistance (321). 
5.1.2.3 Pyrazinamide susceptibility testing  
Until recently, phenotypic approaches have formed the basis of pyrazinamide 
susceptibility testing. The WHO recommends culture-based susceptibility 
testing for pyrazinamide but has endorsed no methods for doing so; tests are 
rarely performed in the diagnostic workflow (308). Phenotypic tests present 
unreliable results, particularly when the clinical inoculum is too large and 
physiological stressors such as an acidic environment are not present (322–
325). Nonetheless, several are available, including: 
• The BACTEC™ MGIT™ PZA test (Becton Dickinson, Sparks, MD), 
described in section 1.5.1.2, based on growth of MTBC in an automated 
system with a critical PZA concentration of 100 µg/mL.  
• The Wayne’s test (201), a colorimetric test that determines whether the 
PZAse enzyme is active. It requires subjective interpretation of the 
colorimetric changes and is limited by unacceptable rates of false-
resistance (294,322,326). 
• The Microscopic-observation drug susceptibility (MODS) assay (200), 
described in section 5.1.2.1, determines microscopic growth in the 
presence of 800 !g/ml PZA. 
 
Genotypic approaches to PZA resistance testing have been proposed, though 
none have yet been commercialised. It has been reported that identification of 
mutations in pncA and its promoter can determine PZA resistance in MDR-
TB isolates with high positive-predictive values and can rule out PZA 
resistance in non-MDR-TB with high negative-predictive values (322,327). A 
review by Ramirez-Busby et al estimated that this would lead to a sensitivity 
of 83% and specificity of 90% (306). Caveats arise from the unclear 
relationship between PZA susceptibility genotypes and phenotypes and the 
17% of PZA resistant samples that would go undetected. A simple gene-based 
assay, such as the GeneXpert, is not going to be feasible for improved 
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prediction of PZA resistance since even the known mutations are distributed 
across the entire large pncA gene. As at least three other genes have a role in 
the clinical resistance, these too may need to be amplified and screened or 
sequenced to achieve the desirable sensitivity and specificity for the assay. 
However, addition of rpsA, panD and hadC to a genotypic diagnostic is 
thought to lead to insignificant improvement in sensitivity. Instead, a 
comprehensive molecular test, such as whole genome sequencing as 
discussed in section 5.1.2.2. would need to target the whole pncA gene 
sequence and screen for 600+ variants (327–331). 
5.1.8 Rationale for the Study  
Given the threat presented by the global burden of drug resistant TB, efficient 
detection and treatment of strains with resistance to any drug is central to 
worldwide elimination efforts. Methods currently used for characterisation of 
drug susceptibility have a number of short-comings, including delays in 
detection, prohibitive expense and poor accuracy of the test. Improving on 
these methods is essential to on-going success in patient treatment and 
meeting the WHO goals for control of TB.  
 
Collaboration with researchers in Peru was established in summer 2015. A 
sample set was available that had previously been phenotypically 
characterised by MODS for rifampicin, isoniazid and pyrazinamide 
resistance, and by the BACTEC 960 PZA MGIT and Wayne's assays. Using 
whole-genome sequencing at the University of Warwick, it was decided to 
characterise the genetic basis of resistance in these strains and how this related 
to the performance of the phenotypic diagnostic assays used. The aims and 
rationale of undertaking this research were to: 
• Determine the mutations associated with pyrazinamide resistance in this 
dataset, adding further evidence to conversations about the role of pncA 
and the involvement genes, rpsA, panD and hadC, whose role in PZA 
susceptibility remains unclear. 
• Investigate the relationship between phenotypic pyrazinamide 
susceptibility test outcomes and the genetic basis of resistance. Poor 
reproducibility of PZA diagnostics has undermined its routine use in the 
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clinic and understanding the genetic mechanisms of susceptibility that 
might contribute to this, particularly for PZA MODS for which no 
previous studies were found to address this, is limited. 
• Characterise the genetic basis of susceptibility as determined by the 
MODS assay for rifampicin and isoniazid resistance, adding to the 
understanding of the shortcomings in accuracy of these methods.  
• Compare and evaluate the performance of whole genome sequencing 
and individual bioinformatic tools for prediction of drug susceptibility 
from whole-genome sequence data. All available high-throughput 
widely available bioinformatic tools were evaluated. It was expected 
that, being based on different algorithms for identifying mutations and 
using different databases that relate genotype to phenotype, that their 
susceptibility predictions would also differ. By relating this to the 
phenotypic results, this would allow evaluation of performance that 
could feedback to improvements in these tools.  
The MODS assay is conducted after inoculation of culture media directly with 
sputum and the outcomes reflect the strains present in potentially 
heterogeneous sputum. In order to be directly comparable, this heterogeneity 
was maintained in the other phenotypic DST methods and in the whole-
genome sequences. The influence of heterogeneity on performance of these 
diagnostic was therefore also evaluated. 
5.2 Methods 
Full details of materials and methods can be found in chapter two. The 
laboratory and bioinformatics workflow for this study is shown in Figure 5.1 
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5.2.1 Sample collection and processing 
Samples were collected, cultured and subjected to phenotypic analyses by my 
collaborators in Peru. Sixty-nine sputum samples were obtained, each from a 
different patient, in the DIRESA-Callao region and Hospital Dos de Mayo, 
Lima, Peru in the periods July-December 2015 and October-December 2015, 
respectively. Samples were processed at Universidad Peruana Cayetano 
Heredia. As part of an on-going project, the sputa had been characterised as 
smear-positive by microscopy, decontaminated and primary cultures were 
obtained on solid 7H10 medium. Cultured material was stored at -80 ˚C. The 
samples selected for this study were selected from the project independent of 
drug resistance profile (Table 5.1). 
 
Drug susceptibility testing for the first-line antibiotics rifampicin, isoniazid 
and pyrazinamide was performed by staff in Peru using the following 
phenotypic methods: 
• Microscopic-observation drug susceptibility (MODS) assay critical drug 
concentrations: 0.4 !g/ml INH, 1.0 !g/ml RIF, 400 !g/ml PZA, 800 
!g/ml PZA 
• BACTEC™ MGIT™ 960 PZA assay (MGIT), inoculated with cultured 
isolates and a critical drug concentration of 100 µg/mL PZA. 
• Wayne’s pyrazinamidase assay of cultured sample 
Phenotypic testing was unavailable for first-line drugs, ethambutol and 
streptomycin and for all second-line  
 
 
5.2.2 DNA extraction and genome sequencing 
DNA extractions were performed at Universidad Peruana Cayetano Heredia 
from multiple-colony sweeps from solid media, after re-culture from 
multiple-colony frozen stocks. DNA was extracted using the CTAB method 
and the protocol as described previously. DNA extracts were sent to the 
University of Warwick where all further laboratory and bioinformatic 
analyses by the author. DNA extracts were quantified and converted to 
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sequencing libraries using the Illumina Nextera XT method. All 69 samples 
were sequenced on one run of the Illumina MiSeq using 2 x 301 bp paired-end 
reads to produce FASTQ files. 
5.2.3 Genomic prediction of drug resistance 
The quantity of sequence reads and the coverage of the TB reference genome 
was determined after alignment against H37Rv using the Botwie2 pre-set 
parameter –-very-sensitive-local then visualised with Qualimap. Clinically 
relevant drug resistance was predicted from genetic variants after comparison 
to known resistance-associated mutations catalogued in databases, using the 
recently developed software tools Mykrobe predictor (212), PhyResSE (213), 
and KVarQ (285). All three tools were used as the results varied owing to 
differences in variant calling protocols and in the catalogues of drug 
resistance mutations used. Approaches that provided the number of reads 
from each allele enabled identification of hetero-resistance at positions with a 
depth of coverage > 10 and the minor allele as >10% of the total reads. 
 
For phenotypically resistant samples where no known resistance-associated 
mutations could be identified, genetic variants were sought in the relevant 
resistance-associated genes. This approach was also applied to the 
identification of mutations in the pncA, rpsA, panD and hadC gene regions 
associated with pyrazinamide resistance. These genetic variants between the 
clinical isolates from Peru and the H37Rv TB reference genome were 
identified with VarScan2, excluding: 
• variants in known repetitive regions (191) 
• SNPs that fell near INDELs 
• positions with coverage less than 5 bases, quality score below 20, 
minimum variant frequency below 0.1 or a p-value less than 0.001.  
A maximum-likelihood phylogenetic tree was computed by PhyResSE. 
5.2.4 Lineage typing and identification of mixed lineages 
The lineages of strains present were identified using MGplacer and verified 
by comparison to the epidemiological types provided by PhyResSE and 
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Mykrobe. MGplacer was also used to screen for mixed lineages and identify 
the lineages present. Samples were reported to have mixed lineages when 
MGplacer reported that over 5% mixed reads were present and this was 
confirmed by visual inspection of reads with Artemis. 
5.3 Results 
Sputum from patients in the Lima and Callo regions of Peru was characterised 
to understand the genetic basis of drug resistance in these samples, 
particularly against pyrazinamide, and to evaluate the performance of DST 
approaches. The 69 smear-positive samples selected for this study had been 
analysed by our Peruvian collaborators by MGIT, MODS and Wayne’s 
methods of phenotypic pyrazinamide susceptibility testing and MODS for 
phenotypic rifampicin and isoniazid testing. Analyses were conducted from 
primary cultures of sputum, either using multiple colonies from an LJ slope 
or broth culture, to capture the diversity of M. tuberculosis within the sample. 
Genomic coverage from each sample ranged from 25 to 91-fold coverage of 
the genome. Sequences were used to predict genotypic drug resistance 
against rifampicin, isoniazid, pyrazinamide, ethambutol, streptomycin, 
fluoroquinolones and the aminoglycoside agents using the Mykrobe 
predictor, PhyResSE and KVarQ software tools. When resistance-associated 
mutations could not be identified in a phenotypically resistant sample, SNP 
calling was undertaken in the relevant resistance-associated genes. For all 
samples, SNP-calling was undertaken in pyrazinamide resistance-associated 
genes. Heterogeneity amongst the strains cultured from each sputum sample 
was characterised by detecting mixed coverage by PhyResSE, defining mixed 
lineages by MGplacer and identifying heterogeneous alleles at resistance-
associated genomic positions; this informed the understanding of the DST 
method performances. All samples were identified as containing M. 
tuberculosis sensu stricto strains. 
5.3.1 Lineage and drug resistance predictions  
Mykrobe, PhyResSE and KVarQ were first used to identify resistance-
associated mutations in all samples. M. tuberculosis lineages were assigned 
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using these same tools and MGplacer (Table 5.1). These mutation profiles 
were the used to evaluate the performance of the tools for testing and 
predicting drug resistance.
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Table 5.1: All drug resistance associated mutations, as predicted by any bioinformatic analysis tool, and the major 
lineages predicted by MGplacer  
Clinical definitions have been predicted based on this full drug resistance profile. A coloured background to the cell indicates that 
resistance is associated with the mutation; a white background to the cell indicates drug sensitivity; a different colour is used for each 
drug for ease of visual inspection only. For clinical definitions, a dark grey background is used for strains that may be considered XDR-
TB given the genomic predictions and the shade of grey gets progressively lighter for pre-XDR-TB and MDR-TB, then the background 























































   
   
   
   
   
   







































gene rrs XDR 














gene rrs XDR 








in RpsL     MDR 








in RpsL     MDR 
MP176 2.2.1     Arg212Arg in RpsA   
Lys43Arg 
in RpsL     DS 























































   
   
   
   
   
   

























MP035 2.2.1     Arg212Arg in RpsA         DS 
MP124 2.2.1     Arg212Arg in RpsA         DS 
MP306 2.2.1     Arg212Arg in RpsA         DS 




PncA     
Ala90Val in 
gyrA   Pre-XDR 
MP169 4.1.1   Ser315Thr in KatG          DS 
MP186 4.1.1               DS 
MP360 4.1.1.3 Ser450Leu in RpoB 
Ser315Thr 
in KatG   
Gly406Ala 
in EmbB       MDR 
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MP042 4.1.2.1 His445Leu in RpoB 
Ser315Thr 
in KatG   
Gly406Ser 
in EmbB       MDR 
MP026 4.1.2.1   Ser315Thr in KatG           DS 




          DS 
MP126  4.1.2.1           Asp94Gly in GyrA   DS 
MP051 4.1.2.1               DS 
MP082 4.1.2.1               DS 
MP111 4.1.2.1               DS 
MP199 4.1.2.1               DS 
MP200 4.1.2.1               DS 
MP210 4.1.2.1               DS 
MP307 4.1.2.1               DS 























































   
   
   
   
   
   

























MP315 4.1.2.1               DS 
MP190 4.3.2 Ser450Leu in RpoB 
Ser315Thr 
in KatG     
C491T in 
gene rrs     MDR 
MP028 4.3.2   Ser315Thr in KatG     
C491T in 
gene rrs     DS 
MP203 4.3.2         C491T in gene rrs     DS 
MP248 4.3.2         C491T in gene rrs     DS 
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in PncA         MDR 
MP182  4.3.3 Asp435Val in RpoB 
Ser315Thr 
in KatG           MDR 
MP013 4.3.3 Asp435Tyr in RpoB 
Ser315Thr 
in KatG           MDR 
MP054 4.3.3 Ile491Phe in RpoB 
Ser315Thr 
in KatG           MDR 
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PncA         MDR 
MP041 4.3.3   Ser315Thr in KatG           DS 
MP005 4.3.3   Ser315Thr in KatG           DS 
MP073 4.3.3   Ser315Thr in KatG           DS 
MP118 4.3.3   Ser315Thr in KatG           DS 
MP069 4.3.3               DS 
MP092 4.3.3               DS 























































   
   
   
   
   
   







































in rpoC  
Ser315Thr 
in KatG           MDR 
MP059 4.4.1.1               DS 
MP284 4.7               DS 




          MDR 
MP038 4.9         A514C in gene rrs     DS 
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Heterogeneity within samples became apparent on bioinformatic analysis. 
The software tool, KVarQ, reported ‘mixed coverage’ in samples MP031, 
MP050, MP054, MP069, MP075, MP118, MP182, MP186, MP241, MP275, 
MP307, MP313, MP364 and MP367. On inspection of SNPs called in these 
samples, heterogeneous alleles could be observed at numerous positions 
across the genome, confirming that there were heterogeneous strains within 
these samples. Understanding this heterogeneity was important to assessing 
its impact on drug susceptibility typing, a primary aim of this study.  
 
MGplacer, a tool that places metagenomic sequence reads onto a phylogenetic 
tree, was used to identify the lineages of strains within the samples. MGplacer 
identified samples with multiple lineages present and the major strain in each 
sample concurred with those identified by other software tools. The outputs 
from MGplacer were filtered such that only samples with two or more distinct 
lineages, excluding the ancestral lineage (lineage 7), could be considered 
mixed (Table 5.2). Read alignments were visually inspected at the lineage 
defining SNP positions to validate the determination of mixed infection. 
 
In some samples, heterogeneous alleles were observed at sites associated with 
drug resistance by the Mykrobe and PhyResSE tools. A number of samples 
were identified with heteroresistance to one or more drugs (Table 5.3), with 
variable frequencies of resistant reads depending on the SNV-calling 
algorithm used by the tool. All samples showing heteroresistance were 
phenotypically resistant to the relevant drug, by MODS for rifampicin and 
isoniazid or BACTEC MGIT for pyrazinamide, with the exception of 
resistance to isoniazid by the inhA promoter mutation in sample MP313. For 
second-line drugs, phenotypic susceptibility results were not available. Both 
mixed lineages and heteroresistant alleles could be identified in some 
samples, MP118, MP186 and MP313.  
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Table 5.2: Mixed lineage samples and their associated lineage branches and proportions, as reported by MGplacer 
Sample  
Major lineage Minor lineage 
Proportion 




















MP118 79.3 77.6-80.8 4.3 4.3.3 0.98 20.7 19.2-22.4 4.1 4.1.1 0.84 
MP313 84.8 83.4-86.1 4.3 4.3.3 0.99 15.2 13.9-16.6 4.1.2 4.1.2.1 0.98 
MP275 92.7 92.0-93.4 2.2.1 2.2.1.2 0.03 7.3 6.6-8.0 4.3 4.3.3 0.8 
MP210 94.8 94.0-95.6 4.1.2 4.1.2.1 0.92 5.2 4.4-6.0 4.3 4.3.2 0.9 
MP182 98.5 98.2-98.8 4.3 4.3.3 1 1.5 1.2-1.8 2.2.1 2.2.1.2 0.9 
MP186 98.9 98.7-99.2 4.1.1 4.1.1.3 1 1.1 0.8-1.3 2.2 2.2.1 0.76 
MP315 99.0 98.7-99.3 4.1.2 4.1.2.1 1 1.0 0.7-1.3 4.3 4.3.3 0.71 
MP096 99.3 98.7-99.6 4.3 4.3.3 1 0.7 0.4-1.3 4.3.4 4.3.4.2 0.83 
MP307 99.5 99.3-99.7 4.1.2 4.1.2.1 1 0.5 0.3-0.7 4.3 4.3.3 0.8 
MP169 99.6 99.4-99.7 4.1.1 4.1.1.1 0 0.4 0.3-0.6 4.3 4.3.3 0.58 
MP284 99.6 99.5-99.7 4 4.7 1 0.4 0.3-0.5 2.2 2.2.1 0.85 
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Table 5.3: Heteroresistant mutations predicted to cause resistance by Mykrobe and PhyResSE 
Sample Mutation Mykrobe read ratio (R/S) PhyResSE read ratio (R/S) 
MP031 Ser450Leu in RpoB 5/12 11/32 
MP118 Ser315Thr in KatG 18/7 25/16 
MP313 inhA promoter mutation -15(C>T) 27/8 34/11 
MP313 Ser450X in RpoB 22/2 29/2 
MP313 His51Arg in PcnA n/a 26/4 
MP186 A1401X in rrs 3/25 n/a 
MP241 Ala90X in GyrA 20/4 28/6 
MP367 His51Arg in PncA n/a 13/2 
MP050 Lys43Arg in RpsL 32/6 48/8 
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Mykrobe also predicted low frequency drug resistance alleles or ‘minor 
alleles’ where a low proportion reads were associated with a resistance 
mutation and the sample was not otherwise predicted to be clinically resistant 
(Table 5.4). Some of these minor alleles were found as the only mutation for 
the given drug whilst others were found in addition to a second mutation that 
was predicted to cause resistance to the same drug. There were 21 samples 
with only a minor allele mutation where no further mutation that was 
predicted to cause resistance in the same drug. All but one of these were 
sensitive by the phenotypic methods available and Mykrobe did not predict 
that these samples were resistant. 
 
Table 5.4: Low frequency resistance alleles reported by Mykrobe predictor 
Colours represent susceptibility status indicated by the drug susceptibility test 
method; red indicates resistance-association whilst green indicates an antibiotic 
sensitive- association. Fractions indicate the number of reads in which the 
resistance-associated allele (numerator) and sensitive alleles (denominator) were 
reported by genomic prediction tools. 
Sample Drug Phenotypic DST Minor allele mutation 
Major allele 
mutation 
MP320 RIF R Gly42X in RpoB: 1/25 Asp435X in RpoB: 25/0 
MP248 RIF S Asp335X in RpoB: 1/32 — 
MP341 RIF R Phe425X in RpoB: 2/14 Asp435X in RpoB: 16/0  
MP050 RIF S Phe425X in RpoB: 2/22 Leu452X in RpoB: 30/0 
MP360 RIF R Phe425X in RpoB: 2/31  Ser450X in RpoB: 28/0  
MP082 RIF S Phe425X in RpoB: 1/30 — 
MP118 RIF S Gly426X in RpoB :1/17  — 
MP059 RIF S Gly426X in RpoB: 1/24 — 
MP248 RIF S Gly426X in RpoB: 1/33  — 
MP282 RIF R Gly426X in RpoB: 1/26  Ser450X in RpoB: 24/0 
MP182  RIF R Thr427X in RpoB: 1/33 Asp435X in RpoB: 29/2 
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Sample Drug Phenotypic DST Minor allele mutation 
Major allele 
mutation 
MP186 RIF S Ser428X in RpoB: 1/23  — 
MP118 RIF S Ser431X in RpoB: 1/18 — 
MP118 RIF S Ser431X in RpoB: 1/18 — 
MP268 RIF S Gln432X in RpoB: 1/33 — 
MP075 RIF R Phe433X in RpoB: 1/14 Ser450X in RpoB: 18/0 
MP186 RIF S Met434X in rpoB: 1/27 — 
MP275 RIF R Asp435X in RpoB: 1/32  Ser450X in RpoB: 31/0  
MP073 RIF S Asn438X in RpoB: 2/47 — 
MP026 RIF S Pro439X in RpoB: 2/39 — 
MP200 RIF S Gly442X in RpoB: 1/23 — 
MP031 RIF R Gly442X in RpoB: 2/20  Ser450X in RpoB: 5/12  
MP028 RIF S Gly442X in RpoB: 2/66 — 
MP005 RIF R His445X in RpoB: 2/57 — 
MP176 RIF S Arg447X in RpoB: 2/46  — 
MP186 RIF S Ser428X in RpoB: 1/23  — 
MP092 RIF S Ser450X in RpoB: 1/23 — 
MP176 RIF S Ser450X in RpoB: 2/41 — 
MP248 INH S inhA promoter mutation -16nt (A>X): 1/20 — 
MP176 INH S inhA promoter mutation -8nt (T>X): 1/33 — 
MP190 ETB n/a Met306X in EmbB: 1/32 — 
MP038 ETB n/a Met306X in EmbB: 2/22 — 
MP073 ETB n/a Met306X in EmbB: 2/46 — 
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Sample Drug Phenotypic DST Minor allele mutation 
Major allele 
mutation 
MP313 FLQ n/a Asp89X in GyrA: 1/32 — 
MP202 FLQ n/a Pro86X in GyrA: 1/23  Asp94X in GyrA: 26/0 
MP005 FLQ n/a Pro86X in GyrA: 2/58 — 
MP170 SM n/a C517X in gene rrs: 1/32 — 
5.3.2 Genotypic definition of pyrazinamide resistance 
Before the performance of susceptibility tests could be evaluated, the 
resistance status associated with each mutation needed to be defined. Given 
that no gold-standard DST is available for pyrazinamide, the available 
evidence about susceptibility was evaluated to draw conclusions. Neither 
MODS nor genotypic analysis methods could be considered as gold standard 
for rifampicin and isoniazid susceptibility testing, so it was not possible to 
conclude the susceptibility status of samples to these drugs, especially those 
with discordance across the DST methods.  
5.3.2.1 Pyrazinamide 
Phenotypic pyrazinamide susceptibility testing was undertaken using the 
MGIT, MODS and Wayne’s assays. Predictions of pyrazinamide resistance 
were made using PhyResSE and KVarQ and all mutations in the pncA, rpsA, 
panD and hadC gene regions associated with pyrazinamide resistance were 
identified by calling SNPs (Table 5.5). It is well established that not every 
mutation in the genes associated with pyrazinamide resistance necessarily 
causes resistance (310,311) so the results of all DST methods were taken into 
consideration when making predictions about which mutations would cause 
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Table 5.5: Results of drug susceptibility testing for pyrazinamide with the 
various phenotypic methods and genomic prediction tools  
Red font indicates that the result is associated with resistance; green font indicates 
association with sensitivity; black font indicated that no susceptibility prediction 
was made. Fractions indicate the number of reads in which the resistance-associated 
allele (numerator) and sensitive alleles (denominator) were reported by genomic 
prediction tools. The number of resistant and sensitive reads are not reported by 

















PhyResSE KVarQ SNP calling 
MP00
5 S S S — — — 
MP01
3 S S S — — — 
MP04
1 S S S — — — 
MP04
2 S S S — — — 
MP05
1 S S S — — — 
MP05
4 S S S — — — 
MP05
9 S S S — — — 
MP06
3 S S S — — — 
MP06
9 S S S — — — 
MP07
3 S S S — — — 
MP08
2 S S S — — — 
MP11
8 S S S — — — 
MP12
0 S S S — — — 
MP12
6 S S S — — — 

















PhyResSE KVarQ SNP calling 
MP16
7 S S S — — — 
MP16
9 S S S — — — 
MP18
2 S S S — — — 
MP18
6 S S S — — — 
MP19
0 S S S — — — 
MP19
9 S S S — — — 
MP20
0 S S S — — — 
MP20
3 S S S — — — 
MP21
0 S S S — — — 
MP28
4 S S S — — — 
MP30
7 S S S — — — 
MP31
5 S S S — — — 
MP36
0 S S S — — — 
MP32














5 S S S — — 
Arg212Arg in 
RpsA: 40/2 

















PhyResSE KVarQ SNP calling 
MP30












2 S R S — — — 
MP01
9 S S R — — — 
MP02
6 S S R — — — 
MP02
8 S S R — — — 
MP03
8 S S R — — — 
MP11
1 S S R — — — 
MP24
8 S S R — — — 
MP26
8 S S R — — — 
MP20






















6 S S R — — 
Arg212Arg in 
RpsA: 52/0 

















PhyResSE KVarQ SNP calling 
MP03




7 R S R 










3 R S R 






PncA: 26/4  
AlAla381Val
al in RpsA: 
29/8 
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5 R S R 
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PhyResSE KVarQ SNP calling 
MP24
7 R R R 





1 R R R 








1 R R R 










2 R R R 










0 R R R 










4 R R R 










5 R R R 








6 R R R 








6 R R R 








1 R R R 








7 R R R 
























PhyResSE KVarQ SNP calling 
MP28








Some samples were considered to certainly be resistant. For 12 samples, the 
phenotyping tests concordantly determined that samples were pyrazinamide 
resistant. The genomic software tools collectively predicted resistance in all of 
these samples and these were associated with the Ile6Ser, His51Arg, 
His57Leu, His71Arg, Gln10Pro or Gln10Arg mutations in PncA. These 
mutations were also identified in other samples, all of which were resistant 
by the MGIT assay and a second phenotypic method. Samples that were 
MGIT sensitive did not have these mutations and were resistant by only one 
method or concordantly sensitive. The relationship between this set of 
mutations and MGIT resistance was clearly very strong, being supported by 
a secondary DST method. The mutations had previously been identified to 
cause resistance such that they were included in the databases of the WGS 
tools so, along with MGIT resistance, they were considered associated with 
pyrazinamide resistance in this study. 
 
Two further mutations were reported by KVarQ in association with 
pyrazinamide resistance but had mixed associations with phenotypic 
resistance: 
• The mutation, Lys48Thr in PncA, was found in two samples that were 
resistant by MODS only and a further two samples that were 
concordantly pyrazinamide sensitive.  
• The Pro62Ser mutation in PncA was found in sample MP050 that was 
phenotypically resistant by the MODS method only. A second mutation, 
Arg212Arg, in resistance-associated gene, RpsA, was also found in this 
sample. 
Both mutations, Lys48Thr and Pro62Ser in PncA, were reported by the KVarQ 
software in association with pyrazinamide resistance, and could be identified 
by PhyResSE but without association with resistance. Given that these 
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mutations were associated with phenotypic sensitivity by the MGIT and 
Wayne’s assays and with resistance by only the KVarQ prediction tool, they 
were considered to be associated with phenotypic sensitivity in this study. 
 
The Arg212Arg mutation in RpsA was found by SNV-calling in four 
concordantly phenotypically sensitive samples and as the only mutation in 
two samples resistant by MODS only. It was found in sample MP282 with the 
secondary mutation, Ile6Ser in PncA which has already been established to 
have a strong association with phenotypic resistance, including by the MGIT 
assay, and in sample MP050, discussed above. All instances of this mutation 
were found in samples containing the 2.2.1 lineage of M. tuberculosis. Another 
mutation, Ala381Val in RpsA, was identified by all genotyping methods but 
not associated with resistance by the tools. It was observed to accompany 
every instance of the known-resistance mutation, His51Arg in pncA which 
occurred in phenotypically resistant samples, but was absent from any other 
sample. Given that neither Arg212Arg nor Ala381Val in RpsA were predicted 
to cause resistance through any sequence-based tool and that they were never 
associated with MGIT resistance in the absence of a secondary pyrazinamide-
associated mutation, these mutations were not considered to underlie 
resistance in this study. 
 
The samples without mutations in pyrazinamide-associated genes were 
considered to be truly sensitive to the drug given that they were never found 
to be associated with MGIT resistance and only ever found to be associated 
with either MODS or Wayne’s test resistance, never both.  
5.3.2.2 Rifampicin 
For rifampicin, susceptibility was determined with MODS, Mykrobe, 
PhyResSE and KVarQ. The mutations, Asp435Val, Asp435Tyr, Leu430Pro,	
Ser450Leu,	His445Leu, Leu452Pro and Ile491Phe were found in RpoB and 
associated with MODS resistance with a few exceptions (Table 5.7). Despite 
MODS indicating resistance, no mutation was identified by the software in 
the sample, MP005. For this sample, SNP calling was conducted in the genes, 
rpoB, embB and Rv2629, and their putative promoter regions but no mutation 
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could be identified. Compensatory mutations, Ile491Val and Val483Gly in 
RpoC, were additionally reported by KVarQ in samples MP075 and MP120, 
respectively. Many ‘minor alleles’ were identified by Mykrobe that were not 
considered resistant by the tools due to the low frequency resistant alleles at 
the mutation position. These minor alleles were found both as the only 
mutation in a sample and in conjunction with other low frequency mutations 
or mutations that were predicted to cause resistance.  
5.3.2.3 Isoniazid 
For isoniazid, assessment by MODS, Mykrobe, PhyResSE and KVarQ was 
used to determine susceptibility. Only two genetic mutations were 
responsible for isoniazid resistance in these isolates, Ser315Thr in KatG and a 
mutation 15 bases upstream of the inhA gene. One sample, MP063, was 
identified with both of these mutations. Two minor alleles were reported by 
Mykrobe but not associated with resistance with the tool. 
5.3.2.4 Other drugs 
Resistance to ethambutol, streptomycin, fluoroquinolones and 
aminoglycosides was not determined phenotypically. Evidence of resistance 
to these drugs was only be provided by the sequence-based predictions and 
included the mutations Tyr319Ser, Met306Ile, Gly406Ser and Gly406Ala in 
EmbB; C491T, A514C and A1401G in gene rrs; Lys43Arg in RpsL; Asp94Gly, 
Ser91Pro and Ala90Val in GyrA. It is unclear whether a mutation in genes 
associated with resistance to these other drugs might confer true clinical or 
phenotypic resistance from these data presented here alone. All that can be 
determined is whether a tool predicted resistance or not. Only one resistance-
causing mutation was ever predicted per sample. Minor alleles were also 
identified amongst mutations associated with resistance to these drugs.  
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5.3.3 Performance of susceptibility testing and 
prediction methods 
The rate of detection of resistance predicted by each DST method varied for 
each of the mutations identified (Table 5.6). Some discrepancies between the 
susceptibility results from each DST method were associated with samples 
with mixed lineages, heteroresistance or “mixed coverage” reported by 
PhyResSE (Table 5.7). The overall sensitivity and specificity of each DST 
method for PZA resistance were evaluated relative to the conclusions of the 
MGIT assay, given its strong association with susceptibility predicted in the 
mutations (Table 5.8). Neither MODS nor genotypic analysis methods could 
be considered as gold standard for rifampicin and isoniazid susceptibility 
testing, so it was not possible to determine a susceptibility status of samples 
in association with these drugs. Comparisons of the results of each method 
for each mutation could be assessed nonetheless. 
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Table	5.6	Rate	of	prediction	of	resistance	for	susceptibility-associated	mutations	found	in	this	study	Minor	alleles	are	not	considered	here.  



































Ala381Val in RpsA 	 PZA	 R	 7	 100	 57.1	 100	 n/a	 100	 100	
Gln10Arg	in	PncA	 PZA	 R	 11	 100	 54.5	 81.8	 n/a	 100	 81.8	
His71Arg	in	PncA	 PZA	 R	 2	 100	 50	 100	 n/a	 100	 100	
Gln10Pro	in	PncA	 PZA	 R	 1	 100	 100	 100	 n/a	 100	 100	
Ile6Ser	in	PncA	
Arg212Arg in RpsA 	 PZA	 R	 1	 100	 100	 100	 n/a	 100	 100	
His57Leu	in	PncA	 PZA	 R	 1	 100	 100	 100	 n/a	 100	 100	
Arg212Arg	in	RpsA	 PZA	 S	 6	 0	 0	 33.3	 n/a	 0	 0	
Lys48Thr	in	PncA	 PZA	 S	 4	 0	 0	 50	 n/a	 0	 100	
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Arg212Arg in RpsA 	 PZA	 S	 1	 0	 0	 100	 n/a	 0	 100	
No mutation in 
pyrazinamide-
associated genes 
PZA	 S	 35	 0	 2.9	 20	 n/a	 0	 0	
Asp435Val in RpoB RIF n/a	 17 n/a	 n/a	 88.2	 100 100 100 
Asp435Tyr in RpoB RIF n/a	 1 n/a	 n/a	 0	 100 100 100 
Leu430Pro in RpoB RIF n/a	 1 n/a	 n/a	 0	 100 100 100 
Ser450Leu in RpoB RIF n/a	 14 n/a	 n/a	 100	 100 100 92.8 
His445Leu in RpoB RIF n/a	 1 n/a	 n/a	 100	 100 100 100 
Leu452Pro in RpoB RIF n/a	 1 n/a	 n/a	 0	 100 100 100 
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Ile491Phe in RpoB RIF n/a	 1 n/a	 n/a	 100	 0 100 0 
No mutation in 
rifampicin-
associated genes 
RIF	 n/a 33	 n/a	 n/a	 3.0	 0	 0	 0	
Ser315Thr	in	KatG	 INH	 n/a 37	 n/a	 n/a	 100	 100	 100	 97.3	
inhA promoter 
mutation -15 C>T)	 INH	 n/a 9	 n/a	 n/a	 11.1	 100	 100	 100	
Ser315Thr	in	KatG 
and inhA promoter 
mutation -15 (C>T) 
INH	 n/a 1	 n/a	 n/a	 100	 0	 100	 100	
No mutation in 
isoniazid-
associated genes 
INH n/a 22 n/a n/a 0	 0 0 0 
Tyr319Ser in EmbB 
 
ETB n/a 11 n/a n/a n/a 0 100 0 
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Met306Val in EmbB 
 
ETB n/a 4 n/a n/a n/a 100 100 100 
Met306Ile in EmbB 
 
ETB n/a 3 n/a n/a n/a 100 100 100 
Gly406Ser in EmbB 
 
ETB n/a 2 n/a n/a n/a 0 100 0 
Gly406Ala in EmbB ETB n/a 1 n/a n/a n/a 0 100 100 
C491T in gene rrs SM n/a 4 n/a n/a n/a 0 0 100 
A514C in gene rrs SM n/a 1 n/a n/a n/a 100 100 100 
Lys43Arg in RpsL SM n/a 5 n/a n/a n/a 100 100 100 
Asp94Gly in GyrA FLQ n/a 6 n/a n/a n/a 100 100 100 
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Ser91Pro in GyrA FLQ n/a 1 n/a n/a n/a 100 100 100 
Ala90Val in GyrA FLQ n/a 3 n/a n/a n/a 100 100 66.7 
A1401G in gene rrs AG	 n/a 8 n/a n/a n/a 100 87.5 87.5 
 
 























































PncA	 PZA	 R	 Wayne’s(S)	 MP369	 	
Gln10Pro	in	





PZA	 R	 n/a	 n/a	 	
His57Leu	in	
PncA	 PZA	 R	 n/a	 n/a	 	
Arg212Arg	in	
RpsA	 PZA	 S	 MODS	(R)	 MP035,	MP176	 	
PZA	 S	 MODS,	KVarQ	(R)	 MP027,	MP202	 	

























Method Sample(s) Observations 
Lys48Thr	in	

















RpoB RIF n/a	 MODS	(S)	 MP027		 	
Asp435Tyr in 
RpoB RIF n/a	 MODS	(S)	 MP013	 	
Leu430Pro in 
RpoB RIF n/a	 MODS	(S)	 MP019	 	
Ser450Leu in 






RpoB RIF n/a	 n/a	 n/a	 n/a	
Leu452Pro in 











RIF	 n/a MODS	(R)	 MP005	 	
Ser315Thr	in	
KatG	 INH	 n/a KVarQ	(S)	 MP027	 	












































































ETB n/a PhyResSE	(R)	 MP042,	MP50	 	
Gly406Ala in 
EmbB ETB n/a 
Mykrobe	
(S)		 MP360	 	

























Method Sample(s) Observations 
C491T in gene 
rrs SM n/a KVarQ	(R)	
MP028,	MP190,	
MP203,	MP248	 	
A514C in gene 
rrs SM n/a n/a	 n/a	 n/a	
Lys43Arg in 
RpsL SM n/a n/a	 n/a	 n/a	
Asp94Gly in 
GyrA FLQ n/a n/a	 n/a	 n/a	
Ser91Pro in 
GyrA FLQ n/a n/a	 n/a	 n/a	
Ala90Val in 















Table 5.8 Performance of drug susceptibility testing methods for 
Pyrazinamide relative to BATEC 960 MGIT PZA assay 
Testing 
method 
Sensitivity relative to 
BACTEC (%) 







This study looks at three topics using this single sample set: The mutations 
that underlie pyrazinamide resistance and performance of methods for 
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determining resistance to the drug; performance of the MODS method, and 
performance of sequence-based drug susceptibility prediction tools. In doing 
so, it has assessed strain heterogeneity in samples in terms of mixed lineages 
and heteroresistance in DST.  
5.4.1 Mutations in pyrazinamide resistance genes   
Owing to the unclear relationship amongst pyrazinamide phenotypes and 
genotypes, consideration of which samples were resistant to the drug was 
necessary before evaluating the testing and prediction methods. In doing this, 
the study presented here has defined the role of mutations in pyrazinamide 
resistance-genes by their susceptibility to the drug. The study recognised the 
strong association between MGIT resistant samples and resistance-causing 
mutations that were included in the drug resistance databases of sequence-
based prediction tools. Novel allelic substitutions associated with MGIT-
determined pyrazinamide resistance were also identified and the previous 
observation, that some mutations in genes associated with pyrazinamide 
resistance are not causative of resistance to the drug.  
5.4.1.1 Resistance-causing mutations 
In this study, 24 of 69 samples (34.8%) were considered PZA resistant. 
Resistance was caused by the mutations, His51Arg, Gln10Arg, His71Arg, 
Gln10Pro, Ile6Ser and, His57Leu in PncA. Mutations have been previously 
observed at all of the amino acid positions however, the substitutions of 
His57Leu and Ile6Ser in PncA have not been previously observed. These 
mutations were identified by KVarQ and PhyResSE, as well as by SNV-
calling, indicating the ability of these tools to remain ‘open-minded’ about 
allele substitution.  Some of these resistance-causing mutations were observed 
with additional mutations in pyrazinamide resistance genes.  
 
Reference to the mutation, His57Leu in PncA could not be found in the 
literature but many other allele substitutions at this position have been 
identified. In M. tuberculosis sensu stricto, a number of amino acid changes 
occur resulting in glutamine, proline, asparagine, aspartate or tyrosine 
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residues, all with a 0.985 probability of being PZA resistant (327). Codon 57 is 
essential in binding of the Fe2+ metal ion; site-directed mutagenesis of M. 
tuberculosis to introduce alanine in place of wild-type histidine led to 
suppression of metal binding and reduced enzymatic activity from 81.9 U/mg 
protein in the wild-type to just 0.5 U/mg protein in the mutant (332). In the 
intrinsically pyrazinamide resistant species, M. bovis, an aspartate residue 
takes the equivalent place to His57, and both the His57Ala and M. bovis PZAse 
have comparable enzyme activities and metal ion binding properties (332). 
Clearly substitution at this codon with a number of amino acids, with various 
side chain properties, has a high likelihood of causing pyrazinamide 
resistance. Histidine has a positively charged side chain, whilst, like alanine 
and proline, leucine is a non-polar amino acid. Similar to other substitutions 
described, leucine would likely disrupt the metal binding properties of the 
enzyme, rendering it resistant to pyrazinamide. The His57Leu mutation was 
concluded to be associated with PZA resistance and was concordantly 
predicted to cause drug resistance by all DST methods. 
 
The mutation, Ile6Ser in PncA has not been well described in the literature, 
though other allele substitutions at this amino acid position are better 
characterised (333). Codon six is included in the hydrophobic core of the 
PZAse protein. Amino acid substitution at this position is not an absolute 
indicator of resistance as substitutions of the non-polar wild-type residue, 
isoleucine to another non-polar residue, leucine, have been found in 120 PZA 
sensitive samples and only 8 PZA resistant samples (306). However, amino 
acid substitution to the polar residue, threonine, has been associated with a 
0.98 probability of causing resistance, a 0.015 probability of sensitivity (327) 
and an MIC of 100-300 ug/mL (306). As serine, found here, is also a polar 
residue, it may also be likely to disrupt the hydrophobic interior of the protein 
which is concurrent with the absent PZAse activity as indicated by the 
Wayne’s assay of this sample. The mutation was concluded to cause resistance 
and all DST methods were concordant on this susceptibility. 
 
The His51Arg mutation in pncA was only ever seen here in combination with 
the Ala381Val mutation in RpsA. This latter mutation was only identified by 
SNP calling in the pyrazinamide resistance-associated genes and, though the 
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mutation was identified by PhyResSE, the software tools did not report this 
mutation as causing resistance. The samples with this combination of 
mutations all fell in the same sublineage, 4.3.3, and share common resistance 
profiles for all drugs. The mutations may be observed together due to the 
derivation of the strains from a common ancestor. The Ala381Val mutation in 
RpsA hasn’t been described in the literature and it remains unclear whether 
this represents a second resistance-causing mutation, a helper mutation or is 
irrelevant to pyrazinamide resistance. 
 
The Arg212Arg mutation in RpsA was observed in addition to the Pro62Ser 
and Ile6Ser mutations in PncA but it was also found as the only mutation in a 
pyrazinamide associated gene in other samples. It is discussed in greater 
depth in section 5.4.1.2. 
5.4.1.2 Other resistance-associated mutations 
Beyond samples with a resistance-causing mutation, a further eleven samples 
in this study had other mutations in genes associated with pyrazinamide 
resistance, pncA and rpsA. The role of these mutations was evaluated with 
view of the predictions made by the sequence-based tools, the phenotypic 
susceptibility results and information provided in the literature. 
 
In the study presented here, four samples had a Lys48Thr mutation in PncA. 
These were phenotypically sensitive by the BACTEC MIGIT PZA assay and 
Wayne’s test but two of the four samples showed resistance by the MODS 
assay. This mutation has been observed in previous studies of Peruvian 
tuberculosis isolates and infrequently elsewhere throughout the world 
(328,334,335). Conclusions vary between studies as to the degree of 
susceptibility or resistance-associated with this mutation. The Wayne’s assay 
reported susceptible results with this mutation, however, strains with this 
mutation had markedly reduced PZAse activity at 10.45 mmol POA 
/min/mg PZAse relative to 38.4 mmol POA /min/mg PZAse in the wild-
type (329,336). In PZA-broth, samples with the Lys48Thr mutation were able 
to grow to 20% of the wild-type growth level, rendering the strains resistant 
by this metric (336). The MIC has previously been determined as less than or 
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equal to 50 µg/mL, at the upper end of the 8-64 µg/mL epidemiological wild-
type cut off (329,337). Whilst this is below the 100 µg/mL critical 
concentration of PZA used in the MGIT assay, explaining the sensitive MGIT 
result, this may not be below the clinical exposure levels in patients. Work by 
Gumbo et al  (338) showed that in patients of 48 kg body mass receiving 2 g 
pyrazinamide per day, the standard dosage, the breakpoint MIC was 37.5 
µg/mL at pH 5.8 or 50 µg/mL at pH 6.0; but that the breakpoint fell to as low 
as 25 µg/mL (pH 6.0) with a 2 g dose as body mass increased. This suggests 
that a standard drug regimen, especially for a heavier patient, would not be 
sufficient to treat infection with TB strains that have a Lys48Thr mutation in 
the pncA gene, though increased dosage may be beneficial. In instances such 
as these, the strain could be said to have intermediate sensitivity to 
pyrazinamide, in accordance with the SIR classification 
(Sensitive/Intermediate/Resistant) of susceptibility (339). Whilst MGIT 
resistance is thought to indicate true resistance, it may fail to detect low-level 
resistance given the high critical concentration of PZA that it uses (329). MIC 
data for the other mutations found in MGIT sensitive samples are not 
available meaning that the impact of these mutations on clinical susceptibility 
may not be predicted.  
 
One isolate carries a Pro62Ser mutation in PncA and appears to be sensitive 
by the MGIT and Wayne’s assay and is resistant only by MODS. Some isolates 
with a Pro62Arg substitution have previously been defined as phenotypically 
sensitive, whilst other samples with this mutation have been determined to 
be resistant (327). Other substitutions, Pro62His and Pro62Leu in PncA, are 
exclusively associated with resistance and found to have MICs of >800 ug/mL 
and 400 ug/mL, respectively. Both show an absence of PZAse activity in the 
Wayne’s assay (336,340). Clearly some mutations at this position can cause 
high levels of PZA resistance. However, without full characterisation of the 
PZA phenotype in terms of MIC, it remains uncertain whether this novel 
mutation is associated with clinical resistance. 
 
The synonymous Arg212Arg mutation in RpsA was observed exclusively in 
samples of the 2.2.1 sublineage and in all of the samples in this sublineage. It 
was not reported to cause resistance by any of the sequence-based resistance 
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prediction tools though the mutation was identified by PhyResSE. Instead 
PhyResSE indicated that the mutation defined a lineage (341). This mutation 
was observed by SNP-calling in both MGIT sensitive and resistant samples. 
In the former, it was the only mutation in the pyrazinamide resistance-
associated genes or in combination with the Pro62Ser mutation in PncA. In 
the resistant sample, it was found combination with the Ile6Ser mutation in 
PncA which was thought to confer the observed resistance, as discussed 
above. The presence of this synonymous mutation clearly does not determine 
pyrazinamide susceptibility. 
 
The role of some mutations to cause resistance to pyrazinamide is clear but 
for other mutations, their role in pyrazinamide resistance is less well defined. 
Further investigation into these mutations, including correlation with MIC 
data and clinical outcomes with a variety of lineage backgrounds, is necessary 
to determine their role in the SIR classification of resistance and how to treat 
strains with these mutations in the clinic (339). The mutations that were 
considered to underlie PZA resistance were all found in PncA, not in other 
genes. This supports a previous suggestion that a PCR–single-strand 
conformational polymorphism method may be used in this setting for 
detection of PZA resistance, given that the WHO aim is to identify 90% of 
resistance (342). This would be advantageous because it is relatively cheap, 
rapid and reliable and might facilitate correct PZA usage in the drug regimen 
from start of therapy (343).  
5.4.2 Performance of pyrazinamide susceptibility 
detection methods 
Determination of resistance to pyrazinamide has been plagued by the poor 
performance of susceptibility testing methods. This study sought to explain 
some of the limitations of these methods with view of the mutations 
underlying the resistance. As expected, the methods employed to determine 
pyrazinamide resistance in this study varied in their performance 
characteristics. Patterns of resistance misclassification were identified 
associated with particular mutations for some methods. 
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5.4.3.1 MGIT 
The MGIT assay has been considered as the gold standard approach here for 
determination of PZA susceptibility because mutations deemed likely to 
cause resistance, His51Arg, Gln10Arg, His71Arg, Gln10Pro, Ile6Ser and, 
His57Leu in PncA, have been found in every sample that was resistant by the 
MGIT assay and never in those that have been determined as sensitive. 
Mutations were identified in samples deemed MGIT sensitive and, as 
discussed with regards to the mutations Lys48Thr and perhaps Pro62Ser in 
PncA, these mutations may confer low level or intermediate resistance that is 
not detected by the MGIT assay.  
5.4.3.2 Wayne’s test 
The Wayne’s assay falsely identified resistance in only one of the samples in 
this set, giving it a 97.8% specificity. It failed to identify nine truly resistant 
samples, making the sensitivity only 60.9%. This problem with sensitivity 
occurred with five of eleven instances of the Gln10Arg mutation in PncA, one 
of two occurrences of the His71Arg mutation in PncA and three of seven 
occurrences of the His51Arg mutation in PncA coupled with R381V in RpsA. 
The impact of these mutations on PZAse activity is unclear, however the 
Wayne’s assay suggests the enzyme may have retained some activity in some 
of the samples with these mutations. Three of these false sensitive samples 
reported by the Wayne’s assay contained mixed infections, though only one, 
MP313, showed heteroresistance relative to pyrazinamide; four other 
heterogeneous samples with homogeneous PZA resistance mutations were 
correctly identified by the Wayne’s assay.  The sample heterogeneity was not 
a consistent issue amongst the samples where the Wayne’s test falsely 
reported sensitivity. Given few samples with other mutations found in this 
dataset, it is not clear whether this represents a significant association 
between these mutations and poor Wayne’stest performance. A larger data 
set would be required to provide statistical power to validate this.  
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5.4.3.3 MODS  
Using the MGIT assay as the gold standard for PZA DST, the sensitivity of 
MODS in this sample set was high, at 91.3%. For two of eleven samples with 
the Gln10Arg mutation in PncA, MODS did not detect resistance that was 
predicted by the other methods. There were particular issues with its 
specificity which was only 73.9%: MODS reported false resistance in 12 of 46 
samples considered sensitive. MODS indicated resistance in two of four 
samples with the Lys48Thr mutation in PncA, a mutation that was not 
associated with resistance by any of the sequence-based tools or MGIT. The 
mutation was seen in these samples in the absence of identifiable sample 
heterogeneity. In samples containing this mutation, growth in PZA-broth has 
been found to be comparable to only 20% of the growth in PZA-free broth 
(336) and it may convey intermediate resistance. Here, this may have been 
enough growth to have indicated resistance by MODS in these two samples. 
MODS also falsely predicted resistance in the one sample with a Pro62Ser 
mutation in PncA and Arg212Arg mutation in RpsA, and one of six samples 
with only the Arg212Arg mutation in RpsA. For these other mutations that 
were associated with MGIT sensitivity but MODS resistance, phenotypic 
characterisation of MIC was not available. Given that resistance by MODS is 
determined by visualisation of microscopic growth of a strain in PZA-broth, 
it might identify intermediate resistance in samples where the MIC may be 
too low for resistance to be identified by MGIT. That said, MODS also 
identified seven of 35 samples without mutations to be pyrazinamide 
resistant. The poor apparent specificity of PZA MODS as used in this study is 
a limiting factor to its widespread use for clinical DST. This is unfortunate 
owing to the low cost of testing with this method but with a better 
understanding of the clinical susceptibility of strains, the role of MODS in the 
landscape of PZA resistance detection might be different in the future. Used 
in combination with the Wayne’s test, the two methods would only 
concordantly identify 12 resistant isolates though this approach would omit 
all ‘false resistance’ indicated by MODS. Neither of these approaches, 
individually or in combination, provide acceptable rates of accurate PZA 
detection should MGIT resistance be considered true resistance.  
 
  154 
5.4.3.4 Sequence-based tools 
Collectively, the sequence based tools predicted all of the mutations 
considered to cause resistance to pyrazinamide. PhyResSE was the only 
individual tool to offer complete concordance with the MGIT assay which was 
considered determinant of certain resistance. Mykrobe did not predict 
resistance to pyrazinamide. KVarQ did not predict resistance from Gln10Arg 
in PncA in the samples MP247 and MP342, the latter of which was also 
predicted to be sensitive by the Wayne’s assay, yet it did predict resistance 
caused by this mutation in other samples. Other methods were also 
inconsistent with determining resistance in samples with this mutation, 
however each method predicted sensitivity associated with this mutation in a 
different sample. The algorithms for detection of mutations in a sample are 
variable across the tools and it seems likely that the KVarQ algorithm 
excluded the mutations in MP247 and MP342 as seen here. Algorithms need 
to be improved in such a way to optimise sensitivity and specificity of the 
predictions that they make.  
 
Mutations other than those associated with MGIT resistance could also be 
detected. KVarQ predicted resistance in samples MP276, MP320, MP027 and 
MP202 caused by the Lys48Thr mutation in PncA, unlike the other predictions 
tools. On evaluation in this study, this mutation was considered to potentially 
be associated with a resistant or intermediate pyrazinamide susceptibility 
phenotype.  KVarQ also predicted resistance in the two samples, MP027 and 
MP050, caused by Pro62Ser in PncA, in agreement with the MODS 
phenotypic method. Similarly, the role of these mutations in PZA resistance 
is unclear. As discussed previously, further evaluation of the role of these 
mutations in resistance is necessary and will improve the performance of 
sequence-based pyrazinamide prediction through more appropriate 
inclusion of mutations in databases. SNV-calling determined further 
mutations, including those in RpsA that were not predicted to cause 
resistance by any of the tools and not considered to cause resistance after 
evaluation of the literature. Given that these mutations are present in 
resistance-associated genes, the exclusion of these mutations from the 
  155 
databases used to call resistance is both necessary and occurring 
appropriately, at least in view of this dataset. 
 
5.4.3 Evaluation of MODS for susceptibility prediction in 
rifampicin and isoniazid 
The MODS assay was conducted directly on broth cultures directly from 
decontaminated sputum and should represent some of the diversity of TB 
strains within the sputum sample, though this is biased by culture. Whole 
genome sequencing of multiple colony sweeps across solid media culture 
from each sample was used to analyse some of the diversity within the 
samples. By comparing the results from MODS and this WGS approach, the 
capacity for MODS to characterise resistance, including heteroresistance, in 
samples could therefore be evaluated, though a bias may have been 
introduced during solid media growth that was also conducted prior to WGS. 
The performance of PZA MODS has already been evaluated in section 5.4.3.3 
so this section of the thesis will focus on RIF and INH MODS. For all drugs 
evaluated, RIF, INH, and PZA, MODS detected resistance in all but one 
sample where heteroresistance was apparent. It only failed to detect the 
heteroresistance caused by the inhA promoter mutation in MP313 which 
seems to be a problem with identifying resistance caused by that mutation 
rather than heterogeneity, as discussed below. 
 
There were five instances of discordance between MODS and the results of 
any sequence-based DST method for rifampicin resistance. In five samples, 
MODS did not detect resistance but the resistance-causing mutations, 
Leu430Pro, Asp435Tyr, Asp535Val and Leu452Pro, were identified by all of 
the software tools. This discordance between MODS and WGS-based 
methods for high confidence resistance-associated mutations indicates that 
MODS lacks sensitivity. This may not be caused by the mutation in the sample 
since these mutations are also seen in other samples that were correctly 
identified to be resistant by MODS. In sample MP005, no rifampicin 
resistance-associated mutation was identified but MODS detected rifampicin 
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resistant. As the gold standard method, MGIT testing, is not available in this 
location the phenotypic susceptibility results cannot be verified.  
 
For most samples, there was concordance between INH MODS and 
predictions made by the sequence-based tools. MODS consistently 
determined that the samples were sensitive to isoniazid where INH 
resistance-conferring mutations were not reported. MODS failed to recognise 
resistance in eight out of nine samples that had only the inhA promoter 
mutation in isoniazid resistance-associated regions, including sample MP313 
which was heteroresistant. The one sample where resistance was reported by 
MODS had the same lineage background as other samples with this mutation 
that were reported to be sensitive by MODS. Walker et al previously found 
that 73 of 79 isolates with this mutation were phenotypically resistant 
according to MGIT analysis (224), supporting the role of this mutations in 
causing resistance. This mutation has previously been associated with low-
level or intermediate isoniazid resistance when using other drug 
susceptibility testing methods particularly when compared to resistance 
caused by the Ser315Thr mutations in KatG (344–348). Though a standard, 0.4 
µg/mL concentration of isoniazid was used for MODS, it may be above the 
minimum inhibitory concentration (MIC) associated with the inhA promoter 
mutation. Many studies have used both 0.1 and 0.4 µg/mL isoniazid for 
MODS or simply the lower concentration to determine INH resistance 
(272,274–276,349). Moore et al (274) concluded that use of only 0.4 µg/mL 
isoniazid did not reduce performance of the DST method in a study 
conducted in Peru, however they did not identify the mutations conferring 
resistance in these strains. When the higher concentration was used by Huang 
et al (281), many samples were sensitive by the MODS assay but resistant by 
the proportion method that uses only 0.2ug/mL INH. The sample with both 
the Ser315Thr mutation in KatG and the inhA promoter mutation was 
phenotypically resistant in this study, concordant with previous assertions 
that the presence of both mutations results in a higher MIC (344). This study 
indicates that MODS with 0.4 µg/mL isoniazid may fail to identify samples 
with the inhA promoter mutation causing intermediate resistance to isoniazid. 
This is supported by results of a meta-analysis of MODS sensitivity and 
specificity that found lower MODS sensitivity when using 0.4 µg/mL 
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isoniazid than 0.1 µg/mL (278). This mutation is also associated with, though 
not predictive of, ethionamide co-resistance (345).  
5.4.4 Evaluation of sequence-based tools for prediction 
of drug susceptibility 
5.4.4.1 All whole genome sequencing analyses 
Whole genome sequencing and the combination of PhyResSE, Mykrobe and 
KVarQ for rifampicin, isoniazid and pyrazinamide susceptibility prediction 
collectively predicted all but one instance of resistance to the drugs. The one 
sample, MP005, that was RIF resistant by MODS but did not show any 
mutations may have been due to poor MODS specificity as rifampicin 
resistance-associated mutations are well-described. Alternatively, the 
possibility exists that further mechanisms for rifampicin resistance are yet to 
be discovered. WGS was able to identify well-described resistance-conferring 
mutations in MODS sensitive samples in four instances for rifampicin and 
eight instances for isoniazid. Resistance-causing mutations for isoniazid were 
otherwise concordant with the susceptibility phenotypes offered by MODS. 
Relative to detection of resistance by MGIT, WGS approaches were able to 
collectively detect all mutations that were conferred resistance to PZA. It is 
not clear how the mutations in MGIT sensitive samples might relate to clinical 
drug susceptibility. A better understanding of the genotype-phenotype 
relationship related to these mutations is necessary for conclusive WGS-based 
diagnosis.  
 
Resistance prediction based on whole genome sequencing has the advantage 
of determining susceptibility to all drugs with a single test, including for little-
evaluated second-line drugs. Ten XDR or pre-XDR strains were predicted 
here using the combined results of the sequence-based tools. Drug 
susceptibility prediction of second-line antibiotics is limited by the unclear 
relationship between genotype and phenotype and the predictions made here 
could not be validated as no phenotypic DST was available. These pre-XDR 
and XDR strains would not have been identified in the many locations that 
lack DST for second-line drugs. In the Peruvian setting, only 48% of the 
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confirmed rifampicin-resistant M. tuberculosis is tested for resistance against 
second-line drugs. It appears that resistance characterisation beyond 
rifampicin testing improves the rate of treatment success in Peru given that 
treatment succeeds for only 35% of RR/MDR-TB patients yet 65% of XDR-TB 
patients for whom the diagnosis would have been confirmed (269). As such, 
identifying resistance in patients is essential for treating them with the 
appropriate drugs in the appropriate regimen and, in the case of pre-XDR TB 
monitoring them for progression of the strains to further drug resistance. 
Whole genome sequencing could offer the necessary complete profiling of 
drug resistance in settings such as this one in Peru, progressing the diagnosis 
and treatment capacity within the setting if implemented. 
5.4.4.2 Individual sequence-based tools 
Individually, no WGS-based tool predicted all of the resistance-conferring 
mutations that were reported collectively.  
• Mykrobe does not report resistance to PZA, with the authors citing that 
all mutations relating to this drug resistance being poorly predictive 
(212). It did not report both mutations related to INH resistance found in 
sample MP063; the inhA promoter mutation was not identified in this 
sample only but the Ser315Thr mutation in KatG was reported. It also 
did not identify the resistance-causing Ile491Phe	mutation	in	RpoB.	The 
Gly406Ala, Gly406Ser and Tyr319Ser mutations in EmbB and the C491T 
mutation in the rrs gene were reported to cause resistance by the other 
sequence-based tools but not Mykrobe. It is unclear why these omissions 
were made. Mykrobe features an unusual way of mutation reporting, 
with the replacement amino acid in a substitution denoted by X rather 
the specific amino acid. It also reports ‘minor alleles’ where a few or often 
one read amongst those reported has a resistant allele but the clinical 
significance of this is not discussed explicitly in either the report or the 
publication describing the tool. 
• PhyResSE predicted all mutations that caused resistance to rifampicin, 
isoniazid and pyrazinamide, aside from in one sample with a very small 
proportion of reads causing heteroresistance as discussed above. It did 
not predict resistance against second-line drugs in all samples as 
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identified by other tools, including the C491T mutation in gene rrs and 
one of eight instances of the A1401G mutation in gene rrs. This latter 
sample was heteroresistant at the 1401 nucleotide in rrs with only three 
of 35 reads with the resistant allele. There were a number of mutations 
for which PhyResSE was the only method to identify the mutation. This 
may be a reflection of over-prediction of resistance-associated with 
mutations that do not confer phenotypic resistance. It could be that 
Mykrobe and PhyResSE are failing to detect resistance-conferring 
mutations. Nonetheless, it goes to show the importance of a clear 
understanding of genotype and phenotype yet again. 
• KVarQ failed to identify mutations in quite a list of samples: two of 11 
samples with the Gln10Arg mutation in PncA; one of 14 samples with 
the Ser450Leu mutation in RpoB though this sample was heteroresistant; 
the only sample with the Ile491Phe mutation in RpoB; one of 37 samples 
with the Ser315Thr mutation in KatG; all 11 samples with the Tyr319Ser 
mutation in EmbB and both Gly406Ser mutations in EmbB (though it did 
identify the mutation Gly406Ala in the same gene); one of three samples 
with the Ala90Val mutation in GyrA though this sample was 
heteroresistant and one in eight samples with the A1401G mutation in 
gene rrs which was also heteroresistant. For some of these omitted 
samples, the mutation appears to have not been predicted due to 
heteroresistance at the given allele, for others the mutation may not be 
present in the underlying database. KVarQ did predict resistance 
associated with the Lys48Thr	and	Pro62Ser	with	Arg212Arg mutations	 in	
PncA. 
 
Whilst it appears that all resistance-associated mutations in this small sample 
set have been identified, the databases of resistance mutations and algorithms 
used by each tool to determine resistance are inconsistent. Inclusion or 
omissions of mutations in the database is more problematic for those 
associated with resistance to pyrazinamide, ethambutol and the other second-
line drugs identified. This is probably owing to the complicated picture of 
susceptibility for these drugs where the presence of a mutation may, or may 
not, indicate clinical resistance. Although the algorithms used to call SNPs 
occasionally impact the resistance mutations that are identified, this mainly 
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affects the numbers of reads associated with each resistance allele. This has a 
notable impact on the identification of heteroresistance, particularly by 
KVarQ that failed to identify any resistance in three of six heteroresistant 
samples. As the understanding of the genotype-phenotype relationship of 
drug susceptibility improves, our ability to compile databases with more 
clinically impactful predictions will also improve. Software that reports well-
validated MIC and dosage recommendations based on the mutations and 
linked to clinical outcome data identified is feasible and may hopefully soon 
be possible. This could open up opportunities for treatment that could 
otherwise be diminished by the binary resistant/susceptible approach to drug 
susceptibility, especially benefitting patients with predicted XDR-TB. 
5.4.4.3 Characterisation of heterogeneity using sequence-based 
tools  
Mixed cultures or clinical samples potentially contain multiple strains of M. 
tuberculosis with heterogeneity in their lineage, drug resistance profile or 
elsewhere throughout their genomes though the latter is insignificant to 
diagnosis. KVarQ identified 14 samples with ‘mixed coverage’ which 
included samples that have mixed lineages, mixed drug susceptibility profiles 
and mixed alleles in other parts of the genome that have no impact on either 
lineage or drug resistance. Neither PhyResSE nor Mykrobe offered any 
indication of mixed lineages. MGplacer was used specifically to identify 
mixed lineages and found 11 samples with heterogeneous lineages and 
specified the lineages present. This study is the first to use MGplacer in 
contemporary samples (206,210). Only Mykrobe and PhyResSE predicted 
heteroresistance as KVarQ did not report allele frequencies but all of the 
samples with heteroresistance were identified by KVarQ to have ‘mixed 
coverage’. Seven heteroresistant samples were identified. Mykrobe failed to 
detect heteroresistance associated with pyrazinamide in one sample since it 
does not predict resistance to this drug. PhyResSE failed to detect 
heteroresistance in one distinct sample. For this, it seems likely that the 
frequency of resistant alleles was too low to be reported using the tool’s 
prediction algorithm since Mykrobe reported only three of 25 reads were 
contained the resistant allele.  
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Whole genome sequencing allowed for characterisation of mixed lineage 
samples with very low rations of minor to major strains using MGplacer but 
not such low ratios of resistant to sensitive reads at heteroresistant alleles. 
MGplacer defines each lineage with multiple SNPs; for heteroresistance was 
determined based on one mutation position. It would be expected that a 
greater depth of sequencing per sample would result in identification of 
heterogeneity in further samples that contain mixed infections, especially for 
samples with lower proportions of the minor strain(s). ‘Deep-sequencing’ of 
mixed TB strains to a very high and very expensive depth of coverage has 
previously been shown to detect minor strains that comprised 0.64% to 
35.83% of the population in the sample (350). Such deeper sequencing might 
help to explain the presence of low frequency drug resistance alleles detected 
in many samples by Mykrobe, particularly associated with rifampicin 
resistance. These samples tend to have only one read with the resistant allele 
whilst the others are susceptible. Such results may occur due to biases or 
sequencing errors or they may represent the true diversity of strains within 
the sample that would be more apparent with deeper sequencing (351). 
Should the latter be the case, these low frequency resistance alleles might be 
amplified during first-line drug treatment (165). In the publication 
introducing the Mykrobe software package, Bradley et al. mention ‘minor 
alleles’ and their useful predictive value for determining clinically relevant 
resistance (212). They do not define the allele frequency that constitutes a 
‘minor allele’, however, so it is unclear what the relevance of these results are, 
as Bradley et al. determine it.  
5.4.5 Conclusions 
Going forwards, this study highlighted a number of areas where further 
research and considerations should be made. First, a better understanding of 
the phenotypes and clinical outcomes associated with the Lys48Thr and 
Pro62Ser mutations in PncA is required to confirm their place in the sensitive-
intermediate-resistant classification of susceptibility. In turn, this will inform 
an improved understanding of the performance of all of the pyrazinamide 
susceptibility determination methods employed here, particularly MODS 
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which appeared over-sensitive relative to MGIT and the sequence-based tools 
for which the performance could easily be improved given modifications to 
the databases underlying them. The performance of MODS for detecting 
isoniazid resistance was compromised in samples with the mutation in the 
inhA promoter region and might be improved with reconsideration of the 
critical concentration of INH used in this assay. Use of samples with multiple 
heterogeneous M. tuberculosis strains had no consistent impact on the 
phenotypic DST methods. Heterogeneity negatively influenced predictions 
by KVarQ which should be addressed with alternative algorithms for 
prediction of mutations. Mykrobe would be improved by inclusion of 
pyrazinamide prediction, a clear explanation of the basis for ‘minor alleles’ 
and their impact and reporting of allele substitutions. All tools would be 
improved with a clinically and phenotypically validated database of 
mutations, particularly for predicting ethambutol, streptomycin, 
fluoroquinolone and aminoglycoside resistance. The presence of multiple 
lineages in a sample was not reported by any of the sequence-based tools, 
though ‘mixed coverage’ was described by KVarQ, yet doing so would be 
advantageous to epidemiological analysis and surveillance efforts. 
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6. Discussion 
6.1 Genomics in the diagnosis of tuberculosis  
Tuberculosis is the world’s leading cause of death from an infectious 
disease(1). It infected an estimated 10.4 million people in 2016 alone (1). 
Control of the disease epidemic is threatened by both the vast number of 
infected individuals and antibiotic resistance that is being acquired into 
strains and spread between people. There are already people infected with 
strains resistant to so many antibiotics that they are incurable within their 
national tuberculosis programme and potentially with any anti-tuberculosis 
therapy available anywhere in the world (97,110–112). Halting and reversing 
this epidemic is the mission set out by the END TB programme and is of such 
importance that it is integrated into the Sustainable Development Goals. 
Achieving the aims of a 90% reduction of deaths and an 80% reduction of 
incidence by 2030 relative to 2015 is dependent on improving diagnosis of 
tuberculosis and getting more people into effective treatment regimens (1). 
This requires diagnostic tools with improved technical capacity to diagnose 
TB that will be accessed by more people who have the disease (216). Access to 
diagnostic tools is greatly linked to national development and income status. 
In the most developed and wealthiest countries, the future objective is 
towards developing and using tools with the ultimate technical capacity for 
diagnosis. Recently this has begun to include whole genome sequencing 
(WGS) (219–222,238,352). In low income countries, compromises are made in 
diagnostic capacity and outcome to fit with lower financial budgets (129). 
Here, future objectives tend towards detecting disease amongst as many 
people as possible that have suspected active infection and offering DST to 
the individuals most at risk of drug resistant tuberculosis. Diagnostic 
innovation is needed in both settings to meet the diagnostic goals and 
ultimately, the goals in global health. 
 
Throughout this thesis, my primary aim has been improving TB diagnosis by 
reaching ultimate technical performance of genomics as a diagnostic tool, 
ideally using unbiased direct sequencing of sputum. In the duration of this 
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PhD, the role of genomics in TB diagnosis has been developed from infancy 
to clinical reality and is seeking evaluation for endorsement by the World 
Health Organisation (1). In September 2013, a number of studies had used 
whole genome sequencing of solid-cultured isolates in research. The exciting 
new development was the proof-of-principle that sequencing could be 
undertaken in a much quicker time frame using early positive liquid culture 
to characterise drug resistance and epidemiological type of the MTBC strain 
(238). Since then, a number of improvements have been made to the technical 
capacity of clinical genomics, addressing limitations in 
• Sputum processing and DNA extraction 
• Genotype-phenotype relationship associated with drug resistance  
• Detecting and characterising genetic heterogeneity in clinical samples  
• Sequencing platform performance 
• Bioinformatic tools 
Now, whole genome sequencing is used in well-resourced reference 
laboratories for retrospective species identification and epidemiological 
analyses. It has been used prospectively to also achieve drug susceptibility 
testing predictions (219,222). On-going efforts seek to further address these 
areas of limitations. 
6.1.1 Direct sequencing of tuberculosis 
Obtaining sufficient mycobacterial DNA from sputum in order to sequence 
the genomes of MTBC in a clinically relevant time frame has been a major 
challenge for integration of genomics into prospective diagnosis of 
tuberculosis. WGS is typically undertaken after selective culture of the 
microorganisms of interest, but owing to the slow replication rate of 
mycobacteria, this is prohibitively time-consuming when diagnosing TB. 
Instead, sequencing would ideally be conducted using DNA obtained from 
sputum in a ‘direct’ manner, circumventing the need for MTBC culture.  
 
The study presented in chapter three was the first published to undertake 
DNA extraction and genomic sequencing in a direct manner for the diagnosis 
of tuberculosis (353). Low coverage of the MTBC genomes was obtained from 
smear-positive sputum. This was sufficient to detect TB and to identify the 
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species and lineages of the aetiological mycobacteria but did not offer the 
depth of sequencing necessary for drug susceptibility testing.  
 
A subsequent publication by Brown et al (354), described specifically 
capturing M. tuberculosis DNA using biotinylated RNA baits from SureSelect 
(Agilent, USA) from sputum. This resulted in 20 genomes from 24 smear-
positive sputa with 90% genome coverage at ≥ 20x depth that were suitable 
for drug susceptibility prediction; two low coverage genomes from two 
smear-negative culture-positive sputa and two high quality and five low 
quality genomes (<1x depth of coverage) from a total of eight smear-negative 
culture-negative sputa. Possible resistance-conferring mutations were 
identified in 88% of instances of phenotypic resistance to a drug and in 94% 
of instances of phenotypic drug susceptibility no known resistance mutation 
was identified. Detection of TB from smear positive sputa was attributed to 
dead bacilli, which may be likely when sputum is obtained from patients who 
are completing anti-TB treatment but it is not clear whether this was the case 
in this publication. The diagnostic approach they proposed took one week, 
less than any WHO-endorsed approach to susceptibility testing for drugs 
other than rifampicin, and cost US$350 per sample at the time of their 
investigation. This same methodological approach was used more recently 
when prospectively diagnosing a patient. It provided clarity on inconclusive 
results obtained from LPAs and allowed the treatment regimen to be refined 
such that it might be better tolerated, less toxic, more likely to be completed 
and still effective (220). 
 
Votintseva et al (355) demonstrated a faster and cheaper direct-WGS approach. 
They sequenced DNA obtained directed from smear-positive sputa after 
decongesting and decontaminating it, washing it with saline and removal of 
human DNA using the MolYsis Basic5 kit (Life technologies, USA). Sufficient 
reads were obtained from Illumina MiSeq sequencing to conduct DST in only 
62% of samples giving results concordant with phenotypic DST. They 
estimated that this method could be achieved in 44 hours and cost £96 per 
sample with the Illumina MiSeq or in 16 hours, costing £196 per sample with 
the Illumina MiniSeq. They also demonstrated the potential to undertake the 
approach with the Oxford Nanopore Technologies (ONT) R9.4 MinION 
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sequencing platform in 12.5 hours from a mixture of culture-negative sputum 
DNA and M. bovis BCG DNA, though not directly from a clinical sample.  
 
It remains to be seen whether tuberculosis may be diagnosed with a universal 
diagnostic approach that might also detect other pathogens in sputum. As 
observed in the recent studies summarised above, the limitation continues to 
be the small proportion of MTBC-derived reads amongst the abundance of 
read data obtained from other organisms, whether host or other microbes. It 
seems likely that in most sputum samples investigated in this study, the 
problem lies with the abundance of human DNA in the extracts as illustrated 
by the high proportion of human-derived reads in most samples in chapters 
three and four. Though in some samples an overwhelming majority of reads 
are neither derived from MTBC nor host DNA, this is not typical and may not 
reflect the composition of samples with a high proportion of human-derived 
reads, after human DNA has been depleted. Tentative evidence to support 
this comes from the results of samples sequenced by method B that employed 
decontamination of sputum prior to DNA extraction. Sequencing revealed a 
similar proportion of MTBC-associated reads as in samples extracted by 
methods E and F where the microbiome was not decontaminated and only a 
small amount of human DNA, if any, may have been depleted (according to 
the results of chapter four). It seems that there could be a high ratio of MTBC-
derived DNA to DNA derived from other microflora in samples with 
typically high proportions of human DNA after that has been depleted. The 
MolYsis approach used by Votintseva et al (355) fulfils the objective to deplete 
human DNA and may offer the opportunity to sequence only the microflora 
of a sputum sample, including the MTBC.  
 
Whether sufficient coverage of the MTBC present could be obtained from 
microbiomes depleted of human DNA is unclear, as is the ability to detect 
other (co-)infections from a minimally sequenced metagenome. It would 
depend on the abundance of MTBC-derived reads relative to reads derived 
from the rest of the microflora. Certainly in the samples with high proportions 
of microflora other than tuberculosis, both here and in the work by Votintseva 
et al  (355), the coverage of MTBC has been low, possibly too low for drug 
susceptibility predictions. Should depletion of human DNA alone not be 
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adequate to both characterise the microbiome and tuberculosis, partial 
enrichment of MTBC using an approach targeted amplification and/or MTBC 
capture, as used by Brown et al (354) may be more feasible. Deep metagenomic 
sequencing was recently used to prospectively rule out Mycobacterium 
tuberculosis as the cause of meningitis, instead identifying a helminth, Taenia 
solium, and after anti-helminthic treatment the patient’s case improved (356). 
Metagenomic sequencing was undertaken from cerebrospinal fluid not 
sputum but it still marks development in this field. Further investigation of 
these sample processing methods should be undertaken, keeping in mind the 
lessons from chapter four about study design when intending to illustrate 
depletion of human DNA from small numbers of sputum samples, which in 
highly heterogeneous within the sample and between patients. 
 
As yet no ideal sputum processing method has been developed that could 
rapidly and cheaply characterise tuberculosis directly from sputum (357), let 
alone achieve this with a universal diagnostic method.  Significant progress 
towards these goals has been made and this will likely continue in the future 
(358).  
6.1.2 Drug susceptibility testing from genomic sequence 
data 
Molecular methods of drug susceptibility testing have long been plagued by 
our limited understanding of the genetic basis of clinical resistance for drugs 
other than rifampicin and isoniazid. Strong concordance between DST 
predictions and susceptibility phenotypes for both these drugs and 
pyrazinamide was demonstrated in chapter five. There were only a few cases 
of discordance between the genetic and phenotypic methods and these could 
be attributed to the performance of the MODS and/or Wayne’s assays which 
are not the gold standard DST approach for any of these drugs. Ideally those 
discrepancies for RIF and INH should be assessed by phenotypic re-
characterisation with the gold standard liquid culture assay. Novel codon 
substitutions in a relatively small number of PZA resistant strains indicate 
that there is yet more to understand about the basis of pyrazinamide 
susceptibility, as does the presence of the Lys48Thr mutation in PncA where 
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its role in susceptibility is not clear. Further studies to characterise resistance-
associated mutations are needed for better understanding of their role in 
susceptibility. 
 
Specific to genomic diagnosis, prediction of DST relies on variation detection 
algorithms and comparison to databases of known resistance mutations. 
When this PhD commenced in September 2013, this DST prediction relied on 
custom analysis pipelines and limited resistance databases (84,359) but now 
there are several open-access user-friendly available tools for this purpose 
(86,212,213,285,360,361). As illustrated in chapter five, the predictions made 
by these tools are highly variable as no common standardised prediction 
algorithms nor verified database of resistance mutations are available for use. 
The key issues here were the inclusion of particular mutations in the database 
used by the bioinformatic tool and their predicted role in drug susceptibility, 
their reporting of mutations with previously unreported amino acid 
substitutions, detection of mutations at sites displaying heteroresistance and 
low coverage samples. These tools also provided information about 
epidemiological types but did not identify strains in mixed lineage samples.  
The performance of the tools has recently been compared, coming to similar 
conclusions about their variability as presented here, further defining the 
sources of variations and making recommendations for development of the 
tools (346,362). This includes standardisation of bioinformatic methods, 
making the results from each tool comparable and reliance on resistance 
mutations with clearly understood clinical implications. A clinically validated 
database for interpretation of resistance-associated mutations is in 
development by the ReSeqTB initiative for this purpose (363). It must be 
maintained as new mutations will be discovered (223) and new drugs will be 
included in treatment regimens for which DST will be required. It is clear that 
WGS has a role in the future of clinical DST, indeed its clinical benefit has 
already been established (219–222,238,352).    
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6.1.3 Heterogeneity analysis using whole genome 
sequencing 
Heterogeneity of tuberculosis in sputum may be derived from infection with 
multiple distinct strains of MTBC or diversification of a single strain that has 
evolved within the host. With the former scenario, mixed lineages of TB may 
be apparent and in both scenarios hetero-resistance, or heterozygosity at 
genomic sites known to be associated with drug resistance, may occur. This 
heterogeneity can be reflected in culture from sputum analysis of multiple 
isolates or from liquid culture that was inoculated with sputum. With any 
culturing step, bias in in the strains and loss or gain of mutations may occur 
(229).  
 
Much heterogeneity, both with mixed lineages and heteroresistance, was 
observed in the samples sequenced from Peru (chapter five) and may reflect 
high frequency of TB transmission within the study population. Phenotypic 
DST can detect resistance in as few as 1% of strains (148) and whilst it is clear 
that this cannot be achieved with the routine depth of sequencing of 20-100x 
genome coverage, the threshold for detecting true diversity in a sample is 
unclear. Heterozygosity may be observed even from ‘clonal’ isolates and may 
arise from sequencing bias (351) so it is unclear whether low frequency 
variation at resistance-associated sites is a true reflection of in-host 
heterogeneity. Analysis of heterogeneity was useful in this work as a lens with 
which to evaluate the diagnostic tools in the investigation whilst detecting 
this heteroresistance is also useful for patient management and for 
understanding whether resistance may have been transmitted or acquired in-
host.  
 
Strain typing in chapter five was achieved using phylogenetic placement such 
that strains with multiple lineages could be identified. Construction of 
phylogenetic trees and assessing transmission of TB between people, as 
ideally desired when using genomics for outbreak investigation or 
surveillance, is especially challenging in heterogeneous samples (364,365) 
owing to the dependence on SNPs. This may be circumvented with a Bayesian 
approach to phylogeny as demonstrated in a recent analysis of Ebola virus 
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transmission (366). Studies of mixed samples might also benefit from the 
longer reads available through ONT sequencing approaches as for other 
pathogens (367) or deep sequencing to fully resolve in-host diversity (350).  
6.1.4 The future of diagnostic genomics 
The use of genomics in diagnosis is now well established for strain typing and 
epidemiological analysis in reference laboratories and actionable drug 
susceptibility predictions in prospective analyses. There is still much room for 
improvement in direct sequencing methods, refinement of sequencing 
techniques, bioinformatic analyses and interpretation of results, as described 
in this thesis, but also plenty of hope that this can be achieved.  
 
The WHO expects to assess ‘molecular sequencing’ for DST in 2018 (1). It is 
not certain whether this means whole genome sequencing or which kind of 
processing may be used to generate the DNA extract for sequencing. 
Nevertheless, it includes developing a list of high confidence mutations and 
assessing its accuracy relative to phenotypic methods, potentially as an 
alternative to them (1). It could be imagined that WGS might be integrated 
into a diagnostic algorithm in a similar manner to that described by Witney et 
al  (368) in an intermediate-level or reference laboratory with highly 
developed infrastructure. Without significant automation of the process, 
highly skilled staff would be required to carry out the laboratory preparation 
of samples and undertake sequencing, which may potentially be deemed a 
high-level biosafety risk. A standardised diagnostic analysis pipeline and 
mutation database would be required and the role of newly discovered 
mutations in drug susceptibility would need to be determined with 
phenotypic DST (369). Sequencing from early positive MGIT cultures has 
produced results in a median of nine days in the hands of Pankhurst et al (370); 
direct sequencing produced results in five days in the hands of Nimmo et al  
(220) and this could potentially be reduced even further with the methods 
employed by Votintseva et al  (355). At this stage, direct sequencing comes 
with compromises in sensitivity of diagnosis given challenges with reliably 
recovering the whole genome. The performance of genomics for the diagnosis 
of tuberculosis is variable, depending on the methods used. 
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The technical superiority of genomics has been narrowed somewhat in recent 
years. Until 2016, the only rapid DST available was for rifampicin and 
isoniazid susceptibility (155,159) and WGS provided DST for all other drugs 
quicker than any other method (222). Since the endorsement of the rapid line 
probe assays for FLQs and SLIDs (160), resistance to these drugs can now be 
achieved rapidly too. Similarly, the release of the GeneXpert Ultra assay (157) 
has raised the bar for sensitivity and specificity detection, and the LF-LAM 
assay has improved diagnosis of TB in HIV-positive individuals (138). These 
are undoubtedly significant developments but go to show how competitive 
genomic diagnosis must be in order for its performance to be worth the large 
investment in money and resources to implement this tool. It is certainly not 
one that will be available everywhere in the immediate future. Targeted 
genotypic tools may come to market earlier and cheaper. 
6.2 Diagnosis in developing countries and the role 
of genomics 
All of the work presented in this thesis was all conducted in collaboration 
with developing countries; at least a third of my research time was spent in 
The Gambia. There were issues, delays, communication issues and setbacks 
that would have been unlikely to occur had these studies been undertaken 
entirely in the United Kingdom, but that the work was carried in these 
settings is exemplary to the kind of cutting-edge research that is feasible in 
such locations. Testament to this, the MRC Unit, The Gambia is currently 
setting up a regional centre of excellence focusing on genomics and has 
produced a number of recent publications using genomics (208,371–375). It 
has been argued that genomics may be integrated into the diagnostic 
laboratory networks of other developing countries, should logistical, financial 
and ethical issues be circumvented (376). From my own experience that seems 
feasible in the not-too-distant future, not for routine diagnosis, but for TB 
outbreaks or unusual cases of antibiotic resistance against many drugs (264). 
Of course, there is a broad spectrum of countries that might be considered 
‘developing’ and, even regions in the same country have vastly different 
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diagnostic capacities. In some settings, the high demands of TB genomics 
would not be feasible and diagnosis is currently challenged to offer any DST 
at all. There are plenty of diagnostic methods other than genomics, at lower 
cost and requiring fewer resources, that may make up the entirety of the 
diagnostic algorithm in lower income, lower resource settings, as discussed 
in this thesis. These provide highly beneficial diagnostic capacity but with 
some technical limitations. Innovation to understand these approaches, using 
studies such as the one presented in chapter five, provide the opportunity to 
improve them.  
6.3 Conclusions 
The work presented throughout this thesis has highlighted the inherent 
difficulties faced for diagnosing tuberculosis, both in countries where cutting-
edge technology may be implemented and those that rely only on more 
traditional methods. Achieving the ultimate END TB goals to reduce the 
mortality and incidence of disease associated with tuberculosis depends on 
meeting targets of diagnosing 90% of people who develop TB then 
successfully treating 90% of them (342). Improvements to the technical 
capacity of diagnostic tools is critical for this. Despite recent developments 
documented by other researchers, it is clear that further work, such as 
presented in this thesis, remains necessary to unleash the full potential of 
genomics for diagnosing tuberculosis, to improve existing diagnostic tools 
and to create new ones. 
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Supplementary materials 
Table S1: Sample characteristics and basic outcomes from metagenomic 
analysis of samples extracted by methods E and F in chapter three 





E1 +++ 564 303988 
E2 +++ 324 2943076 
E3 +++ 4.4 821772 
E4 ++ 3780 1275312 
E5 ++ 30 2018802 
E6 ++ 970 831798 
E7 + 0.588 188620 
E8 + 32.4 3278340 
F1 +++ 27.8 989442 
F2 +++ 2.28 2170640 
F3 ++ 71 1617808 
F4 ++ 250 1204408 
F5 ++ 7.7 1537676 
F6 ++ 48.8 2411708 
F7 + 25 2818238 
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Table S2: Demographic and phenotypic data for samples in chapter five 
Sample Sex Age Treated 



































MP051 M 43 N S S S S S DS 
MP059 M 22 N S S S S S DS 
MP069 F 50 N S S S S S DS 
MP082 M 23 N S S S S S DS 
MP124 F 38 N S S S S S DS 
MP126 M n/a N S S S S S DS 
MP167 F 56 N S S S S S DS 
MP186 F 20 N S S S S S DS 
MP199 F 70 N S S S S S DS 
MP200 F 19 N S S S S S DS 
MP203 M 20 N S S S S S DS 
MP210 M 37 N S S S S S DS 
MP284 F 41 N S S S S S DS 
MP306 M 61 N S S S S S DS 
MP307 M 29 n/a S S S S S DS 
MP315 M 57 Y S S S S S DS 
MP019 M 53 Y S S S S R DS 
MP035 M 27 N S S S S R DS 
MP038 M 57 N S S S S R DS 
MP111 M 30 N S S S S R DS 
MP176 M 38 Y S S S S R DS 
MP248 M 35 N S S S S R DS 
MP268 M 18 N S S S S R DS 
MP092 M 61 Y S S S R S DS 
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MP175 M 30 N S S R S R DS 
MP032 M 28 N S S R R R DS 
MP040 M 17 N S S R R R DS 
MP013 M 42 N S R S S S DS 
MP041 M 29 N S R S S S DS 
MP073 M 57 N S R S S S DS 
MP118 F 75 N S R S S S DS 
MP169 M 31 N S R S S S DS 
MP026 M 18 N S R S S R DS 
MP027 M 46 Y S R S S R DS 
MP028 M 39 N S R S S R DS 
MP050 M 22 N S R S S R DS 
MP313 M 33 N R S R S R RR 
MP031 M 47 N R S R R R RR 
MP294 M 36 N R S R R R RR 
MP005 F 83 Y R R S S S MDR 
MP042 F 23 N R R S S S MDR 
MP054 M 53 N R R S S S MDR 
MP063 M 23 Y R R S S S MDR 
MP120 M 18 N R R S S S MDR 
MP182 M 67 n/a R R S S S MDR 
MP275 M 20 N R R S S S MDR 
MP276 F 37 N R R S S S MDR 
MP308 n/a n/a n/a R R S S S MDR 
MP320 F 50 n/a R R S S S MDR 
MP360 M 21 N R R S S S MDR 
MP202 F 50 Y R R S S R MDR 
MP190 F 19 N R R S S S MDR 
  212 
MP078 M 31 N R R R S R MDR 
MP177 M 36 Y R R R S R MDR 
MP249 F n/a N R R R S R MDR 
MP342 M 66 N R R R S R MDR 
MP364 M 28 n/a R R R S R MDR 
MP367 M 31 n/a R R R S R MDR 
MP369 M 18 N R R R S R MDR 
MP123 M 37 N R R R R S MDR 
MP170 M 21 Y R R R R S MDR 
MP075 M 40 N R R R R R MDR 
MP096 M 38 N R R R R R MDR 
MP241 M 32 N R R R R R MDR 
MP247 n/a n/a N R R R R R MDR 
MP282 F 68 Y R R R R R MDR 
MP287 M 20 N R R R R R MDR 
MP341 M 36 N R R R R R MDR 
MP366 M 15 N R R R R R MDR 
Red font indicates that the result is associated with resistance; green font indicates sensitivity. 
. 
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Table S3: Results of drug susceptibility testing for rifampicin in chapter 
five Red font indicates that the result is associated with resistance; green font indicates sensitivity. 
The number of resistant and sensitive reads were not reported by KVarQ. Mykrobe reported 
mutations with only the position and reference allele, not the allele present in the sample.  
Sample  MODS  Mykrobe (R/S) PhyResSE (R/S) KVarQ 
MP284 S — — — 
MP032 S — — — 
MP035 S — — — 
MP038 S — — — 
MP040 S — — — 
MP041 S — — — 
MP051 S — — — 
MP069 S — — — 
MP111 S — — — 
MP124 S — — — 
MP126  S — — — 
MP167 S — — — 
MP169 S — — — 
MP175 S — — — 
MP199 S — — — 
MP203 S — — — 
MP210 S — — — 
MP306 S — — — 
MP307 S — — — 
MP315 S — — — 
MP082 S Phe425X in RpoB: 1/30 — — 
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MP118 S 
Gly426X in RpoB 
:1/17  




Gly426X in RpoB: 
1/33 
Asp335X in rpoB: 
1/32 
— — 
MP059 S Gly426X in RpoB: 1/24 — — 
MP200 S Gly442X in RpoB: 1/23 — — 
MP028 S Gly442X in RpoB: 2/66 — — 
MP073 S Asn438X in RpoB: 2/47 — — 
MP026 S Pro439X in RpoB: 2/39 — — 
MP268 S Gln432X in RpoB: 1/33 — — 
MP176 S 
Arg447X in RpoB: 
2/46 




Ser428X in RpoB: 
1/23 




Ser450X in RpoB 
1/23 
— — 
MP019 S Leu430X in RpoB: 28/0 




MP013 S Asp435X in RpoB: 41/0 




MP027 S Asp435X in RpoB: 49/0 
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MP050 S 
Leu452X in RpoB: 
30/0 
Phe425X in RpoB: 
2/22 




MP005 R His445X in RpoB: 2/57 — — 
MP054 R — Ile491Phe in RpoB: 81/0 — 
MP031 R 
Ser450X in RpoB: 
5/12 
Gly442X in RpoB: 
2/20 
Ser450Leu in RpoB: 
11/32 — 
MP042 R His445X in RpoB: 33/0 




MP063 R Asp435X in RpoB: 14/0 




MP123 R Asp435X in RpoB: 20/0 




MP078 R Asp435X in RpoB: 25/0 




MP177 R Asp435X in RpoB: 27/1 




MP202 R Asp435X in RpoB: 30/0 




MP249 R Asp435X in RpoB: 30/0 




MP096 R Asp435X in RpoB: 34/0 




MP170 R Asp435X in RpoB: 37/0 




MP247 R Asp435X in RpoB: 42/0 




MP342 R Asp435X in RpoB: 21/0 




MP287 R Asp435X in RpoB: 37/0 




MP364 R Asp435X in RpoB: 38/0 
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MP276 R Asp435X in RpoB: 57/0 





Asp435X in RpoB: 
16/0 
Phe425X in RpoB: 
2/14 




MP182  R 
Asp435X in RpoB: 
29/2 
Thr427X in RpoB: 
1/33 





Asp435X in RpoB: 
25/0 
Gly42X in RpoB: 
1/25 





Ser450X in RpoB: 
31/0  
Asp435X in RpoB: 
1/32 





Ser450X in RpoB: 
28/0 
Phe425X in RpoB: 
2/31 





Ser450X in RpoB: 
18/0 
Phe433X in RpoB: 
1/14 







Ser450X in RpoB: 
24/0 
Gly426X in RpoB: 
1/26 




MP313 R Ser450X in RpoB: 22/2 




MP241 R Ser450X in RpoB: 39/0 




MP367 R Ser450X in RpoB: 13/0 




MP369 R Ser450X in RpoB: 19/0 




MP294 R Ser450X in RpoB: 23/0 
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MP308 R Ser450X in RpoB: 27/0 




MP366 R Ser450X in RpoB: 27/0 




MP190 R Ser450X in RpoB: 35/0 




MP120 R Ser450X in RpoB: 20/1 







Table S4: Results of drug susceptibility testing methods for isoniazid in 
chapter five 
Sample  MODS  Mykrobe (R/S) PhyResSE (R/S) KVarQ  
MP035 S — — — 
MP038 S — — — 
MP051 S — — — 
MP059 S — — — 
MP069 S — — — 
MP082 S — — — 
MP092 S — — — 
MP111 S — — — 
MP124 S — — — 
MP126  S — — — 
MP167 S — — — 
MP186 S — — — 
MP199 S — — — 
MP200 S — — — 
MP203 S — — — 
MP210 S — — — 
MP284 S — — — 
MP306 S — — — 
  218 
MP307 S — — — 





































































































MP063 R Ser315X in KatG: 13/0 
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MP054 R  Ser315X in gene KatG: 49/0 




MP050 R Ser315X in gene KatG: 22/0 




MP241 R Ser315X in gene KatG: 31/0 




MP177 R Ser315X in gene KatG: 40/0 




MP073 R Ser315X in gene KatG: 44/0 




MP169 R Ser315X in gene KatG: 62/0 




MP027 R Ser315X in gene KatG:49/0 
Ser315Thr in KatG: 
66/0 — 
MP075 R Ser315X in KatG: 12/0 




MP041 R Ser315X in KatG: 17/0 




MP118 R Ser315X in KatG: 18/7 
Ser315Thr in KatG: 
25/16 — 
MP247 R Ser315X in KatG: 22/0 




MP123 R Ser315X in KatG: 24/0 




MP202 R Ser315X in KatG: 25/0 




MP078 R Ser315X in KatG: 28/0 




MP341 R Ser315X in KatG: 28/0 




MP366 R Ser315X in KatG: 28/0 




MP013 R Ser315X in KatG: 30/0 




MP042 R Ser315X in KatG: 30/0 
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MP120 R Ser315X in KatG: 30/0 




MP026 R Ser315X in KatG: 32/0 




MP182  R Ser315X in KatG: 33/0 




MP170 R Ser315X in KatG: 34/0 




MP249 R Ser315X in KatG: 35/0 




MP190 R Ser315X in KatG: 37/0 




MP096 R Ser315X in KatG: 38/0 




MP028 R Ser315X in KatG: 67/0 




MP005 R Ser315X in KatG: 72/0 




MP369 R Ser315X in KatG:10/0 




MP282 R Ser315X in KatG:16/0 




MP308 R Ser315X in KatG:20/0 




MP360 R Ser315X in KatG:22/0 




MP364 R Ser315X in KatG:24/0 




MP275 R Ser315X in KatG:28/0 




MP342 R Ser315X in KatG:30/0 




MP287 R Ser315X in KatG:35/0 




MP320 R Ser315X in KatG:42/0 




  221 
MP276 R Ser315X in KatG:46/0 




Red font indicates that the result is associated with resistance; green font indicates sensitivity. The 
number of resistant and sensitive reads are not reported by KvarQ. Mykrobe reported mutations 
with only the position and reference allele, not the allele present in the sample.  
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Table S5: Results of drug susceptibility testing for ethambutol, streptomycin, fluoroquinolones and aminoglycosides Red font 
indicates that the result is associated with resistance; green font indicates association with sensitivity; black font indicated that no susceptibility 
prediction was made. Fractions indicate the number of reads in which the resistance-associated allele (numerator) and sensitive alleles 
(denominator) were reported by genomic prediction tools. The number of resistant and sensitive reads is not reported by KVarQ. 
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2  — — — — — — — — — — — — 
MP18
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Red	font	indicates	that	the	result	is	associated	with	resistance;	green	font	indicates	sensitivity.	The	number	of	resistant	and	sensitive	reads	are	not	reported	by	KvarQ. 
Mykrobe reported mutations with only the position and reference allele, not the allele present in the sample.	 
 
 
